Anti-VLA-4 antibodies with reduced effector function
By introducing stabilizing amino acids into the Fc region of the antibody and adjusting the glycosylation state, the problem of insufficient effect function and half-life of the antibody during the treatment process is solved, and a safer and longer-lasting therapeutic effect is achieved.
Patent Information
- Application Number
- CN202411177547.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-04-12
- Filing Date
- 2019-05-31
- Publication Date
- 2024-12-06
AI Technical Summary
Existing antibodies have side effects caused by effector functions during the treatment process, and their half-life is short, making it difficult to use stably for a long time.
Developed anti-VLA-4 antibodies containing modified Fc regions, by introducing stabilizing amino acids and adjusting glycosylation state, reduce the effect function of the antibody while improving its stability and half-life.
It has achieved the reduction of the inflammatory side effects of the antibody, prolonged the half-life, and improved the long-term stability and safety of the treatment, and is suitable for use as a therapeutic agent.
Smart Images

Figure CN119080931A_ABST
Abstract
Description
[0001] This application is a divisional application of an application filed on May 31, 2019, with application number 201980051574.2 and invention name “Anti-VLA-4 antibodies with reduced effector function”. Technical Field
[0002] The present invention relates to α4 binding antibodies and fragments thereof.
[0003] Sequence Listing
[0004] This application contains a sequence listing that has been submitted by EFS-Web and is incorporated herein by reference in its entirety. The sequence listing was created on April 12, 2019, is named Anti_VLASequence PatentIN_ST25 and is 208 kilobytes in size. Background of the Invention
[0006] Integrins are members of a large family of cell surface receptors that mediate cell-cell and cell-matrix interactions. They exist as non-covalent αβ heterodimers with varying combinations of α and β chains and share extensive structural homology. Integrins mediate a wide variety of physiological processes and are implicated in a wide variety of pathological conditions. The α4 chain is primarily confined to leukocytes and can associate with two β chains, β1 and β7.
[0007] VLA-4 (also known as α4β1) and α4β7 play an important role in the pathophysiology of inflammatory diseases. VLA-4 is a member of the β1 integrin cell surface receptor family. VLA-4 contains an α4 chain and a β1 chain and participates in cell-cell interactions. Its expression is mainly restricted to lymphocytes, including T lymphocytes, and bone marrow cells, including microglia and macrophages. VLA-4 binds to the endothelial cell ligand VCAM-1 (vascular cell adhesion molecule-1) and can mediate the attachment of T lymphocytes and B lymphocytes to the heparin II binding fragment of human plasma fibronectin. VLA-4 regulates normal leukocyte trafficking (Lobb and Hemler, J. Clin. Invest. 94(5):1722-1728, 1994) and provides key co-stimulatory signals that support cell activation (Clark and Brugge, Science 268(5208):233-9, 1995). During inflammatory responses, VLA-4 regulates the migration of leukocytes into damaged tissues and has therefore been recognized as an attractive therapeutic target. In vivo studies using blocking monoclonal antibodies (Lobb and Hemler, supra; Enders et al., Brain 121(Pt 7):1257-66, 1998; Ramos-Barbon et al., Am J Respir Crit Care Med. 163(1):101-8, 2001), inhibitory peptides (Molossi et al., J Clin Invest. 95(6):2601-10, 1995; Abraham, 1997; van der Laan et al., J Neurosci Res. 2002 Jan 15;67(2):191-9, 2002), and small molecule antagonists (Kudlacz et al., J. Pharmacol. Exp. Ther. 301(2):747-52, 2002) have validated the critical role of α4β1 integrin in leukocyte-mediated inflammation.
[0008] α4β1 mediates cell adhesion by binding to either of two protein ligands, VCAM-1 or fibronectin (e.g., a fibronectin variant containing an alternatively spliced connecting segment 1 (CS1)) (Osborn et al., Cell 59(6):1203-11, 1989; Wayner et al., J. Cell Biol. 109(3):1321-30, 1989). Other potential ligands have been identified (Bayless et al., J. Cell Sci. 111(Pt 9):1165-74, 1998); however, the biological significance of these interactions is less clear. The interaction between α4β1 and its ligand is of low affinity, and binding is likely mediated by multivalent interactions. Although α4β1 is constitutively expressed, its interaction with ligands can be mediated by a variety of stimuli, including antigens, anti-T cell receptor mAbs, voriconol esters, divalent cations, and Mn. 2+ The binding of α4β7 to VLA4 is strongly enhanced in the activated state induced by various stimuli and certain β1-specific antibodies. These changes in affinity and / or avidity ultimately determine whether the interaction is effective and stabilize the ligand / integrin complex (Humphries, Curr Opin Cell Biol. 8(5):632-40, 1996). α4β7 is expressed by a more restricted group of leukocytes and is responsible, to some extent, for homing lymphocytes to mucosal lymphoid tissues by binding to the mucosal addressin MadCAM, but it also binds to VCAM-1 and fibronectin. Certain monoclonal antibodies (mAbs) against α4 can block the adhesion function of both VLA4 and α4β7.
[0009] Humanized antibodies can be used as therapeutic agents instead of murine antibodies to avoid the undesirable immune response in humans known as the HAMA (human anti-mouse antibody) response. Humanized antibodies are generally constructed by replacing the complementarity determining regions (CDRs) of a human antibody with the CDRs of an antibody from another species, usually a mouse.
[0010] Antibodies can bind to antigens via their variable regions. Once an antibody binds to an antigen, it targets the antigen for destruction, a process typically mediated at least in part by the constant region or Fc region of the antibody. There are several effector functions or activities mediated by the Fc region of an antibody. One effector function is the ability to bind to complement proteins that can assist in the dissolution of target antigens, such as cellular pathogens, in a process called complement-dependent cytotoxicity (CDC). Another effector activity of the Fc region is binding to Fc receptors (such as FcγRs) on the surface of immune cells or so-called effector cells that can trigger other immune effects. These immune effects (e.g., antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP)) play a role in removing pathogens / antigens by, for example, releasing immune activation factors and regulating antibody production, endocytosis, phagocytosis, and cell killing. In some clinical applications, these reactions are crucial to the efficacy of antibodies, while in other cases, they can provoke unwanted side effects. An example of a side effect mediated by an effector is the release of inflammatory cytokines that cause acute febrile reactions. Another example is the long-term depletion of cells carrying antigens.
[0011] The effector function of antibodies can be avoided by using antibody fragments lacking the Fc region (e.g., such as Fab, F(ab')2, or single-chain Fv (scFv)). However, these fragments have a reduced half-life due to rapid clearance by the kidneys. Fab and scFv fragments have only one antigen binding site instead of two, thereby potentially sacrificing any advantages due to binding affinity and bringing potential challenges in manufacturing. Alternative approaches aim to reduce the effector function of full-length antibodies while retaining other valuable attributes of the Fc region (e.g., extended half-life and heterodimerization). One method of reducing effector function is to produce so-called aglycosylated antibodies by eliminating the sugars connected to specific residues in the Fc region. Aglycosylated antibodies can be produced by, for example, deleting or changing the residues to which sugars are attached, removing sugars under the action of an enzyme, producing antibodies in cells cultured in the presence of a glycosylation inhibitor, or expressing antibodies in cells that cannot glycosylate proteins (e.g., bacterial host cells). Another method is to use an Fc region from an IgG4 antibody rather than IgG1. It is well known that IgG4 antibodies are characterized by lower levels of complement activation and antibody-dependent cellular cytotoxicity than IgG1.
[0012] Monoclonal antibodies against human α4 bind to three functionally distinct morphological epitopes, A, B, and C (Pulido et al., J. Biol. Chem. 266:10241-10245, 1991; Schiffer et al., J. Biol. Chem. 270:14270-14273, 1995). Epitope B is further divided into the B1 epitope and the B2 epitope, which are morphologically indistinguishable but can be defined by the ability of the mAb to induce cell aggregation. Anti-α4 mAbs directed against epitopes A and B2 can induce homotypic cell aggregation, but those directed against epitopes B1 and C do not. Summary of the Invention
[0013] The present invention relates to anti-VLA-4 antibodies and binding fragments thereof comprising germline variable region frameworks that optimize CDR-grafted α4-binding antibodies, such as anti-VLA-4 antibodies. Thus, the present invention encompasses anti-VLA-4 variable heavy (VH) and variable light (VL) chains, and antibody molecules comprising these frameworks. In some embodiments, the VLA-4 is human VLA-4. In some embodiments, the VLA-4 comprises an α4 chain (e.g., a human α4 chain).
[0014] The antibodies may also contain a modified Fc region that alters or reduces effector function and improves stability. Antibodies with modified Fc regions can improve the significant adverse effects observed in antibodies lacking oligosaccharides, particularly the adverse effects on conformation and stability. Antibodies with modified Fc regions may also have altered or reduced effector function and improved stability. The present invention also relates to methods for making the molecules described herein.
[0015] The antibody can improve the problem of the prior art "no effector factor" antibody by providing an improved method for enhancing the stability of the Fc region. For example, the present invention provides stability engineered Fc polypeptides, such as stabilized IgG antibodies or other Fc-containing binding molecules, which include stabilizing amino acids in the polypeptide Fc region. In one embodiment, the present invention provides a method for introducing a mutation that enhances the stability of the Fc region at a specific amino acid residue position in the Fc region of a parent Fc polypeptide. In some embodiments, the stabilized Fc polypeptide has an altered or reduced effector function (compared to a polypeptide that does not include stabilizing amino acids) and exhibits enhanced stability (compared to the parent Fc polypeptide). In some embodiments, the parent Fc polypeptide is human IgG1 (e.g., having a sequence of SEQ ID NO: 83). In some embodiments, the parent Fc polypeptide is human IgG4 (e.g., having a sequence of SEQ ID NO: 84).
[0016] Thus, the antibodies disclosed herein may provide several advantages, including but not limited to the following:
[0017] - providing stabilized aglycosylated Fc polypeptides comprising a stabilized aglycosylated Fc region, such as stabilized fusion proteins or aglycosylated IgG antibodies, which are suitable as therapeutic agents due to their reduced effector function;
[0018] - providing stabilized Fc polypeptides comprising an Fc region derived from an IgG4 antibody, suitable as therapeutic agents due to their reduced effector function, such as stabilized glycosylated or aglycosylated fusion proteins or IgG4 antibodies;
[0019] - efficient methods for generating stabilized Fc polypeptides with minimal changes to the polypeptide (e.g., by introducing changes into a non-stabilized parent polypeptide or by expressing a nucleic acid molecule encoding a stabilized Fc polypeptide);
[0020] - Methods to enhance the stability of Fc polypeptides while avoiding any increase in immunogenicity and / or effector function;
[0021] - Methods for enhancing the tunability, manufacturing and / or long-term stability of Fc polypeptides; and
[0022] - A method of treating a subject in need of treatment with the stabilized Fc polypeptides of the invention.
[0023] In one embodiment, the present invention provides an anti-α4 antibody VH chain having CDRs from a donor anti-α4 antibody, such as an anti-α4 antibody described herein, and a VH framework having regions 1, 2, 3, and 4 of a sequence derived from a VH chain germline variable region sequence or having no more than 5, 10, or 15 differences relative to the VH chain germline variable region sequence. In one embodiment, variable framework region 4 (FR4) is a human consensus sequence. In one embodiment, the complete VH chain framework regions FR1, FR2, FR3, and FR4 are present. In another embodiment, the chain is an antigen-binding fragment of a VH region.
[0024] In one embodiment, the germline sequence is Figure 1 In certain embodiments, the VH framework sequence may differ from the germline sequence, such as SEQ ID NO: 2, by at least one, but not more than 2, 3, 4, 5, 10, or 15, amino acid residues. In one embodiment, the VH framework further comprises residues other than the corresponding human residues. For example, the VH chain comprises atypical residues at one or more of framework positions 24, 67, 76, 80, and 94 (Kabat numbering) of SEQ ID NO: 2.
[0025] In one embodiment, at least one or more of the complementarity determining regions (CDRs) of the variable domain are derived from a donor non-human α4 binding antibody (i.e., a non-human antibody that specifically binds to α4). In one embodiment, the antigen binding region of the CDR-grafted heavy chain variable domain includes CDRs corresponding to positions 26-34 (CDR1), 50-65 (CDR2), and 95-102 (CDR3) (Kabat numbering).
[0026] Thus, in one embodiment, the variable heavy chain (VH) framework has an acceptor sequence derived from the human antibody germline sequence IGHV1-f.
[0027] In another embodiment, at least one amino acid and fewer than 2, 3, 4, 5, or 10 amino acid residues in the FR1 region of VH are not corresponding human germline residues. For example, one or more of the residues may be identical to the non-human antibody framework region from which the CDR sequence is derived. In one embodiment, the amino acid residue at Kabat position 24 is mutated to be identical to the non-human antibody framework region.
[0028] In another embodiment, at least one amino acid and fewer than 2, 3, 4, 5, or 10 amino acid residues in the FR2 region of VH are not corresponding human germline residues. For example, one or more of the residues may be identical to the non-human antibody framework region from which the CDR sequence is derived.
[0029] In another embodiment, at least one amino acid and less than 2, 3, 4, 5 or 10 amino acid residues in the FR3 of the VH chain are not corresponding human germline residues. For example, one or more of the residues may be identical to the non-human antibody framework region from which the CDR sequence is derived. In one embodiment, the amino acid residue at Kabat position 94 is identical to the non-human antibody framework region. In another embodiment, the amino acid residues at Kabat positions 67, 76, 80 and 94 are identical to the non-human antibody framework region.
[0030] In certain embodiments, the VH chain of the antibody has the sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.
[0031] In one aspect, the invention provides an anti-VLA-4 VL chain having CDRs from a donor anti-VLA-4 antibody, such as an anti-VLA-4 antibody described herein, and a VL framework having regions 1, 2, 3, and 4 of a sequence derived from a VL chain germline variable region sequence or having no more than 5, 10, or 15 differences (per region or total) relative to the VL chain germline variable region sequence. In one embodiment, variable framework region 4 (FR4) is a human consensus sequence. In one embodiment, the complete VL chain framework regions FR1, FR2, FR3, and FR4 are present. In another embodiment, the chain is an antigen-binding fragment of a VL region.
[0032] In another embodiment, the germline sequence is Figure 2 In another embodiment, the VL framework sequence may differ from the germline framework sequence, e.g., SEQ ID NO: 7, by at least one, but not more than 2, 3, 4, 5, 10, or 15, amino acid residues. In another embodiment, the VL further comprises residues other than the corresponding human amino acid residues. For example, the VL chain further comprises non-human residues at one or more of framework positions 1, 73, and 87 (Kabat numbering) of SEQ ID NO: 7.
[0033] In one embodiment, the sequence is Figure 2 AAH7035.1 (SEQ ID NO: 12) or a germline engineered version thereof (SEQ ID NO: 13) as depicted in SEQ ID NO: 13. In some embodiments, the VL framework sequence may differ from a germline engineered framework sequence, such as SEQ ID NO: 13, by at least one, but not more than 5, 10, 15, 20, or 25, amino acid residues. In one embodiment, the VL chain includes residues other than the corresponding human residues. For example, the VL chain includes non-human residues at one or more of framework positions 1 and 87 (Kabat numbering) of SEQ ID NO: 12. In another embodiment, the VL includes amino acid substitutions in the framework regions to resemble a different human germline framework sequence, such as the germline sequence IGKV4-1. In certain embodiments, the VL framework sequence is altered at positions 1-3, 5-23, 35-37, 39-42, 45-49, 57, 59-61, 63-64, 70-72, 74-84, 86-88, 99-106 of SEQ ID NO: 12 (Kabat numbering) to be identical to the IGKV4-1 germline sequence.
[0034] In one embodiment, at least one or more of the complementarity determining regions (CDRs) of the variable domains are derived from a donor non-human α4 binding antibody. In another embodiment, the antigen binding region of the CDR-grafted heavy chain variable domain includes CDRs corresponding to positions 24-31 (CDR1), 50-56 (CDR2), and 89-97 (CDR3) (Kabat numbering). Thus, in one embodiment, the VL framework has an acceptor sequence constructed from the IGKV4-1 germline sequence, from the antibody AAH70335.1, or from the germline engineered antibody AAH70335.1.
[0035] In another embodiment, at least one amino acid and fewer than 2, 3, 4, 5, 10, or 15 residues in FR1 of the VL chain are not corresponding human residues. For example, one or more of the residues may be identical to the non-human antibody framework region from which the CDR sequence is derived. In one embodiment, the amino acid residue at the N-terminal position of FR1 is mutated to be identical to the non-human antibody framework region.
[0036] In another embodiment, at least one amino acid and fewer than 2, 3, 4, 5, 10, or 15 residues in FR2 of the VL chain are not corresponding human residues. For example, one or more of the residues may be identical to the non-human antibody framework region from which the CDR sequence is derived.
[0037] In another embodiment, at least one amino acid and less than 2, 3, 4, 5, 10 or 15 residues in the FR3 of the VL chain are not corresponding human residues. For example, one or more of the residues may be identical to the non-human antibody framework region from which the CDR sequence is derived. In another embodiment, the amino acid residue at Kabat position 87 is mutated to be identical to the non-human antibody framework region. In another embodiment, the amino acid residues at Kabat positions 67 and 87 are mutated to be identical to the non-human antibody framework sequence. In another embodiment, the amino acid residues at Kabat positions 67, 73 and 87 of SEQ ID NO: 7 are mutated to be identical to the non-human antibody framework sequence.
[0038] In other embodiments, the VL chain of the antibody has the sequence of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, or SEQ ID NO:11.
[0039] In one embodiment, the VH chain of the antibody has the sequence of SEQ ID NO:4 and the VL chain of the antibody has the sequence of SEQ ID NO:11.
[0040] In one embodiment, the CDRs of the VH and VL receptor framework sequences are selected to be similar to the CDR sequences of non-human (e.g., murine) antibody sequences, wherein the non-human antibody binds to integrin α4 or a fragment thereof. In another embodiment, the sequences of the CDRs are selected to be similar to the sequences of the CDRs of non-human antibodies that bind to the B1 epitope of the VLA-4α4 chain. In one embodiment, the CDRs are selected to be similar to murine monoclonal antibodies, such as HP1 / 2, HP2 / 1, HP2 / 4, L25, P4C2, or 21.6 (Pulido et al., J. Biol. Chem. 266: 10241-10245, 1991; U.S. Patent No. 6,033,665). Modifications can mean, for example, cuts and insertions or changes, such as by directed mutagenesis.
[0041] In another aspect, the present invention provides an antibody or antigen-binding fragment thereof comprising:
[0042] an anti-VLA-4 VL chain described herein, e.g., an anti-VLA-4 VL chain having CDRs from a donor anti-VLA-4 antibody, e.g., an anti-VLA-4 antibody described herein, and LC framework regions 1, 2, and 3 having a sequence derived from a VL chain germline variable region sequence, or a VL framework having no more than 5, 10, or 15 differences relative to the VL chain germline variable region sequence. In one embodiment, variable region 4 is a human consensus sequence; and
[0043] An anti-VLA-4 VH chain described herein, e.g., an anti-VLA-4 VL chain having CDRs from a donor anti-VLA-4 antibody, e.g., an anti-VLA-4 antibody described herein, and LC framework regions 1, 2, and 3 having a sequence derived from a VL chain germline variable region sequence, or a VL framework having no more than 5, 10, or 15 differences relative to the VL chain germline variable region sequence. In one embodiment, variable region 4 is a human consensus sequence.
[0044] In one embodiment, the antibody binds to one or both of α4β1 and α4β7.
[0045] In another aspect, the VL or VH chain or antibody or fragment thereof described herein is detectably labeled.
[0046] In another aspect, the present invention provides a recombinant anti-α4 antibody or an α4-binding fragment thereof, comprising: (a) a variable light chain comprising the sequence of SEQ ID NO: 11; (b) a variable heavy chain comprising the sequence of SEQ ID NO: 4; (c) a human kappa light chain (SEQ ID NO: 11); NO:82); and (d) a constant heavy chain of human IgG1, wherein the constant region comprises at least one mutation selected from the group consisting of S127C, K129R, G135E, G136S, Q203K, I207T, N211D, K222R, P227S, S232Y, C233G, D234 deletion, K235 deletion, T236 deletion, H237P, T238P, L247F, H281Q, K287Q, Y313F, N314Q, A346G, A349S, P350S, or K478 deletion according to the Kabat numbering scheme.
[0047] In some embodiments, the constant heavy chain of human IgG1 comprises, consists of, or consists essentially of at least two mutations selected from: S127C, K129R, G135E, G136S, Q203K, I207T, N211D, K222R, P227S, S232Y, C233G, D234 deletion, K235 deletion, T236 deletion, H237P, T238P, L247F, H281Q, K287Q, Y313F, N314Q, A346G, A349S, P350S, or K478 deletion according to the Kabat numbering scheme.
[0048] In some embodiments, the constant heavy chain of human IgG1 comprises, consists of, or consists essentially of at least three mutations selected from: S127C, K129R, G135E, G136S, Q203K, I207T, N211D, K222R, P227S, S232Y, C233G, D234 deletion, K235 deletion, T236 deletion, H237P, T238P, L247F, H281Q, K287Q, Y313F, N314Q, A346G, A349S, P350S, or K478 deletion according to the Kabat numbering scheme.
[0049] In some embodiments, the constant heavy chain of human IgG1 comprises, consists of, or consists essentially of at least four, or at least five, or at least six, or at least seven, or at least eight, or at least nine, or at least ten, or at least eleven, or at least twelve, or at least thirteen, or at least fourteen, or at least fifteen, or at least sixteen, or at least seventeen, or at least eighteen, or at least nineteen, or at least twenty, or at least twenty-one, or at least twenty-two, or at least twenty-three, or at least twenty Four mutations selected from the group consisting of S127C, K129R, G135E, G136S, Q203K, I207T, N211D, K222R, P227S, S232Y, C233G, D234 deletion, K235 deletion, T236 deletion, H237P, T238P, L247F, H281Q, K287Q, Y313F, N314Q, A346G, A349S, P350S, or K478 deletion according to the Kabat numbering scheme.
[0050] In some embodiments, the constant heavy chain of human IgG1 comprises, consists of, or consists essentially of S127C, K129R, G135E, G136S, Q203K, I207T, N211D, K222R, P227S, S232Y, C233G, D234 deletion, K235 deletion, T236 deletion, H237P, T238P, L247F, H281Q, K287Q, Y313F, N314Q, A346G, A349S, P350S, and K478 deletion according to the Kabat numbering scheme.
[0051] In another aspect, the present invention provides a recombinant anti-α4 antibody or an α4-binding fragment thereof, comprising: (a) a variable light chain comprising the sequence of SEQ ID NO: 11; (b) a variable heavy chain comprising the sequence of SEQ ID NO: 4; (c) a constant light chain of a human kappa light chain (SEQ ID NO: 82); and (d) a constant heavy chain of human IgG4, wherein the constant region comprises at least one mutation selected from the group consisting of S241P, N314Q, Q376R, E377D, M381L, R440K, E450Q, L476P, and K478 deletion according to the Kabat numbering scheme.
[0052] In some embodiments, the constant heavy chain of human IgG4 comprises, consists of, or consists essentially of at least two mutations selected from the group consisting of S241P, N314Q, Q376R, E377D, M381L, R440K, E450Q, L476P, and K478 deletion according to the Kabat numbering scheme.
[0053] In some embodiments, the constant heavy chain of human IgG4 comprises, consists of, or consists essentially of at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight, or at least nine mutations selected from the group consisting of S241P, N314Q, Q376R, E377D, M381L, R440K, E450Q, L476P, and K478 deletion according to the Kabat numbering scheme.
[0054] In some embodiments, the constant heavy chain of human IgG4 comprises, consists of, or consists essentially of one or more of the following mutations: S241P, N314Q, Q376R, E377D, M381L, R440K, E450Q, L476P, and K478 deletion according to the Kabat numbering scheme.
[0055] Note that the C-terminal lysine residue (at position 478 according to the Kabat numbering scheme) is typically deleted after translation or by means. Thus, in some embodiments, the heavy chains of the antibodies described herein (or the Fc portion of their domains) lack a C-terminal lysine. In other words, in some embodiments, the lysine at position 478 (Kabat numbering) is deleted in the heavy chains of the antibodies described herein (or the Fc portion of their domains).
[0056] In some embodiments, the constant heavy chain of human IgG1 without mutations or substitutions has the sequence of SEQ ID NO:83.
[0057] In some embodiments, the constant heavy chain of human IgG4 without mutations or substitutions has the sequence of SEQ ID NO:84.
[0058] In another aspect, the present invention provides a vector comprising DNA encoding the heavy chain of an antibody described herein or an α4-binding fragment thereof. In some embodiments, the DNA of the vector encodes a VH having the sequence of SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5.
[0059] In another aspect, the present invention provides a vector comprising a DNA encoding an antibody light chain or an α4 binding fragment thereof as described herein. In some embodiments, the DNA of the vector encodes a VL chain having a sequence of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11.
[0060] In another aspect, the present invention provides a vector containing DNA encoding an antibody heavy chain or α4-binding fragment thereof described herein and an antibody light chain or α4-binding fragment thereof described herein.
[0061] In another aspect, the present invention provides a host cell comprising a vector as described herein, e.g., a vector capable of expressing a heavy chain and / or light chain antibody or antibody fragment as described herein. In certain embodiments, the host cell is a Chinese hamster ovary (CHO) cell.
[0062] In one aspect, the present invention provides a method for producing a recombinant anti-α4 antibody or an α4-binding fragment thereof, the method being achieved by providing a host cell transfected with (a) a DNA sequence encoding an antibody heavy chain or an α4-binding fragment thereof described herein and (b) a DNA sequence encoding an antibody light chain or an α4-binding fragment thereof, and culturing the transfected cell to produce the recombinant anti-α4 antibody molecule or the α4-binding fragment thereof. The DNA encoding the antibody heavy chain and light chain can be on the same vector or on different vectors.
[0063] In one aspect, the present invention provides a method for producing a recombinant anti-α4 antibody or an α4-binding fragment thereof, the method being achieved by providing a host cell transfected with (a) a DNA sequence encoding the antibody heavy chain or an α4-binding fragment thereof (wherein the DNA sequence has the sequence of SEQ ID NO: 4) and (b) a DNA sequence encoding the antibody light chain or an α4-binding fragment thereof (wherein the DNA sequence has the sequence of SEQ ID NO: 11), and culturing the transfected cell line to produce the recombinant anti-α4 antibody molecule or the α4-binding fragment thereof. The DNA encoding the antibody heavy chain and light chain can be on the same vector or on different vectors.
[0064] In another aspect, the present invention provides a method for treating a disease or condition mediated by an α4 integrin, such as α4β1 (VLA-4) or α4β7 integrin, by administering to a subject in need of such treatment an α4 antibody or antibody fragment as described herein, or a pharmaceutical composition comprising the antibody or fragment. The subject may be suffering from or at risk of developing, for example, an inflammatory, immune, or autoimmune disorder (e.g., central nervous system inflammation, such as multiple sclerosis, meningitis, neuromyelitis optica, neurosarcoidosis, CNS vasculitis, encephalitis, and transverse myelitis), tissue or organ transplant rejection or graft-versus-host disease; acute CNS injury, such as stroke, traumatic brain injury (TBI), or spinal cord injury (SCI); chronic kidney disease; allergies, such as allergic asthma; type 1 diabetes; inflammatory bowel disease, such as Crohn's disease; disease), ulcerative colitis; myasthenia gravis; fibromyalgia; arthritic conditions, such as rheumatoid arthritis, psoriatic arthritis; inflammatory / immune skin conditions, such as psoriasis, vitiligo, dermatitis, lichen planus; systemic lupus erythematosus; Sjogren's Syndrome; hematological cancers, such as multiple myeloma, leukemia, lymphoma; solid cancers, such as sarcomas or carcinomas, such as lung cancer, breast cancer, prostate cancer, brain cancer; and fibrotic conditions, such as pulmonary fibrosis, myelofibrosis, cirrhosis, mesangial proliferative glomerulonephritis, crescentic glomerulonephritis, diabetic nephropathy, and renal interstitial fibrosis. In a preferred embodiment, the present invention provides a method of treating a patient with multiple sclerosis or alleviating the symptoms of a patient with multiple sclerosis, such as clinically isolated syndrome, relapsing-remitting multiple sclerosis, or active secondary progressive multiple sclerosis. In certain embodiments, the multiple sclerosis is a relapsing form of multiple sclerosis. In a preferred embodiment, the present invention provides a method of treating a patient having or at risk of developing epilepsy, including drug-resistant epilepsy. In certain embodiments, the subject or patient is human.
[0065] In another aspect, the present invention provides a method of treating a patient by administering an α4-binding antibody or antibody fragment to the patient. In one embodiment, the patient has a cancer, such as a solid tumor or a hematological malignancy. For example, the patient treated with the α4-binding antibody or antibody fragment may have acute myeloid leukemia (AML) or multiple myeloma (MM).
[0066] In another embodiment, the patient has an inflammatory condition, such as multiple sclerosis, asthma (e.g., moderate to severe asthma), rheumatoid arthritis, diabetes, or Crohn's disease. In another embodiment, the composition is administered according to a regimen. In another embodiment, the method further comprises selecting a patient suitable for treatment with the composition. For example, a patient suitable for treatment has shown signs or symptoms indicative of a disease onset, such as signs or symptoms indicative of MS. In a preferred embodiment, the patient has epilepsy.
[0067] In certain embodiments, the patient is administered a therapeutically effective amount of an α4-binding antibody or antibody fragment. In certain embodiments, the patient is administered an amount of about 0.0003 mg / kg, 0.0004 mg / kg, 0.0005 mg / kg, 0.0006 mg / kg, 0.0007 mg / kg, 0.0008 mg / kg, 0.0009 mg / kg, 0.0010 mg / kg, 0.0015 mg / kg, or 0.0020 mg / kg to about 0.0025 mg / kg, 0.003 mg / kg, 0.005 mg / kg, 0.010 mg / kg, 0.0125 mg / kg, 0.025 mg / kg, 0.050 mg / kg, 0.060 mg / kg, 0.070 mg / kg, 0.080 mg / kg, 0.090 mg / kg, 0.100 mg / kg, 0.110 mg / kg, 0.120 mg / kg, 0.130 mg / kg, 0.140 mg / kg, 0.150 mg / kg, 0.160 mg / kg, 0.170 mg / kg, 0.180 mg / kg, 0.190 mg / kg, 0.200 mg / kg, 0.210 mg / kg, 0.220 mg / kg, 0.230 mg / kg, 0.240 mg / kg, 0.250 mg / kg, 0.260 mg / kg, 0.270 mg / kg, 0.280 mg / kg, 0.290 mg / kg, 0.300 mg / kg, 0.310 mg / kg, 0.320 mg / kg In some embodiments, the patient is administered an amount of about 0.025 mg / kg to about 10 mg / kg of an α4 binding antibody or antibody fragment. In some embodiments, the patient is administered an amount of about 0.0625 mg / kg to about 0.080 mg / kg, 0.100 mg / kg, 0.200 mg / kg, 0.300 mg / kg, 0.3125 mg / kg, 0.40 mg / kg, 0.50 mg / kg, 0.6 mg / kg, 0.7 mg / kg, 0.8 mg / kg, 0.9 mg / kg, 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg or 10 mg / kg of an α4 binding antibody or antibody fragment. In some embodiments, the patient is administered an amount of about 0.0625 mg / kg to about 8.0 mg / kg of an α4 binding antibody or antibody fragment. In some embodiments, the α4-binding antibody or antibody fragment is administered to the patient in an amount of about 0.3 mg / kg to about 6.0 mg / kg. In some embodiments, the α4-binding antibody or antibody fragment is administered to the patient in an amount of about 0.5 mg / kg to about 5.0 mg / kg.
[0068] In another embodiment, the method further comprises administering to the patient a second therapeutic agent, such as a chemotherapeutic agent, a thrombolytic agent, a neuroprotective agent, an anti-inflammatory agent, a steroid, a cytokine, or a growth factor.
[0069] In one embodiment, the patient is administered a humanized anti-VLA-4 antibody or fragment thereof described herein, eg, HuHP1 / 2, H1L1, H1L2, or H1L3.
[0070] In one embodiment, the composition containing the α4-binding antibody is administered according to a regimen, e.g., at regular intervals. For example, the composition can be administered daily, weekly, or monthly; weekly, twice weekly, three times weekly, four times weekly, or more; or every two weeks, every three weeks, every four weeks, or at longer intervals.
[0071] In one embodiment, the dose can be adjusted based on the clearance rate of the patient's previously administered anti-α4 antibody. For example, in one embodiment, a second or subsequent dose is not administered to the patient until the level of anti-α4 antibody in the patient's system falls below a predetermined level. In one embodiment, a sample from the patient (e.g., a plasma, serum, blood, or urine sample) is assayed for the presence of anti-α4 antibody, and if the level of anti-α4 antibody is above a predetermined level, the second or subsequent dose is not administered to the patient. If the level of anti-α4 antibody in the patient's system is below a predetermined level, the second or subsequent dose is administered to the patient.
[0072] In one embodiment, the composition is administered continuously, for example, over a period of more than 30 minutes but less than 1, 2, 4, or 12 hours.The composition containing the antibody and the second agent can be administered by any appropriate method, for example, subcutaneously, intramuscularly, or intravenously.
[0073] In some embodiments, the antibody and the second agent are each administered at the same dose as the prescribed dose of each for monotherapy. In other embodiments, the antibody is administered at a dose equal to or less than the amount required to achieve efficacy when administered alone. Similarly, the second agent can be administered at a dose equal to or less than the amount required to achieve efficacy when administered alone.
[0074] Another aspect provided in the present disclosure is a method of evaluating a patient by determining whether the patient meets preselected criteria, and if the patient meets the preselected criteria, approving, providing, prescribing, or administering a VLA-4 binding antibody formulation described herein to the patient. In one embodiment, the preselected criteria are that the patient has failed to adequately respond to, for example, a previous alternative therapeutic treatment or regimen for treating MS. In another embodiment, the preselected criteria are the absence of any signs or symptoms of progressive multifocal leukoencephalopathy (PML), or the absence of any diagnosis of PML. In some cases, selection is based on the absence of risk factors for PML, for example, the subject has not tested positive for JC virus DNA or has not tested positive for JC virus antibodies. In another embodiment, the criteria are as described in PCT / US07 / 75577 (published as WO2008 / 021954), which is incorporated herein by reference, describing methods and systems for drug distribution and for providing drugs to patients.
[0075] In another aspect, a method for distributing a composition described herein is provided. The composition contains an α4-binding antibody. The method comprises providing a package containing sufficient unit doses of the drug to a recipient (e.g., an end user, a patient, a physician, a retail or wholesale pharmacy, a distributor, or a hospital pharmacy department, a nursing home clinic, or an HMO) to treat a patient for at least 6, 12, 24, 36, or 48 months. In another aspect, the invention provides a method for evaluating the quality of a package or batch of packages of a composition described herein containing an α4-binding antibody (e.g., to determine whether it has expired). The method comprises evaluating whether the package has expired. The expiration date is at least 6, 12, 24, 36, or 48 months from a preselected event (e.g., manufacturing, assaying, or packaging), for example, more than 24 or 36 months. In some embodiments, a decision or step is made as a result of the analysis. For example, depending on whether the product has expired, the antibody in the package is used or discarded, sorted, selected, released or retained, shipped, moved to a new location, released to the market, sold or offered for sale, withdrawn from the market, or no longer offered for sale, depending on whether the product has expired.
[0076] In another aspect, the invention provides a package containing at least two unit doses of an aqueous composition comprising an α4-binding antibody. In one embodiment, all unit doses contain the same amount of antibody, and in other embodiments, there are unit doses of two or more strengths or two or more different formulations, e.g., having different strengths or release properties.
[0077] In another aspect, the present invention includes methods for instructing a recipient to administer a formulation containing an α4-binding antibody. The methods include instructing a recipient (e.g., an end user, a patient, a physician, a retail or wholesale pharmacy, a distributor, or a hospital pharmacy department, a nursing home clinic, or an HMO) to administer the antibody to the patient according to the regimen described herein. The methods may also include instructing the recipient to administer the antibody before the expiration date. The expiration date is at least 6, 12, 24, 36, or 48 months from a preselected event (e.g., manufacturing, assaying, or packaging), such as more than 24 or 36 months. In one embodiment, the recipient also receives a supply of the antibody, such as a unit dose supply of the antibody.
[0078] In one embodiment, the stabilized polypeptide comprises a chimeric Fc region, wherein the stabilized polypeptide comprises at least one constant domain derived from a human IgG4 antibody and at least one constant domain derived from a human IgG1 antibody.
[0079] In one embodiment, the Fc region is a glycosylated Fc region.
[0080] In one embodiment, the Fc region is an aglycosylated Fc region.
[0081] In one embodiment, the Fc region is an aglycosylated Fc region comprising glutamine (Q) at position 297 (EU numbering) or 314 (Kabat numbering) of the Fc region.
[0082] In one embodiment, the chimeric Fc region comprises a CH2 domain from an IgG antibody of the IgG4 isotype and a CH3 domain from an IgG antibody of the IgG1 isotype. In some embodiments, the chimeric Fc region comprising a CH2 domain from an IgG antibody of the IgG4 isotype and a CH3 domain from an IgG antibody of the IgG1 isotype further comprises a glutamine (Q) residue instead of a naturally occurring arginine (N) residue at position 297 (EU numbering) and position 314 (Kabat numbering) in the Fc region.
[0083] In one embodiment, the chimeric Fc region comprises a hinge, CH1 and CH2 domains from an IgG antibody of the IgG4 isotype and a CH3 domain from an IgG antibody of the IgG1 isotype, and wherein the antibody comprises proline at amino acid positions 228 (EU numbering) and 241 (Kabat numbering). In some embodiments, the chimeric Fc region comprises a hinge, CH1 and CH2 domains from an IgG antibody of the IgG4 isotype and a CH3 domain from an IgG antibody of the IgG1 isotype, and wherein the antibody comprises proline at amino acid positions 228 (EU numbering) and 241 (Kabat numbering), further comprising glutamine (Q) residues instead of naturally occurring arginine (N) residues at positions 297 (EU numbering) and 314 (Kabat numbering) in the Fc region.
[0084] In one embodiment, the IgG antibody is a human antibody.
[0085] In one embodiment, the aglycosylated Fc region comprises a chimeric hinge domain.
[0086] In one embodiment, the chimeric hinge domain comprises a substitution at amino acid position 228 (EU numbering), 241 (Kabat numbering) with a proline residue.
[0087] In one embodiment, the antibody comprises a VH chain having a sequence of SEQ ID NO: 4, a VL chain having a sequence of SEQ ID NO: 11, a chimeric Fc region comprising a hinge, CH1 and CH2 domains from an IgG antibody of the IgG4 isotype, and a CH3 domain from an IgG antibody of the IgG1 isotype, and wherein the antibody comprises substitutions of glutamine residues (Q) at positions 297 (EU numbering) and 314 (Kabat numbering) in the CH2 region; substitutions of proline residues (P) at amino acid positions 228 (EU numbering) and 241 (Kabat numbering) in the hinge region; and a deletion of lysine (K) at position 447 (EU numbering) (position 478, Kabat numbering) in the CH3 region.
[0088] In one embodiment, the antibody comprises a heavy chain having the sequence of SEQ ID NO:80 and a light chain having the sequence of SEQ ID NO:81.
[0089] In one embodiment, the antibody comprises the heavy chain of SEQ ID NO: 86, ie, IgG4 HP1 / 2H1 heavy chain (wild type; glycosylated).
[0090] In one embodiment, the antibody comprises the heavy chain of SEQ ID NO: 87, ie, IgG4 HP1 / 2 heavy chain S228P (EU numbering) (also referred to as IgG4P; glycosylated).
[0091] In one embodiment, the antibody comprises the heavy chain of SEQ ID NO: 88, ie, IgG4 HP1 / 2H1 heavy chain S228P L235E (EU numbering) (also known as IgG4PE; glycosylated).
[0092] In one embodiment, the antibody comprises the heavy chain of SEQ ID NO: 89, ie, IgG4 HP1 / 2H1 heavy chain S228P T299A (EU numbering) (without the carbohydrate group).
[0093] In one embodiment, the antibody comprises the heavy chain of SEQ ID NO: 90, ie, IgG1 HP1 / 2H1 heavy chain N297Q (EU numbering) (without the carbohydrate group).
[0094] In certain therapeutic antibodies, such as antibodies with IgG4 constant regions, perturbations may produce bispecific monoclonal antibodies that are monovalent to the therapeutic antibody target (e.g., VLA4) and monovalent to another antigen. In one embodiment, the antibody can eliminate perturbations or reduce the susceptibility of the antibody to perturbations, thereby reducing PK / PD variability. In certain embodiments, the antibody can increase the potency of the bivalent monoclonal antibody and eliminate the bispecificity due to perturbations. In certain embodiments, the antibody can exhibit higher binding affinity and / or show higher sustained receptor occupancy than its unmutated counterpart.
[0095] Other features and advantages of the invention will be apparent from the following description and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0096] This patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0097] Figure 1 Three sequence variants of the HP1 / 2 heavy chain (SEQ ID NO: 1) to the human heavy germline IGHV1-f (SEQ ID NO: 2) are shown. Lowercase letters above the sequence indicate insertions according to the Kabat numbering scheme.
[0098] Figure 2Four sequence variants of the HP1 / 2 light chain (SEQ ID NO: 6) to the germline IGKV4-1 antibody sequence (SEQ ID NO: 7) (designs L0-SEQ ID NO: 8, L1-SEQ ID NO: 9, and L2-SEQ ID NO: 10) or the human kappa germline engineered AAH7033.1 antibody sequence (SEQ ID NO: 12) (design L3-SEQ ID NO: 11) are shown. Lowercase letters above the sequence indicate insertions according to the Kabat numbering scheme.
[0099] Figure 3 is a graph depicting the results of ELISA assays.
[0100] Figure 4 is a graph depicting the results of ELISA assays.
[0101] Figure 5
[0014] Figure 1 is the amino acid sequence of IgG4 Fc (hinge + CH2 + CH3 domains) (SEQ ID NO: 14). The hinge region is depicted in bold, and the CH3 domain is underlined. The boxed "S" is Ser228 (EU numbering, i.e., Ser241 in Kabat numbering). The circled "N" is Asn314 in Kabat numbering (Asn297 in EU numbering).
[0102] Figure 6 is a graph depicting flow cytometry data from HuHP1 / 2 binding to various tumor cell lines. "HP1 / 2" refers to humanized HP1 / 2.
[0103] 7A to 7C is a set of graphs depicting the inhibition of HuHP1 / 2 binding of AML cell lines to wells coated with fibronectin or VCAM1-Ig. Figure 7A Depicted are the inhibition of HL60 and KG1 cell binding to FN-coated wells. Figure 7B Depicted is the inhibition of KG1 cell binding to wells coated with VCAM1-Ig. Figure 7C Depicts inhibition of HL60 cell binding to wells coated with FN and VCAM1-Ig when incubated with 20 μg / mL HuHP1 / 2 (solid bars). Open bars indicate the percentage of cell adhesion in the presence of an isotype control. "HP1 / 2" refers to humanized HP1 / 2.
[0104] Figures 8A to 8C A set of graphs depicting the inhibition of HuHP1 / 2 binding of MM cell lines to wells coated with fibronectin or VCAM1-Ig are presented. Figure 8A Depicted are the inhibition of U266 and H929 cell binding to FN-coated wells. Figure 8BDepicted are the inhibition of U266 and H929 cell binding to wells coated with VCAM1-Ig. Figure 8C Depicts inhibition of U266 cell binding to wells coated with FN and VCAM1-Ig when incubated with 20 μg / mL HuHP1 / 2 (solid bars). Open bars indicate the percentage of cell adhesion in the presence of an isotype control. "HP1 / 2" refers to humanized HP1 / 2.
[0105] Figures 9A to 9C A set of graphs depicting the inhibition of HuHP1 / 2 binding of CLL cell lines to wells coated with fibronectin or VCAM1-Ig are presented. Figure 9A Depicted are the inhibition of Mec1 and JM1 cell binding to FN-coated wells. Figure 9B Depicted are the inhibition of Mec1 and JM1 cell binding to wells coated with VCAM1-Ig. Figure 9C Depicts inhibition of Mec1 cell binding to wells coated with FN and VCAM1-Ig when incubated with 20 μg / mL HuHP1 / 2 (filled bars). Open bars indicate the percentage of cell adhesion in the presence of isotype control. "HP1 / 2" refers to humanized HP1 / 2.
[0106] Figure 10 Depicts the structure of a typical antigen-binding polypeptide (IgG antibody) and the functional properties of the antibody's antigen binding and effector functions (e.g., Fc receptor (FcR) binding). Also shown is how the presence of sugars (glycosylation) in the antibody CH2 domain can alter effector functions (FcR binding) without affecting antigen binding.
[0107] 11A to 11D Depicts the two interacting CH3 domains from the IgG1 X-ray crystal structure (pdb code 1hzh) Figure 11A ). IgG1 residues K409 / K440 (EU numbering / Kabat numbering) and D399 / D427 (EU numbering / Kabat numbering) are highlighted. Figure 11B Depicts alignment of human IgG1 / κ constant domain sequences using structure-based HMM (Wang et al., 2009, Proteins 76 :99, 2009.) Residue positions in CL, CH1, and CH3 that participate in interdomain interactions, as well as amino acid positions that have strong covalent interactions with those that directly contact carbohydrates, are highlighted in gray. Kabat and EU numbering are provided below the alignment. Figure 11CRibbon diagram depicting the structure of the IgG1-CH2 domain (Sondermann et al., 406(6793):267-73, 2000). The valine residue buried by N-linked carbohydrates within the CH2 domain and the unique 6-amino acid loop are labeled. Figure 11D Depicts an alignment of the native IgG1-CH2 sequence and the fully modified IgG1-CH2 sequence. Modified residue positions are shown in black. The EU numbering of the modified positions is shown above the alignment.
[0108] FIG. 12A to FIG. 12B Depicts the turbidity of an exemplary IgG Fc construct of the invention after stirring ( Figure 12A ) and monomer content%( Figure 12B ).
[0109] Figure 13 Depicted are the relative peak heights over time for IgG Fc constructs kept at low pH (pH 3.1).
[0110] Figure 14 Depicted are the initial binding rates of exemplary IgG1 and IgG4 Fc constructs of the invention to Fcγ receptors as measured by solution affinity surface plasmon resonance.
[0111] FIG. 15A to FIG. 15B Depicts the calculation of binding of exemplary IgG1 and IgG4 Fc constructs of the invention to CD64 (FcγRI) ( Figure 15A ) and CD16 (FcγRIIIa V158) ( Figure 15B ) titration curve with IC50.
[0112] 16A to 16B Depicts the reduced binding of IgG1 T318K (Kabat numbering) (T299K, EU numbering) to CD64 (FcγRI) compared to IgG1 T318A (Kabat numbering) (T299A, EU numbering) and IgG1 wild type ( Figure 16A ) and exemplary IgG4 Fc constructs incorporating the T318K (Kabat numbering) (T299K, EU numbering) mutation have reduced binding to CD64 (FcγRI) compared to other exemplary IgG4 Fc constructs incorporating the T318A (Kabat numbering) (T299A, EU numbering) mutation and IgG1 wild type ( Figure 16B ) titration curve.
[0113] Figure 17Depicted are binding of an exemplary IgG4 Fc construct incorporating the T299K mutation to CD16 (FcγRIIIa V158) compared to other exemplary IgG4 Fc constructs incorporating the T299A mutation and IgG1 wild type.
[0114] Figure 18 Titration curves used to assess binding of exemplary IgG1 and IgG4 Fc constructs of the invention to complement factor CIq are depicted.
[0115] Figure 19A and Figure 19B Titration curves used to assess binding of various Fc constructs to CD64 and CD16, respectively, are shown. Figure 19C It was shown that the N314Q (Kabat numbering) (N297Q, EU numbering) IgG4-CH2 / IgG1-CH3 and T318A (Kabat numbering) (T299A, EU numbering) antibodies had the same half-life (slightly shorter than aglycosylated IgG1).
[0116] Figure 20A Titration curves for evaluating binding of the T318X (Kabat numbering) (T299X, EU numbering) construct to CD64 are shown, as well as the positively charged side chains T318R (Kabat numbering) (T299R, EU numbering) and T318KA (Kabat numbering) (T299K, EU numbering) conferring low affinity to CD64. Figure 20B Titration curves used to assess CD64 binding to various alternative constructs are shown. Figure 20C and Figure 20D shows the titration curve used to assess the binding of the construct to CD32aR, and Figure 20E and Figure 20F Binding of the constructs to CD16 is shown. Figure 20G and Figure 20H The results of C1q ELISA are shown.
[0117] Figure 21A Titration curves used to assess binding of constructs to CD64 are shown, and Figure 21B Titration curves used to assess binding of constructs to CD16 are shown.
[0118] Figure 22A Includes the nucleotide and amino acid sequences of the HP1 / 2hG4P agly (N297Q, EU numbering) G1κ light chain (H1L3). The nucleotide sequence (showing the DNA corresponding to SEQ ID NO: 91) and amino acids 1-233 of the light chain sequence (SEQ ID NO: 92) are shown. Amino acids 1-19 (and the encoding DNA sequence) shown in bold italics contain the synthetic LC signal peptide. The mature N-terminus begins at amino acid position 20 (S).
[0119] Figure 22B Includes the nucleotide and amino acid sequences of the HP1 / 2hG4P agly (N297Q, EU numbering) G1 heavy chain (H1L3). The nucleotide sequence (DNA is shown and corresponds to SEQ ID NO: 93) and amino acids 1-469 of the heavy chain (SEQ ID NO: 94) are shown. Amino acids 1-22 (DNA sequence shown in italics) contain a recoded synthetic signal peptide. The mature N-terminus begins with amino acid position 23 (E).
[0120] Figure 23A Included is the amino acid sequence comprising the signal sequence (underlined) of the HP1 / 2hG4P agly (N297Q, EU numbering) G1 kappa light chain (H1 L3).
[0121] Figure 23B The amino acid sequence of HP1 / 2hG4P agly (N297Q, EU numbering) G1 kappa light chain (H1 L3) includes the mature light chain of SEQ ID NO:81 and the mature heavy chain of SEQ ID NO:80.
[0122] Figure 24 UV spectra of a protein having a mature light chain of SEQ ID NO:81 (mature light chain of HP1 / 2hG4P agly (N297Q, EU numbering) G1H1L3 ND001) and a mature heavy chain of SEQ ID NO:80 (mature heavy chain of HP1 / 2hG4P agly (N297Q, EU numbering) G1H1L3 ND004 / ND006) are provided.
[0123] Figure 25 The SDS-PAGE results of proteins having a mature light chain of SEQ ID NO: 81 (mature light chain of HP1 / 2hG4P agly (N297Q, EU numbering) G1H1L3 ND001) and a mature heavy chain of SEQ ID NO: 80 (mature heavy chain of HP1 / 2hG4P agly (N297Q, EU numbering) G1H1L3 ND004 / ND006) are shown. Non-reducing conditions are shown in the two lanes on the left (rows 1 and 2), and reducing conditions are shown in the two lanes on the right (rows 3 and 4). Lane 1 is HP1 / 2hG4P agly (N297Q, EU numbering) G1 H1L3 ND001) under non-reducing conditions; lane 2 is a molecular weight marker under non-reducing conditions; lane 3 is HP1 / 2hG4P agly (N297Q, EU numbering) G1 H1L3 ND001) under reducing conditions, and lane 4 is a molecular weight marker under reducing conditions.
[0124] Figure 26 Shown are the IEF results for a protein having the mature light chain of SEQ ID NO: 81 (mature light chain of HP1 / 2hG4P agly (N297Q, EU numbering) G1 H1 L3 ND001) and the mature heavy chain of SEQ ID NO: 80 (mature heavy chain of HP1 / 2hG4P agly (N297Q, EU numbering) G1 H1 L3 ND004 / ND006).
[0125] Figure 27 Shown are the results of analytical size exclusion chromatography of a protein having a mature light chain of SEQ ID NO: 81 (mature light chain of HP1 / 2hG4P agly (N297Q, EU numbering) G1 H1 L3 ND001) and a mature heavy chain of SEQ ID NO: 80 (mature heavy chain of HP1 / 2hG4P agly (N297Q, EU numbering) G1 H1 L3 ND004 / ND006).
[0126] Figures 28 to 30 The DSC results of the protein having the mature light chain of SEQ ID NO: 81 (mature light chain of HP1 / 2hG4Pagly (N297Q, EU numbering) G1 H1L3 ND001) and the mature heavy chain of SEQ ID NO: 80 (mature heavy chain of HP1 / 2hG4Pagly (N297Q, EU numbering) G1 H1L3 ND004 / ND006) are shown. The melting curves of the HP1 / 2hG4Pagly (N297Q, EU numbering) G1H1L3 intact antibody, Fc and Fab2 fragments are shown in FIG. Figure 28 、 Figure 29 and Figure 30 middle.
[0127] Figure 31The results of SDS-PAGE analysis of HP1 / 2 samples under non-reducing conditions are shown. Each sample was loaded at 6 and 3 μg / lane. Molecular weight markers are shown on the left side of the figure. SDS-PAGE was performed on a 4-20% polyacrylamide gradient gel from Invitrogen and the gel was stained with Simply Blue stain (Invitrogen) and destained with distilled water. Lane 1 is 6ug / lane of HP1 / 2hG4P agly (N297Q, EU numbering) G1 H1L3; lane 2 is 6ug / lane of HP1 / 2hG4P agly (T299A); lane 3 is 6ug / lane of natalizumab G4P agly; lane 4 is 6ug / lane of natalizumab G4P; lane 5 is 3ug / lane of HP1 / 2hG4P agly (N297Q, EU numbering) G1 H1L3; lane 6 is 3ug / lane of HP1 / 2hG4P agly (T299A); lane 7 is 3ug / lane of natalizumab G4P agly; lane 8 is 3ug / lane of natalizumab G4P.
[0128] Figure 32A The results of SEC analysis of the HP1 / 2 sample are shown. The sample was run on a Superdex Increase 5 / 150 GL column (GE 28-9909-45) at a flow rate of 0.2 ml / min in PBS (10 mM sodium phosphate, 0.15 M NaCl, pH 7.5).
[0129] Figure 32B SEC analysis results for HP1 / 2hG4P agly (N297Q, EU numbering) G1 H1L3, HP1 / 2hG4P agly (T299A), natalizumab G4P agly, and natalizumab G4P are shown. Samples were run on a Superdex 200Increase 5 / 150GL column (GE 28-9909-45) at a flow rate of 0.2 ml / min in PBS (10 mM sodium phosphate, 0.15 M NaCl, pH 7.5).
[0130] Figure 33a and Figure 33b The DSC results of humanized HP1 / 2H1 / L3 huIgG4P agly (N297Q, EU numbering) / IgG1 chimera (GP1 / 2GrP agly / G1) and humanized HP1 / 2G1 / L3 huIgG4P agly (T299A, EU numbering) (HP1 / 2hG4P) are shown, respectively.
[0131] Figure 34is a line graph showing the pharmacokinetic time course in cynomolgus monkeys following single intravenous bolus administration of 3 mg / kg HP1 / 2H1 / L3 huIgG4Pagly (N297Q, EU numbering) / IgG1 chimera (GP1 / 2GrPagly / G1) (referred to as HP12 in the figure; open circles), 30 mg / kg HP12 (filled circles), and 3 mg / kg natalizumab (Tysabri, closed triangles).
[0132] Figure 35 is a line graph showing the free receptor time course in cynomolgus monkeys following a single intravenous bolus administration of 3 mg / kg HP1 / 2H1 / L3 huIgG4Pagly (N297Q, EU numbering) / IgG1 chimera (GP1 / 2GrPagly / G1) (referred to in the figure as HP12; open circles), 30 mg / kg HP12 (closed circles), and 3 mg / kg natalizumab (Tysabri, closed triangles).
[0133] Figure 36 is a bar graph showing the expression levels of CD49 (α4 integrin) in humans (Human 1 and Human 2) and cynomolgus monkeys (Cynomolgus 1 and Cynomolgus 2).
[0134] Figures 37A to 37D are line graphs showing the predicted receptor occupancy time course following single intravenous administration of natalizumab (red line) and HP1 / 2 (black line) at the indicated doses.
[0135] Figure 38 Graphs are provided depicting the predicted receptor occupancy at Cmax following administration of specific doses of HP1 / 2 (referred to in the graph as HP12, open circles) and natalizumab (closed triangles). DETAILED DESCRIPTION
[0136] Antibodies against VLA-4 have been shown to be useful in treating diseases. For example, the anti-VLA-4 antibody natalizumab ( ) for the treatment of relapsing forms of multiple sclerosis and Crohn's disease. However, for certain conditions, such as the treatment of acute conditions such as spinal cord injury (SCI) or traumatic brain injury (TBI), or treatments that require a limited number of administrations, such as the treatment of cancer, it may be appropriate to treat with an anti-VLA-4 antibody that binds with a different affinity than that of natalizumab, such as higher affinity binding and / or has a different pharmacological profile (e.g., with lower in vivo pharmacokinetic / pharmacodynamic variability). These antibodies may also be used to treat conditions such as multiple sclerosis, as less frequent treatment may be required or administration by means other than infusion may be more effective. The ability to treat with lower doses may also reduce the risk of adverse events such as PML. Therefore, the present invention provides antibodies with these desirable properties.
[0137] Certain antibodies of the invention disclosed herein have exhibited the unexpected characteristic of newly designed humanized α4-binding antibodies, with binding affinities for α4 that are 10-fold higher than the binding affinity of the anti-α4 antibody natalizumab.
[0138] The antibodies also have a stabilized Fc region with reduced effector function, for example, by including one or more stabilizing amino acids in the Fc region of the Fc polypeptide. In some embodiments, the stabilizing amino acids stabilize the Fc region of the polypeptide without affecting the glycosylation and / or effector function of the polypeptide, and without significantly altering other desired functions of the polypeptide (e.g., antigen binding affinity or half-life).
[0139] In order to provide a clear understanding of the present specification and claims, the following definitions are conveniently provided below.
[0140] definition
[0141] As used herein, the term "effector function" refers to the functional ability of the Fc region or its portion to bind to proteins and / or cells of the immune system and mediate various biological effects. Effector function may be antigen-dependent or antigen-independent. Reduction of effector function refers to reducing one or more effector functions while maintaining the antigen-binding activity of the variable region of the antibody (or its fragment). An increase or decrease in effector function (e.g., Fc binding to Fc receptors or complement proteins) can be expressed as a change factor (e.g., a change of 1-fold, 2-fold, etc.) and can be calculated based on, for example, a percentage change in binding activity determined using an assay well known in the art. As used herein, the term "antigen-dependent effector function" refers to an effector function induced under normal circumstances after an antibody binds to the corresponding antigen. Typical antigen-dependent effector functions include the ability to bind to complement proteins (e.g., C1q). For example, the binding of the complement C1 component to the Fc region can activate the classical complement system, thereby opsonizing and lysing cellular pathogens, a process known as complement-dependent cytotoxicity (CDCC). Complement activation also stimulates inflammatory responses and may also be involved in autoimmune hypersensitivity reactions.
[0142] Other antigen-dependent effector functions are mediated by the binding of antibodies to certain Fc receptors ("FcRs") on cells via their Fc regions. There are many Fc receptors specific for different classes of antibodies, including IgG (gamma receptors or IgγR), IgE (epsilon receptors or IgεR), IgA (alpha receptors or IgαR), and IgM (mu receptors or IgμR). Antibody binding to Fc receptors on the cell surface triggers many important and diverse biological responses, including endocytosis of immune complexes, phagocytosis and destruction of antibody-coated particles or microorganisms (also known as antibody-dependent phagocytosis or ADCP), clearance of immune complexes, lysis of antibody-coated target cells by killer cells (called antibody-dependent cellular cytotoxicity or ADCC), release of inflammatory mediators, regulation of immune system cell activation, placental transfer, and control of immunoglobulin production. Certain Fc receptors, Fcγ receptors (FcγRs), play a key role in abrogating or enhancing immune recruitment. FcγRs are expressed on leukocytes and consist of three distinct classes: FcγRI, FcγRII, and FcγRIII (Gessner et al., Ann. Hematol., (1998), 76:231-48). Structurally, FcγRs are all members of the immunoglobulin superfamily that have an IgG-binding α chain and an extracellular portion composed of two or three Ig-like domains. Human FcγRI (CD64) is expressed on human monocytes and exhibits high affinity binding (Ka = 10 8 -10 9 M -1 ) to monomeric IgG1, IgG3, and IgG4. Human FcγRII (CD32) and FcγRIII (CD16) are specific for IgG1 and IgG3 (Ka < 10 7 M -1 ) has low affinity and can only bind to complex or aggregated forms of these IgG isotypes. In addition, the FcγRII and FcγRIII classes include "A" and "B" forms. FcγRIIa (CD32a) and FcγRIIIa (CD16a) bind to the surface of macrophages, NK cells, and some T cells via transmembrane domains, while FcγRIIb (CD32b) and FcγRIIIb (CD16b) selectively bind to the cell surface of granulocytes (e.g., neutrophils) via a phosphatidylinositol glycan (GPI) anchor. The individual murine homologs of human FcγRI, FcγRII, and FcγRIII are FcγRIIa, FcγRIIb / 1, and FcγR1o.
[0143] As used herein, the term "antigen-independent effector function" refers to an effector function that can be induced by an antibody (whether or not it has bound its corresponding antigen). Typical antigen-independent effector functions include cellular transport, circulation half-life and immunoglobulin clearance, as well as facilitating purification. The structurally unique Fc receptor "neonatal Fc receptor" or "FcRn", also known as the salvage receptor, plays a key role in regulating half-life and cellular transport. Other Fc receptors purified from microbial cells (e.g., Staphylococcal protein A or G) are able to bind to the Fc region with high affinity and can be used to facilitate the purification of Fc-containing polypeptides.
[0144] Unlike FcγRs, which belong to the immunoglobulin superfamily, human FcRn is structurally similar to polypeptides of the class I major histocompatibility complex (MHC) (Ghetie and Ward, Immunology Today, (1997), 18(12):592-8). FcRn is typically expressed as a heterodimer consisting of a complex of a transmembrane α or heavy chain and a soluble β or light chain (β2 microglobulin). FcRn shares 22-29% sequence identity with class I MHC molecules and possesses a non-functional version of the MHC peptide-binding groove (Simister and Mostov, Nature, (1989), 337:184-7). Like MHC, the α chain of FcRn consists of three extracellular domains (α1, α2, α3), and a short cytoplasmic tail anchors the protein to the cell surface. The α1 and α2 domains interact with the FcR binding site in the Fc region of antibodies (Raghavan et al., Immunity, (1994), 1:303-15). FcRn is expressed in the maternal placenta or yolk sac of mammals and is involved in the transfer of IgG from the mother to the fetus. FcRn is also expressed in the small intestine of rodent neonates, where it is involved in the transfer of maternal IgG from ingested colostrum or milk to the brush border epithelium. FcRn is also expressed in many other tissues of numerous species and in various endothelial cell lines. It is also expressed in human adult vascular endothelium, muscle vessels, and liver sinusoids. It is believed that FcRn plays an additional role in maintaining its circulation half-life or serum levels by binding to IgG and recycling it to the serum. FcRn binding to IgG molecules is strictly pH-dependent, with optimal binding at a pH of less than 7.0.
[0145] As used herein, the term "half-life" refers to the in vivo biological half-life of a specific binding polypeptide. Half-life can be represented by the time required for half of the amount administered to a subject to be cleared from the animal's circulation and / or other tissues. When a clearance curve for a given binding polypeptide is constructed as a function of time, the curve is typically biphasic, with a rapid α phase and a longer β phase. The α phase typically indicates that the administered Fc polypeptide reaches equilibrium between the intravascular space and the extravascular space and is determined in part by the size of the polypeptide. The β phase typically indicates that the binding polypeptide is catabolized in the intravascular space. Therefore, in a non-limiting embodiment, the term half-life as used herein refers to the half-life of the binding polypeptide in the β phase. The typical β phase half-life of human antibodies in humans is 21 days. As used herein, the term "polypeptide" refers to a polymer of two or more natural amino acids or non-natural amino acids. The term "Fc polypeptide" refers to a polypeptide comprising an Fc region or a portion thereof (e.g., an Fc portion). In some embodiments, the Fc polypeptide is stabilized according to the methods of the present invention. In optional embodiments, the Fc polypeptide further comprises a binding site operably linked or fused to the Fc region (or portion thereof) of the Fc polypeptide.
[0146] As used herein, the term "protein" refers to a polypeptide (e.g., an Fc polypeptide) or a composition comprising more than one polypeptide. Thus, a protein may be a monomer (e.g., a single Fc polypeptide) or a multimer. For example, in one embodiment, the protein of the present invention is a dimer. In one embodiment, the dimer of the present invention is a homodimer, comprising two identical monomer subunits or polypeptides (e.g., two identical Fc polypeptides). In another embodiment, the dimer of the present invention is a heterodimer, comprising two non-identical monomer subunits or polypeptides (e.g., two non-identical Fc polypeptides or one Fc polypeptide and a second polypeptide other than an Fc polypeptide). The subunits of the dimer may comprise one or more polypeptide chains, wherein at least one of the polypeptide chains is an Fc polypeptide. For example, in one embodiment, the dimer comprises at least two polypeptide chains (e.g., at least two Fc polypeptide chains). In one embodiment, the dimer comprises two polypeptide chains, wherein one or both of the chains are Fc polypeptide chains. In another embodiment, the dimer comprises three polypeptide chains, wherein one, two, or all of the polypeptide chains are Fc polypeptide chains. In another embodiment, the dimer comprises four polypeptide chains, wherein one, two, three or all of the polypeptide chains are Fc polypeptide chains.
[0147] As used herein, the terms "connected", "fused" or "fusion" are used interchangeably. These terms refer to joining two or more elements or components together by any means, including chemical conjugation or recombinant means. Chemical conjugation methods (e.g., using heterobifunctional cross-linking agents) are known in the art. As used herein, the term "gene fusion" or "gene fusion" refers to two or more proteins, polypeptides, or fragments thereof being colinear, covalently linked, or attached via their individual peptide backbones through the gene expression of a single polynucleotide molecule encoding those proteins, polypeptides, or fragments. This gene fusion results in the expression of a single continuous gene sequence. In some embodiments, the gene fusion is in frame, that is, two or more open reading frames (ORFs) are fused to form a longer continuous ORF in a manner that maintains the correct reading frame of the original ORF. Therefore, the resulting recombinant fusion protein is a single polypeptide containing two or more protein segments corresponding to the polypeptides encoded by the original ORFs (the segments are not normally so joined in nature). Although the reading frame is thus continuous throughout the fused gene segment, the protein segments may be physically or spatially separated by, for example, in-frame polypeptide linkers.
[0148] As used herein, the term "Fc region" should be defined as the immunoglobulin portion formed by two or more antibody heavy chain Fc portions. In certain embodiments, the Fc region is a dimeric Fc region. A "dimeric Fc region" or "dcFc" refers to a dimer formed by the Fc portions of two separate immunoglobulin heavy chains. The dimeric Fc region can be a homodimer of two identical Fc portions (e.g., the Fc region of a naturally occurring immunoglobulin) or a heterodimer of two non-identical Fc portions. In other embodiments, the Fc region is a monomer or "single-chain" Fc region (i.e., scFc region). A single-chain Fc region consists of an Fc portion genetically linked to a single polypeptide chain (i.e., encoded in a single continuous gene sequence). Exemplary scFc regions are disclosed in PCT application No. PCT / US2008 / 006260, filed May 14, 2008, which is incorporated herein by reference.
[0149] As used herein, the term "Fc portion" refers to a sequence derived from the portion of the immunoglobulin heavy chain that starts at the hinge region just upstream of the papain cleavage site (i.e., residue 226 (Kabat numbering) / residue 216 (EU numbering) in IgG when the first residue of the heavy chain constant region is considered to be 114) and ends at the C-terminus of the immunoglobulin heavy chain. Thus, the Fc portion may be a complete Fc portion or a portion thereof (e.g., a domain). A complete Fc portion comprises at least a hinge domain, a CH2 domain, and a CH3 domain (i.e., Kabat amino acid positions 226-477; EU amino acid positions 216-446). Additional lysine residues (K) are sometimes present at the extreme C-terminus of the Fc portion, but are typically cleaved from mature antibodies. Unless otherwise specified, each amino acid position within the Fc region has been numbered according to the industry-recognized EU numbering system. In certain embodiments, the Fc portion comprises at least one of the following: a hinge (e.g., an upper hinge region, a middle hinge region, and / or a lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant, portion, or fragment thereof. In some embodiments, the Fc portion comprises at least a CH2 domain or a CH3 domain. In certain embodiments, the Fc portion is a complete Fc portion. In other embodiments, the Fc portion comprises one or more amino acid insertions, deletions, or substitutions relative to a naturally occurring Fc portion. For example, at least one of the hinge domain, the CH2 domain, or the CH3 domain (or a portion thereof) may be deleted. For example, the Fc portion may comprise or consist of: (i) a hinge domain (or a portion thereof) fused to a CH2 domain (or a portion thereof); (ii) a hinge domain (or a portion thereof) fused to a CH3 domain (or a portion thereof); (iii) a CH2 domain (or a portion thereof) fused to a CH3 domain (or a portion thereof); (iv) a CH2 domain (or a portion thereof); and (v) a CH3 domain or a portion thereof.
[0150] It should be noted that the amino acid residues in antibodies have their own numbering scheme. The publication Kabat et al. Sequences of Proteins of Immunological Interest , 5th edition, volume 4, 1991, US Department of Health and Human Services, NIH, USA set forth a numbering scheme sometimes referred to as EU index numbering, as in Kabat et al. However, over time, a new numbering system has emerged, referred to as Kabat numbering.
[0151] In one non-limiting example, the following table sets forth a comparison of EU numbering and Kabat numbering for the heavy chain CH1, CH2, and CH3 domains of human IgG1. Note that the sequence of the human IgG1 constant region is provided in SEQ ID NO: 83.
[0152]
[0153]
[0154]
[0155]
[0156] Note that the amino acid residues in the above table are naturally occurring or typical amino acid residues in human IgG1. Thus, the typical residue at position 297 (EU numbering) (which is position 314 in Kabat numbering) is asparagine (N). Any change in an amino acid residue relative to a typical residue will be referred to as a substitution or mutation.
[0157] Note that due to the similarity of human IgG molecules (e.g., IgG1, IgG2, IgG3, IgG4), the constant regions of all IgG molecules begin with an alanine residue at position 118 (EU numbering) (position 114, Kabat numbering) and end with a C-terminal lysine residue at position 447 (EU numbering) (position 478, Kabat numbering).
[0158] The table below shows the correlation between EU and Kabat numbering in the hinge of human IgG1 starting with the glutamic acid residue at position 216 in EU numbering (226 in Kabat numbering).
[0159]
[0160] The table below shows the correlation between EU and Kabat numbering in the human IgG4 hinge starting with the glutamic acid residue at position 216 in EU numbering (226 in Kabat numbering).
[0161]
[0162] In some embodiments, when a substitution is mentioned herein in a naturally occurring IgG1 or IgG4, the EU or Kabat numbering indicating the substitution will refer to the numbering of the naturally occurring parent molecule (or a domain thereof). For example, if the serine at position 228 in the IgG4 hinge is mutated to, for example, proline, the mutation would be denoted S228P in EU numbering and S241P in Kabat numbering.
[0163] The full-length sequence of a naturally occurring human IgGl heavy chain is thus provided as SEQ ID NO: 83 starting with the canonical alanine residue at position 118 (EU numbering), ie, position 114 (Kabat numbering).
[0164] The full-length sequence of a naturally occurring human IgGl heavy chain is thus provided as SEQ ID NO: 84 starting with the canonical alanine residue at position 118 (EU numbering), ie, position 114 (Kabat numbering).
[0165] As described herein, it will be understood by those of ordinary skill in the art that the Fc portion can be modified so that it differs in amino acid sequence from the intact Fc portion of a naturally occurring immunoglobulin molecule while retaining at least one of the desirable functions conferred by the naturally occurring Fc portion. For example, the Fc portion may comprise or consist of at least a portion of the Fc portion known in the art to be required for FcRn binding or half-life extension. In another embodiment, the Fc portion comprises at least a portion known in the art to be required for FcγR binding. In one embodiment, the Fc region of the present invention comprises at least a portion known in the art to be required for protein A binding. In one embodiment, the Fc portion of the present invention comprises at least a portion of an Fc molecule known in the art to be required for protein G binding. In certain embodiments, the Fc portions of the Fc region are of the same isotype.
[0166] For example, the Fc portion may be derived from an immunoglobulin (e.g., a human immunoglobulin) of the IgG1 or IgG4 isotype. However, the Fc region (or one or more Fc portions of the Fc region) may also be chimeric. A chimeric Fc region may comprise Fc portions derived from different immunoglobulin isotypes. In certain embodiments, at least two of the Fc portions of a dimeric or single-chain Fc region may be derived from different immunoglobulin isotypes. In additional or alternative embodiments, a chimeric Fc region may comprise one or more chimeric Fc portions. For example, a chimeric Fc region or portion may comprise one or more portions derived from an immunoglobulin of a first isotype (e.g., an IgG1, IgG2, or IgG3 isotype), while the remaining Fc regions or portions belong to different isotypes. For example, the Fc region or portion of an Fc polypeptide may comprise a CH2 and / or CH3 domain derived from an immunoglobulin of a first isotype (e.g., an IgG1, IgG2, or IgG4 isotype) and a hinge region derived from an immunoglobulin of a second isotype (e.g., an IgG3 isotype). In another embodiment, the Fc region or portion comprises a hinge and / or CH2 domain derived from an immunoglobulin of a first isotype (e.g., IgG4 isotype) and a CH3 domain derived from an immunoglobulin of a second isotype (e.g., IgG1, IgG2, or IgG3 isotype). In another embodiment, the chimeric Fc region comprises an Fc portion (e.g., a complete Fc portion) from an immunoglobulin of a first isotype (e.g., IgG4 isotype) and an Fc portion from an immunoglobulin of a second isotype (e.g., IgG1, IgG2, or IgG3 isotype). In an exemplary embodiment, the Fc region or portion comprises a CH2 domain from an IgG4 immunoglobulin and a CH3 domain from an IgG1 immunoglobulin. In another embodiment, the Fc region or portion comprises a CH1 domain and a CH2 domain from an IgG4 molecule and a CH3 domain from an IgG1 molecule. In another embodiment, the Fc region or portion comprises a portion of the CH2 domain of a specific antibody isotype, such as Kabat positions 309-360, EU positions 292-340 of the CH2 domain. For example, in one embodiment, the Fc region or portion comprises amino acids 292-340 (EU numbering), 309-360 (Kabat numbering) of CH2 derived from the IgG4 portion and the remainder of CH2 derived from the IgG1 portion (alternatively, 292-340 (EU numbering), 309-360 (Kabat numbering) of CH2 can be derived from the IgG1 portion and the remainder of CH2 derived from the IgG4 portion).
[0167] In other embodiments, the Fc region or portion may comprise a chimeric hinge region. The chimeric hinge may be partially derived from IgG1, IgG2 or IgG4 molecules (e.g., upper middle hinge sequence and lower middle hinge sequence) and partially derived from IgG3 molecules (e.g., middle hinge sequence). In another example, the Fc region or portion may comprise a chimeric hinge that is partially derived from an IgG1 molecule and partially derived from an IgG4 molecule. In a specific embodiment, the chimeric hinge may comprise an upper hinge domain and a lower hinge domain from an IgG4 molecule and a middle hinge domain from an IgG1 molecule. This chimeric hinge can be prepared by introducing a proline substitution (Ser228Pro (EU numbering) at position 228 and at position 241 of the Kabat sequence in the middle hinge domain of the IgG4 hinge region; Ser241Pro (Kabat numbering)) in the middle hinge domain of the IgG4 hinge region. In another embodiment, the chimeric hinge may comprise amino acids from an IgG2 antibody and / or Ser228Pro (EU numbering), Ser241Pro (Kabat numbering) mutations at Kabat positions 246-249, with the remaining amino acids of the hinge being from IgG4 (e.g., a chimeric hinge of the sequence ESKYGPPCPPCPAPPVAGP). Other chimeric hinges are described in U.S. Patent Application No. 10 / 880,320, which is incorporated herein by reference in its entirety.
[0168] "Aglycosylated Fc region" is specifically included within the definition of "Fc region". As used herein, an "aglycosylated Fc region" is an Fc region that lacks covalently attached oligosaccharides or polysaccharides at the N-glycosylation site at EU position 297, Kabat position 314, in one or more Fc portions thereof. In certain embodiments, the aglycosylated Fc region is completely aglycosylated, i.e., all Fc portions thereof lack carbohydrates. In other embodiments, the aglycosylation is partially aglycosylated (i.e., hemiglycosylated). The aglycosylated Fc region may be a deglycosylated Fc region, i.e., an Fc region from which Fc carbohydrates have been removed, for example, by chemical or enzymatic means. Alternatively, the aglycosylated Fc region may be non-glycosylated or unglycosylated, i.e., an antibody expressed without Fc carbohydrates, for example, by mutating one or more residues encoding the glycosylation pattern at N-glycosylation sites such as EU positions 297 or 299, Kabat positions 314 or 318 (e.g., Asn-X-Ser or Asn-X-Thr), by expression in organisms that do not naturally attach carbohydrates to proteins (e.g., bacteria), or by expression in host cells or organisms that have been rendered deficient in their glycosylation machinery by genetic manipulation or by the addition of glycosylation inhibitors (e.g., glycosyltransferase inhibitors). In alternative embodiments, the Fc region is a "glycosylated Fc region," i.e., it is fully glycosylated at all available glycosylation sites.
[0169] The term "parent Fc polypeptide" includes polypeptides (e.g., IgG antibodies) containing an Fc region that needs to be stabilized. In some embodiments, the parent Fc polypeptide is an effector-free Fc polypeptide. Stabilized Fc polypeptides with reduced effector function have been described (see, e.g., PCT Publication No. WO2010 / 085682, which is incorporated herein by reference in its entirety). Thus, the parent Fc polypeptide represents the original Fc polypeptide to which the method of the present invention is applied or which can be used as a reference point for stability comparison. The parent polypeptide may comprise a native (i.e., naturally occurring) Fc region or portion (e.g., a human IgG4 Fc region or portion) or an Fc region having a pre-existing amino acid sequence modification (e.g., insertion, deletion, and / or other changes) of a naturally occurring sequence but lacking one or more stabilizing amino acids.
[0170] The term "mutation" or "mutating" is understood to include physically making mutations in a parent Fc polypeptide (e.g., by changing (e.g., by site-directed mutagenesis) a codon encoding one amino acid in a nucleic acid molecule to produce a codon encoding a different amino acid) or synthesizing a variant Fc region having an amino acid not found in the parent Fc region (e.g., by knowing the nucleotide sequence of a nucleic acid molecule encoding a parent Fc region and by designing a nucleic acid molecule comprising a nucleotide sequence encoding a variant parent Fc region without the need to mutate one or more nucleotides of a nucleic acid molecule encoding a stabilized polypeptide of the invention).
[0171] In an exemplary embodiment, the parent Fc polypeptide comprises an Fc region from an effector-free Fc polypeptide. As used herein, the term "effector-free Fc polypeptide" refers to an Fc polypeptide having altered or reduced effector function compared to a wild-type, aglycosylated antibody of the IgG1 isotype. In some embodiments, the reduced or altered effector function is an antibody-dependent effector function, such as ADCC and / or ADCP. In one embodiment, the effector-free Fc polypeptide has reduced effector function due to modification or reduction of glycosylation in the Fc region of the Fc polypeptide, such as an aglycosylated Fc region. In another embodiment, the effector-free Fc polypeptide has reduced effector function due to incorporation into an IgG4 Fc region or portion thereof (e.g., the CH2 and / or CH3 domains of an IgG4 antibody).
[0172] The term "variant Fc polypeptide" or "Fc variant" includes Fc polypeptides derived from a parent Fc polypeptide. An Fc variant differs from a parent Fc polypeptide in that it comprises one or more stabilizing amino acid residues, for example, due to the introduction of at least one Fc stabilizing mutation. In certain embodiments, the Fc variant of the present invention comprises an Fc region (or Fc portion) that is identical in sequence to the sequence of the parent polypeptide but with the presence of one or more stabilizing Fc amino acids. In some embodiments, the Fc variant will have enhanced stability compared to the parent Fc polypeptide and, optionally, equivalent or reduced effector function compared to the parent Fc polypeptide.
[0173] A polypeptide or amino acid sequence "derived from" a specified polypeptide or protein refers to the source of the polypeptide. In some embodiments, a polypeptide or amino acid sequence derived from a specified sequence has an amino acid sequence that is substantially identical to the sequence or a portion thereof (wherein the portion consists of at least 10-20 amino acids, or at least 20-30 amino acids, or at least 30-50 amino acids) or can be identified by one of ordinary skill in the art as having the amino acid sequence of its origin in the sequence. In the context of polypeptides, a "linear sequence" or "sequence" is the order of amino acids in a polypeptide in the amino to carboxyl terminal direction, wherein adjacent residues in the sequence are contiguous in the primary structure of the polypeptide. A polypeptide (e.g., a variant Fc polypeptide) derived from another polypeptide (e.g., a parent Fc polypeptide) can have one or more mutations relative to the starting or parent polypeptide, e.g., one or more amino acid residues have been substituted with another amino acid residue or have one or more amino acid residues inserted or deleted. In some embodiments, the polypeptide comprises a non-naturally occurring amino acid sequence. These variants must have less than 100% sequence identity or similarity to the starting polypeptide. In one non-limiting embodiment, the variant will have about 75% to less than 100% amino acid sequence identity or similarity, or about 80% to less than 100%, or about 85% to less than 100%, or about 90% to less than 100% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) or about 95% to less than 100% with the amino acid sequence of the starting polypeptide, for example, over the entire length of the variant molecule or a portion thereof (e.g., Fc region or Fc portion). In one embodiment, there is one amino acid difference between the starting polypeptide sequence (e.g., the Fc region of a parent Fc polypeptide) and the sequence derived therefrom (e.g., the Fc region of a variant Fc polypeptide). In other embodiments, there are two to ten amino acid differences (e.g., about 2-20, about 2-15, about 2-10, about 5-20, about 5-15, about 5-10 amino acid differences) between the starting polypeptide sequence and the variant polypeptide. For example, there may be less than about 10 amino acid differences (e.g., two, three, four, five, six, seven, eight, nine, or ten amino acid differences). Identity or similarity with respect to such sequences is defined herein as the percentage of amino acid residues in the candidate sequence that are identical (i.e., identical residues) to the starting amino acid residues, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.
[0174] The Fc polypeptides of the present invention may comprise an amino acid sequence (e.g., at least one Fc region or Fc portion) derived from a human immunoglobulin sequence (e.g., an Fc region or Fc portion from a human IgG molecule). However, the polypeptide may comprise one or more amino acids from another mammalian species. For example, a primate Fc portion or primate binding site may be included in the subject polypeptide. Alternatively, one or more murine amino acids may be present in the Fc polypeptide. In some embodiments, the Fc polypeptides of the present invention are non-immunogenic.
[0175] It will also be understood by those of ordinary skill in the art that the Fc polypeptides of the present invention can be altered so that they differ in amino acid sequence from the parent polypeptide from which they are derived while retaining one or more desired activities of the parent polypeptide (e.g., reduced effector function). In a specific embodiment, nucleotide or amino acid substitutions are made to stabilize the Fc polypeptide. In one embodiment, an isolated nucleic acid molecule encoding an Fc variant can be produced by introducing one or more nucleotide substitutions, additions, or deletions into the nucleotide sequence of the parent Fc polypeptide, thereby introducing one or more amino acid substitutions, additions, or deletions into the encoded protein. Mutations (e.g., stabilizing mutations) can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis.
[0176] As used herein, the term "protein stability" refers to an industry-recognized measure of one or more physical properties of a protein maintained in response to environmental conditions (e.g., increased or decreased temperature). In one embodiment, the physical property is the maintenance of the covalent structure of the protein (e.g., the absence of proteolytic cleavage, unwanted oxidation, or deamidation). In another embodiment, the physical property is the presence of a protein in a properly folded state (e.g., the absence of soluble or insoluble aggregates or precipitates). In one embodiment, the stability of a protein is measured by measuring the biophysical properties of the protein, such as thermal stability, pH unfolding profile, stable removal of glycosylation, solubility, biochemical function (e.g., the ability to bind to a protein (e.g., a ligand, receptor, antigen, etc.) or a chemical moiety, etc.) and / or a combination thereof. In another embodiment, the biochemical function is confirmed by the binding affinity of the interaction. In one embodiment, a measure of protein stability is thermal stability, i.e., resistance to thermal attack. Stability can be measured using methods known in the art and / or described herein. For example, "Tm," also referred to as "transition temperature," can be measured. The Tm is the temperature at which 50% of macromolecules (eg, binding molecules) are denatured and is considered a standard parameter describing the thermal stability of proteins.
[0177] The term "amino acid" includes alanine (Ala or A); arginine (Arg or R); asparagine (Asn or N); aspartic acid (Asp or D); cysteine (Cys or C); glutamine (Gln or Q); glutamic acid (Glu or E); glycine (Gly or G); histidine (His or H); isoleucine (Ile or I); leucine (Leu or L); lysine (Lys or K); methionine (Met or M); phenylalanine (Phe or F); proline (Pro or P); serine (Ser or S); threonine (Thr or T); tryptophan (Trp or W); tyrosine (Tyr or Y); and valine (Val or V). Non-traditional amino acids are also within the scope of the present invention and include norleucine, ornithine, norvaline, homoserine and other amino acid residue analogs, such as those described in Ellman et al., Meth. Enzym. 202: 301-336 (1991). To produce these non-naturally occurring amino acid residues, the procedures of Noren et al., Science 244: 182 (1989) and Ellman et al., supra, can be used. In brief, these procedures involve chemically activating suppressor tRNA with non-naturally occurring amino acid residues, followed by in vitro transcription and translation of RNA. The introduction of non-traditional amino acids can also be achieved using peptide chemistry reactions known in the art. As used herein, the term "polar amino acid" includes amino acids having a net zero charge but having non-zero partial charges in different parts of their side chains (e.g., M, F, W, S, Y, N, Q, C). These amino acids can participate in hydrophobic interactions and electrostatic interactions. As used herein, the term "charged amino acid" includes amino acids that may have a non-zero net charge on their side chains (e.g., R, K, H, E, D). These amino acids may participate in hydrophobic interactions and electrostatic interactions. As used herein, the term "amino acid with sufficient steric bulk" includes those amino acids with side chains that occupy a large 3-dimensional space. Exemplary amino acids with side chain chemistries that have sufficient steric bulk include tyrosine, tryptophan, arginine, lysine, histidine, glutamic acid, glutamine, and methionine, or analogs or mimetics thereof.
[0178] "Amino acid substitution" refers to replacing at least one existing amino acid residue in a predetermined amino acid sequence (the amino acid sequence of the starting polypeptide) with a second different "replacement" amino acid residue. "Amino acid insertion" refers to the incorporation of at least one additional amino acid into a predetermined amino acid sequence. Although insertion will generally consist of the insertion of one or two amino acid residues, larger "peptide insertions" of the present invention can be performed, such as insertions of about three to about five or even up to about ten, fifteen or twenty amino acid residues. The inserted residues may be naturally occurring or non-naturally occurring, as disclosed above. "Amino acid deletion" refers to removing at least one amino acid residue from a predetermined amino acid sequence. As described above, these terms include actual changes to existing physical nucleic acid molecules or changes made to existing nucleic acid sequences during the design process (e.g., on paper or on a computer). In certain embodiments, the polypeptide of the present invention is a binding polypeptide. As used herein, the term "binding polypeptide" (e.g., binding antibody) refers to a polypeptide (e.g., Fc polypeptide) comprising at least one target binding site or binding domain that specifically binds to an indicated target molecule (e.g., an antigen or binding partner). For example, in one embodiment, the binding polypeptide of the present invention comprises an immunoglobulin antigen binding site or a portion of a receptor molecule responsible for ligand binding or a portion of a ligand molecule responsible for receptor binding. The binding polypeptide of the present invention comprises at least one binding site. In one embodiment, the binding polypeptide of the present invention comprises at least two binding sites. In one embodiment, the binding polypeptide comprises two binding sites. In another embodiment, the binding polypeptide comprises three binding sites. In another embodiment, the binding polypeptide comprises four binding sites. In one embodiment, the binding sites are connected in series with each other. In other embodiments, the binding sites are located at different positions of the binding polypeptide, for example, at one or more of the N-terminus or C-terminus of the Fc region of an Fc polypeptide. For example, when the Fc region is an scFc region, the binding site may be connected to the N-terminus, the C-terminus, or both ends of the scFc region. When the Fc region is a dimeric Fc region, the binding site may be connected to one or both N-termini and / or one or both C-termini.
[0179] As used herein, the term "binding domain," "binding site," or "binding portion" refers to a portion, region, or site of a binding polypeptide that has a biological activity (other than Fc-mediated biological activity) that, for example, mediates specific binding to a target molecule (e.g., an antigen, a ligand, a receptor, a substrate, or an inhibitor). Exemplary binding domains include biologically active proteins or portions, antigen binding sites, receptor binding domains of ligands, ligand binding domains of receptors, or enzyme domains. In another example, the term "binding portion" refers to a biologically active molecule or portion thereof that binds to a component of a biological system (e.g., a protein in serum or on a cell surface or in a cell matrix) and the binding causes a biological effect (e.g., as measured by a change in the active portion and / or the component to which it binds (e.g., cleavage of the active portion and / or the component to which it binds, signaling, or enhancement or inhibition of a biological response in a cell or in a subject)).
[0180] As used herein, the term "ligand binding domain" refers to a natural receptor (e.g., a cell surface receptor) or a region or derivative thereof that at least retains the qualitative ligand binding ability of the corresponding natural receptor and / or at least some (or most) biological activity. As used herein, the term "receptor binding domain" refers to a natural ligand or a region or derivative thereof that at least retains the qualitative receptor binding ability of the corresponding natural ligand and / or at least some biological activity. In one embodiment, the binding polypeptide of the present invention has at least one binding domain that is specific for molecules such as cell surface antigens or soluble antigens that are targeted for reduction or elimination. In some embodiments, the binding domain comprises an antigen binding site (e.g., comprising a variable heavy chain sequence and a variable light chain sequence or six CDRs from an antibody placed in an alternating framework region (e.g., a human framework region optionally comprising one or more amino acid substitutions)) or consists of it. As used herein, the term "binding affinity" includes the strength of the binding interaction and therefore includes both actual binding affinity and apparent binding affinity. Actual binding affinity is the ratio of the association rate to the dissociation rate. Thus, conferring or optimizing binding affinity includes altering either or both of these components to achieve a desired level of binding affinity. Apparent affinity can include, for example, the avidity of an interaction.
[0181] As used herein, the term "binding free energy" or "free energy of binding" includes its art-recognized meaning, and particularly as applied to a binding site-ligand or Fc-FcR interaction in a solvent. A decrease in binding free energy increases affinity, while an increase in binding free energy decreases affinity.
[0182] The term "specificity" includes the number of potential binding sites that specifically bind (e.g., immunoreact) to a given target. A binding polypeptide may be monospecific and contain one or more binding sites that specifically bind to the same target (e.g., the same epitope), or a binding polypeptide may be multispecific and contain two or more binding sites that specifically bind to different regions of the same target (e.g., different epitopes) or different targets. In one embodiment, a multispecific binding polypeptide (e.g., a bispecific polypeptide) can be made that has binding specificity for more than one target molecule (e.g., more than one antigen or more than one epitope on the same antigen). In another embodiment, a multispecific binding polypeptide has at least one binding domain specific for a molecule targeted for reduction or elimination and at least one binding domain specific for a target molecule on a cell. In another embodiment, a multispecific binding polypeptide has at least one binding domain specific for a molecule targeted for reduction or elimination and at least one binding domain specific for a drug. In another embodiment, a multispecific binding polypeptide has at least one binding domain specific for a molecule targeted for reduction or elimination and at least one binding domain specific for a prodrug. In another embodiment, the multispecific binding polypeptide is a tetravalent antibody having two binding domains specific for one target molecule and two binding sites specific for a second target molecule.
[0183] As used herein, the term "valence" refers to the number of potential binding domains in a binding polypeptide or protein. Each binding domain specifically binds to a target molecule. When a binding polypeptide comprises more than one binding domain, each binding domain may specifically bind to the same or different molecules (e.g., may bind to different ligands or different antigens, or different epitopes on the same antigen). In one embodiment, the binding polypeptide of the present invention is monovalent. In another embodiment, the binding polypeptide of the present invention is multivalent. In another embodiment, the binding polypeptide of the present invention is divalent. In another embodiment, the binding polypeptide of the present invention is trivalent. In another embodiment, the binding polypeptide of the present invention is tetravalent. In certain aspects, the binding polypeptide of the present invention uses a polypeptide linker. As used herein, the term "polypeptide linker" refers to a peptide or polypeptide sequence (e.g., a synthetic peptide or polypeptide sequence) that connects two domains in the linear amino acid sequence of a polypeptide chain. For example, a polypeptide linker can be used to connect a binding site to the Fc region (or Fc portion) of an Fc polypeptide of the present invention. In some embodiments, these polypeptide linkers provide flexibility to the polypeptide molecule. For example, in one embodiment, the VH domain or VL domain is fused or linked to a polypeptide linker, and the N-terminus or C-terminus of the polypeptide linker is attached to the C-terminus or N-terminus of the Fc region (or Fc portion) and the N-terminus of the polypeptide linker is attached to the N-terminus or C-terminus of the VH or VL domain. In certain embodiments, a polypeptide linker is used to connect (e.g., genetically fuse) two Fc portions or domains of a scFc polypeptide. These polypeptide linkers are also referred to herein as Fc connecting polypeptides. As used herein, the term "Fc connecting polypeptide" refers in particular to a connecting polypeptide that connects (e.g., genetically fuses) two Fc portions or domains. The binding molecules of the present invention may comprise more than one peptide linker.
[0184] As used herein, the term "properly folded polypeptide" includes polypeptides (e.g., binding polypeptides of the present invention) in which all functional domains constituting the polypeptide have unique activities. As used herein, the term "improperly folded polypeptide" includes polypeptides in which at least one functional domain of the polypeptide is inactive. As used herein, a "properly folded Fc polypeptide" or "properly folded Fc region" comprises at least two component Fc portions that are properly folded, such that the resulting Fc region comprises at least one effector function Fc region (e.g., scFc region).
[0185] As used herein, the term "immunoglobulin" includes polypeptides having a combination of two heavy chains and two light chains, whether or not they have any relevant specific immunoreactivity.
[0186] As used herein, the term "antibody" refers to an assembly (e.g., a complete antibody molecule, an antibody fragment, or a variant thereof) that has a significant known specific immunoreactivity to a relevant antigen (e.g., a tumor-associated antigen). Antibodies and immunoglobulins comprise light and heavy chains, with or without interchain covalent linkages. The basic immunoglobulin structure in vertebrate systems is relatively well understood.
[0187] As will be discussed in more detail below, the general term "antibody" includes five different classes of antibodies that can be distinguished biochemically. Fc portions from each antibody class are obviously within the scope of the present invention, and the following discussion will generally be directed to the IgG class of immunoglobulin molecules. With respect to IgG, immunoglobulins comprise two identical light polypeptide chains with a molecular weight of approximately 23,000 daltons and two identical heavy chains with a molecular weight of 53,000-70,000. The four chains are joined by disulfide bonds in a "Y" configuration, with the light chains bracketing the heavy chains, which begin at the mouth of the "Y" and continue through the variable domains.
[0188] Immunoglobulin light chains are classified as κ or λ (kappa, lambda). Each heavy chain class can be combined with a κ or λ light chain. Generally speaking, the light chain and heavy chain are covalently bonded to each other, and when the immunoglobulin is produced by a hybridoma, B cell or genetically engineered host cell, the "tail" portion of the two heavy chains is bonded to each other by covalent disulfide bonds or non-covalent bonds. In the heavy chain, the amino acid sequence extends from the N-terminus of the forked end of the Y configuration to the C-terminus at the bottom of each chain. It will be understood by those skilled in the art that heavy chains are classified as γ, μ, α, δ or ε (gamma, mu, alpha, delta, epsilon), some of which have subclasses (e.g., γ1-γ4). The properties of this chain determine the "class" of the antibody, respectively, IgG, IgM, IgA, IgG or IgE. Immunoglobulin subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, etc., are well characterized and are known to confer functional specialization. Modified versions of each of these classes and isotypes are readily discernible to those skilled in the art in view of the present disclosure and, therefore, are within the scope of the present invention.
[0189] Both light and heavy chains are divided into regions with structural and functional homology. The term "region" refers to a component or portion of a single immunoglobulin (such as the term "Fc region") or a single antibody chain, and includes a constant region or a variable region, as well as more discrete components or portions of the domain. For example, the light chain variable domain includes "complementarity determining regions" or "CDRs" interspersed between "framework regions" or "FRs," as defined herein. Certain regions of an immunoglobulin can be defined as "constant" (C) regions or "variable" (V) regions based on the relative lack of sequence variation within the region of different class members in the case of a "constant region" or the presence of significant variation within the region of different class members in the case of a "variable region." The terms "constant region" and "variable region" can also be used functionally. In this regard, it should be understood that the variable region of an immunoglobulin or antibody determines antigen recognition and specificity. In contrast, the constant region of an immunoglobulin or antibody confers important effector functions, such as secretion, transplacental mobility, Fc receptor binding, complement fixation, and the like. The subunit structures and three-dimensional configurations of the constant regions of different immunoglobulin classes are well known.
[0190] The constant region and variable region of immunoglobulin heavy chain and light chain are folded into domain.The term "domain" refers to an independently folded globular region of a heavy chain or light chain polypeptide comprising, for example, peptide loops (e.g., comprising 3 to 4 peptide loops) stabilized by beta pleated sheets and / or intrachain disulfide bonds. The constant region domains on immunoglobulin light chains are interchangeably referred to as "light chain constant region domains," "CL regions," or "CL domains." The constant domains (e.g., hinge, CH1, CH2, or CH3 domains) on the heavy chain are interchangeably referred to as "heavy chain constant region domains," "CH" region domains, or "CH domains." The variable domains on the light chain are interchangeably referred to as "light chain variable region domains," "VL region domains," or "VL domains." The variable domains on the heavy chain are interchangeably referred to as "heavy chain variable region domains," "VH region domains," or "VH domains."
[0191] By convention, the numbering of the variable and constant region domains increases as they are further away from the antigen binding site or amino terminus of the immunoglobulin or antibody. The N-terminus of each heavy and light immunoglobulin chain is the variable region and the C-terminus is the constant region; the CH3 and CL domains actually comprise the carboxyl termini of the heavy and light chains, respectively. Therefore, the domains of the light chain immunoglobulins are arranged in a VL-CL direction, while the domains of the heavy chains are arranged in a VH-CH1-hinge-CH2-CH3 direction. Unless otherwise stated, the amino acid positions in the heavy chain constant region, including the amino acid positions in the CH1, hinge, CH2 and CH3 domains, are numbered herein according to the EU index numbering system. In contrast, the amino acid positions in the light chain constant region (e.g., CL domains) are numbered herein according to the Kabat index numbering system (see Kabat et al., as above).
[0192] As used herein, the term "VH domain" includes the amino-terminal variable domain of an immunoglobulin heavy chain, while the term "VL domain" includes the amino-terminal variable domain of an immunoglobulin light chain, according to the Kabat index numbering system.
[0193] As used herein, the term "CH1 domain" includes the first (most amino-terminal) constant region domain of an immunoglobulin heavy chain, e.g., extending from about EU position 118 to position 215. The CH1 domain is adjacent to the VH domain and amino-terminally adjacent to the hinge region of the immunoglobulin heavy chain molecule and does not form part of the Fc region of the immunoglobulin heavy chain. In one embodiment, a binding polypeptide of the invention comprises a CH1 domain derived from an immunoglobulin heavy chain molecule (e.g., a human IgG1 or IgG4 molecule).
[0194] As used herein, the term "hinge region" includes the portion of the heavy chain molecule that joins the CH1 domain to the CH2 domain. The hinge region comprises approximately 25 residues and is flexible, thus allowing the two N-terminal antigen-binding regions to move independently. The hinge region can be further divided into three distinct domains: the upper hinge domain, the middle hinge domain, and the lower hinge domain (Roux et al., J. Immunol. 1998, 161: 4083).
[0195] As used herein, the term "CH2 domain" includes, for example, the portion of a heavy chain immunoglobulin molecule extending from about EU position 231 to position 340. The uniqueness of the CH2 domain is that it is not tightly paired with another domain. Instead, two N-connected branched carbohydrate chains are inserted between the two CH2 domains of a complete natural IgG molecule. In one embodiment, the binding polypeptide of the present invention comprises a CH2 domain derived from an IgG1 molecule (e.g., a human IgG1 molecule). In another embodiment, the binding polypeptide of the present invention comprises a CH2 domain derived from an IgG4 molecule (e.g., a human IgG4 molecule). In an exemplary embodiment, the polypeptide of the present invention comprises a CH2 domain (EU positions 231-340) or a portion thereof.
[0196] As used herein, the term "CH3 domain" includes the portion of a heavy chain immunoglobulin molecule extending from the N-terminus of the CH2 domain by about 110 residues, for example, from about position 341 to position 446b (EU numbering system). Additional lysine residues (K) are sometimes present at the extreme C-terminus of the CH3 domain, but are typically cleaved from mature antibodies. The CH3 domain typically forms the C-terminal portion of an antibody. However, in some immunoglobulins, additional domains may extend from the CH3 domain to form the C-terminal portion of the molecule (e.g., the CH4 domain in the μ chain of IgM and the ε chain of IgE). In one embodiment, the binding polypeptide of the present invention comprises a CH3 domain derived from an IgG1 molecule (e.g., a human IgG1 molecule). In another embodiment, the binding polypeptide of the present invention comprises a CH3 domain derived from an IgG4 molecule (e.g., a human IgG4 molecule).
[0197] As used herein, the term "CL domain" includes the first (most amino-terminal) constant region domain of an immunoglobulin light chain, e.g., extending from about Kabat position 107A to position 216. The CL domain is adjacent to the VL domain. In one embodiment, a binding polypeptide of the invention comprises a CL domain derived from a kappa light chain (e.g., a human kappa light chain).
[0198] As indicated above, the variable region of an antibody allows it to selectively recognize and thereby specifically bind to an epitope on an antigen. An antibody that specifically binds to a target may be referred to as a target-binding antibody (e.g., an α4-binding antibody is an antibody that specifically binds to α4). "Specifically binds" means that the antibody (or its variable region) specifically binds to its target (e.g., an epitope on α4 integrin) with an equilibrium dissociation constant (K D ) is less than about 5×10 -5 (i.e. 50 μM), or less than about 1×10 -5 (i.e. 10 uM), or less than about 5×10 -6 (i.e. 5uM), or less than about 1×10 -6 (i.e. 1 uM), or less than about 5×10 -7 (i.e., 500 nM), or less than about 1×10 -7 (i.e., 100 nM), or less than about 5×10 -8 (i.e., 50 nM), or less than about 1×10 -8 (i.e., 10 nM), or less than about 5×10 -9 (i.e., 5 nM), or less than about 1×10 -9 (i.e., 1 nM), or less than about 5×10 -10 (i.e., 500 pM), or less than about 1×10 -10 (i.e., 100 pM), or less than about 5×10 -11 (50 pM), or less than about 1×10-11 (10 pM), or less than about 5×10 -12 (5 pM), or less than about 1×10 -12 (1pm), or less than about 5×10 -13 (500 fM), or less than about 1×10 -13 (100 fM), or less than about 5×10 -14 (50 fM), or less than about 1×10 -14 (10 fM), or less than about 5×10 -15 (5 fM), or less than about 1×10-15 (1 fM). That is, the VL domain of the antibody combines with the VH domain to form a variable region (Fv) that defines a three-dimensional antigen binding site. This quaternary antibody structure forms the antigen binding site present at the end of each arm of the Y. More specifically, the antigen binding site is defined by three complementarity determining regions (CDRs) on each heavy and light chain variable region.
[0199] As used herein, the term "antigen binding site" includes a site that specifically binds (immunoreacts) to an antigen (e.g., a cell surface or soluble antigen). In one embodiment, the binding site includes immunoglobulin heavy and light chain variable regions, and the binding site formed by these variable regions determines the specificity of the antibody. The antigen binding site is formed by variable regions that vary depending on the polypeptide. In one embodiment, the binding polypeptide of the present invention comprises an antigen binding site containing at least one heavy or light chain CDR of an antibody molecule (e.g., whose sequence is known in the art or described herein). In another embodiment, the binding polypeptide of the present invention comprises an antigen binding site containing at least two CDRs from one or more antibody molecules. In another embodiment, the binding polypeptide of the present invention comprises an antigen binding site containing at least three CDRs from one or more antibody molecules. In another embodiment, the binding polypeptide of the present invention comprises an antigen binding site containing at least four CDRs from one or more antibody molecules. In another embodiment, the binding polypeptide of the present invention comprises an antigen binding site containing at least five CDRs from one or more antibody molecules. In another embodiment, the binding polypeptide of the present invention comprises an antigen binding site containing six CDRs from an antibody molecule. Exemplary antibody molecules comprising at least one CDR that can be included in the subject binding polypeptides are known in the art, and exemplary molecules are described herein.
[0200] As used herein, the term "CDR" or "complementarity determining region" means the non-continuous antigen combining sites found within the variable region of both heavy and light chain polypeptides. These specific regions have been described in the following literature: Kabat et al., J.Biol.Chem.252, 6609-6616 (1977) and Kabat et al., Sequences of protein of immunological interest. (1991); and Chothia et al., J.MoI.Biol.196:901-917 (1987) and MacCallum et al., J.MoI.Biol.262:732-745 (1996), wherein the definitions include overlapping or subsets of amino acid residues when compared to each other. The amino acid residues encompassing the CDRs defined by each reference cited above are shown for comparison. In some embodiments, the term "CDR" is a CDR as defined by Kabat based on sequence comparison.
[0201]
[0202] 1 Residue numbering follows the nomenclature of Kabat et al., supra.
[0203] 2 The residue numbering follows the nomenclature of Chothia et al., supra
[0204] 3 Residue numbering follows the nomenclature of MacCallum et al., supra
[0205] As used herein, the term "framework region" or "FR region" includes amino acid residues that are part of the variable region but not part of the CDR (e.g., using the Kabat definition of CDR). Thus, the length of the variable region framework is between about 100-120 amino acids, but only includes those amino acids outside the CDR. With respect to the specific example of the heavy chain variable region and with respect to the CDRs as defined by Kabat et al., framework region 1 corresponds to the variable region domain covering amino acids 1-30; framework region 2 corresponds to the variable region domain covering amino acids 36-49; framework region 3 corresponds to the variable region domain covering amino acids 66-94, and framework region 4 corresponds to the variable region domain from amino acid 103 to the end of the variable region. The framework region of the light chain is similarly separated by each light chain variable region CDR. Similarly, when using the CDR definitions of Chothia et al. or McCallum et al., the framework region boundaries are separated by the ends of individual CDRs, as described above. In some embodiments, the CDRs are as defined by Kabat.
[0206] In naturally occurring antibodies, the six CDRs present on each monomeric antibody are short, non-continuous amino acid sequences that are specifically positioned so that an antigen binding site is formed when the antibody presents its three-dimensional configuration in an aqueous environment. The remainder of the heavy and light chain variable domains show lower intermolecular variability in the amino acid sequence and are referred to as framework regions. The framework region primarily adopts a β-pleated conformation, and the CDRs form a loop that connects the β-pleated structure and, in some cases, forms a portion thereof. Thus, these framework regions serve to form a scaffold that provides for positioning the six CDRs in the correct orientation by interchain non-covalent interactions. The antigen binding site formed by the positioned CDRs defines a surface complementary to the epitope on the immunoreactive antigen. This complementary surface promotes the non-covalent binding of the antibody to the immunoreactive epitope. One of ordinary skill in the art can easily identify the position of the CDRs.
[0207] In certain embodiments, the binding polypeptides of the invention comprise at least two antigen binding domains (e.g., within the same binding polypeptide (e.g., at the N-terminus and C-terminus of a single polypeptide) or linked to the component binding polypeptides of a multimeric binding protein of the invention), thereby providing for the association of the binding polypeptide with the selected antigen. The antigen binding domains need not be derived from the same immunoglobulin molecule. In this regard, the variable region may or may not be derived from any type of animal that can be induced to establish a humoral response and produce immunoglobulins against the desired antigen. Thus, the variable region may be, for example, of mammalian origin, for example, human, murine, non-human primates (e.g., cynomolgus monkeys, macaques, etc.), wolf, camelid (e.g., from camels, llamas, and related species).
[0208] The term "antibody variant" or "modified antibody" includes antibodies that do not exist in nature and that differ in amino acid sequence or amino acid side chain chemistry from that of an antibody of natural origin by at least one amino acid or amino acid modification as described herein. As used herein, the term "antibody variant" includes synthetic antibody forms that have been altered so that they are not naturally occurring forms, for example, antibodies comprising at least two heavy chain portions rather than two complete heavy chains (e.g., domain-deleted antibodies or minibodies); multispecific antibody forms (e.g., bispecific, trispecific, etc.) that have been altered to bind to two or more different antigens or different epitopes on a single antigen; heavy chain molecules joined to scFv molecules; single-chain antibodies; bifunctional antibodies; trifunctional antibodies; and antibodies with altered effector functions, etc.
[0209] As used herein, the term "scFv molecule" includes a binding molecule consisting of a light chain variable domain (VL) or a portion thereof and a heavy chain variable domain (VH) or a portion thereof, wherein each variable domain (or portion thereof) is derived from the same or different antibodies. The scFv molecule may comprise an scFv linker inserted between the VH domain and the VL domain. ScFv molecules are known in the art and are described, for example, in the following literature: U.S. Patent No. 5,892,019; Ho et al., 1989. Gene 77:51; Bird et al., 1988 Science 242:423; Pantoliano et al., 1991. Biochemistry 30:10117; Milenic et al., 1991. Cancer Research 51:6363; Takkinen et al., 1991. Protein Engineering 4:837.
[0210] As used herein, "scFv linker" refers to the portion inserted between the VL and VH domains of an scFv. In some embodiments, the scFv linker can maintain the scFv molecule in an antigen-binding conformation. In one embodiment, the scFv linker comprises or consists of an scFv linker peptide. In certain embodiments, the scFv linker peptide comprises or consists of a gly-ser polypeptide linker. In other embodiments, the scFv linker comprises a disulfide bond.
[0211] As used herein, the term "gly-ser polypeptide linker" refers to a peptide composed of glycine and serine residues. An exemplary gly / ser polypeptide linker comprises the amino acid sequence (Gly4Ser)n. In one embodiment, n=1. In one embodiment, n=2. In another embodiment, n=3, i.e., (Gly4Ser)3. In another embodiment, n=4, i.e., (Gly4Ser)4. In another embodiment, n=5. In another embodiment, n=6. In another embodiment, n=7. In another embodiment, n=8. In another embodiment, n=9. In another embodiment, n=10. Another exemplary gly / ser polypeptide linker comprises the amino acid sequence Ser(Gly4Ser)n. In one embodiment, n=1. In one embodiment, n=2. In a certain embodiment, n=3. In another embodiment, n=4. In another embodiment, n=5. In another embodiment, n=6.
[0212] As used herein, the term "native cysteine" shall refer to a cysteine amino acid that is naturally present at a particular amino acid position in a polypeptide and has not been artificially modified, introduced, or altered. The term "engineered cysteine residue or analog thereof" or "engineered cysteine or analog thereof" shall refer to a non-natural cysteine residue or cysteine analog (e.g., thiol-containing analogs such as thiazoline-4-carboxylic acid and thiazolidine-4-carboxylic acid (thioproline, Th)) that is introduced by synthetic means (e.g., by recombinant techniques, in vitro peptide synthesis, by enzymatic or chemical coupling of peptides, or some combination of these techniques) into an amino acid position in a polypeptide that does not naturally contain a cysteine residue or analog thereof.
[0213] As used herein, the term "disulfide bond" includes a covalent bond formed between two sulfur atoms. The amino acid cysteine contains a thiol group that can form a disulfide bond or disulfide bridge with a second thiol group. In most naturally occurring IgG molecules, the CH1 and CL regions are linked by a natural disulfide bond, and the two heavy chains are linked by two natural disulfide bonds at positions corresponding to 239 and 242 using the Kabat numbering system (226 or 229 in the EU numbering system).
[0214] As used herein, the term "bonded cysteine" shall refer to a native or engineered cysteine residue within a polypeptide that forms a disulfide bond or other covalent bond with a second native or engineered cysteine or other residue present in the same or different polypeptide. An "intrachain bonded cysteine" shall refer to a bonded cysteine that is covalently bonded to a second cysteine present in the same polypeptide (i.e., an intrachain disulfide bond). An "interchain bonded cysteine" shall refer to a bonded cysteine that is covalently bonded to a second cysteine present in a different polypeptide (i.e., an interchain disulfide bond).
[0215] As used herein, the term "free cysteine" refers to a naturally occurring or engineered cysteine amino acid residue (and its analogs or mimetics, such as thiazoline-4-carboxylic acid and thiazolidine-4-carboxylic acid (thioproline, Th)) present in a substantially reduced form within a polypeptide sequence. In some embodiments, free cysteine can be modified with an effector moiety of the invention.
[0216] The term "thiol-modifying agent" shall refer to a chemical reagent that is capable of reacting selectively with a thiol group of an engineered cysteine residue or its analog in a binding polypeptide (e.g., within a polypeptide linker of a binding polypeptide) and thereby providing a means for site-specific chemical addition or cross-linking of an effector moiety to the binding polypeptide, thereby forming a modified binding polypeptide. In some embodiments, the thiol-modifying agent utilizes a thiol or sulfhydryl functional group present in a free cysteine residue. Exemplary thiol-modifying agents include maleimides, alkyl and aryl halides, α-haloacyl groups, and pyridyl disulfides.
[0217] The term "functional moiety" includes, in some embodiments, a moiety that adds a desired function to a binding polypeptide. In some embodiments, the function is added without significantly altering the inherent desired activity of the polypeptide, such as the antigen-binding activity of the molecule. The binding polypeptides of the present invention may comprise one or more functional moieties that may be the same or different. Examples of useful functional moieties include, but are not limited to, effector moieties, affinity moieties, and blocking moieties. Exemplary blocking moieties include moieties having sufficient steric bulk and / or charge to reduce glycosylation (e.g., by blocking the ability of glycosidases to glycosylate the polypeptide). Blocking moieties may additionally or alternatively reduce effector function, for example, by inhibiting the ability of the Fc region to bind to receptors or complement proteins. Non-limiting blocking moieties include cysteine adducts, cysteine, mixed disulfide adducts, and PEG moieties. Exemplary detectable moieties include fluorescent moieties, radioisotope moieties, radiopaque moieties, and the like. With respect to conjugation of chemical moieties, the term "linking moiety" includes a moiety capable of linking the functional moiety to the remainder of the binding polypeptide. The linking moiety may be selected to be cleavable or non-cleavable. Non-cleavable linking moieties generally have high system stability but may also have unfavorable pharmacokinetic properties.
[0218] The term "spacer moiety" is a non-proteinaceous moiety designed to introduce a spacer into a molecule. In one embodiment, the spacer moiety can be an optionally substituted chain having 0 to 100 atoms selected from carbon, oxygen, nitrogen, sulfur, etc. In one embodiment, the spacer moiety is selected to be water-soluble. In another embodiment, the spacer moiety is a polyalkylene glycol, such as polyethylene glycol or polypropylene glycol.
[0219] The term "PEGylated moiety" or "PEG moiety" includes polyalkylene glycol compounds or derivatives thereof, in the presence or absence of a coupling agent or derivatized with a coupling or activating moiety (e.g., with a thiol, triflate, triflate, ethylene oxide, or with a maleimide moiety, such as PEG-maleimide). Other suitable polyalkylene glycol compounds include maleimido monomethoxy PEG, activated PEG polypropylene glycol, and charged or neutral polymers of the following types: polydextrose, polysialic acid, or other carbohydrate-based polymers, amino acid polymers, and biotin derivatives. As used herein, the term "effect moiety" (E) may include diagnostic and therapeutic agents (e.g., proteins, nucleic acids, lipids, drug moieties, and fragments thereof) having biological or other functional activities. For example, a binding polypeptide comprising an effector moiety conjugated to a binding polypeptide has at least one additional function or property compared to an unconjugated polypeptide. For example, a cytotoxic drug moiety (e.g., an effector moiety) is conjugated to a binding polypeptide (e.g., via its polypeptide linker) to form a modified polypeptide having drug cytotoxicity as a second function (i.e., in addition to antigen binding). In another example, conjugation of a second binding polypeptide to a first binding polypeptide can confer additional binding properties. In one aspect, where the effector moiety is a genetically encoded therapeutic or diagnostic protein or nucleic acid, the effector moiety can be synthesized or expressed by peptide synthesis or recombinant DNA methods well known in the art. On the other hand, where the effector is a non-genetically encoded peptide or drug moiety, the effector moiety can be artificially synthesized or purified from a natural source.
[0220] As used herein, the term "drug moiety" includes anti-inflammatory agents, anti-cancer agents, anti-infective agents (e.g., antifungal agents, antibacterial agents, antiparasitic agents, antiviral agents, etc.), and anesthetic therapeutic agents. In another embodiment, the drug moiety is an anticancer agent or a cytotoxic agent. Compatible drug moieties may also include prodrugs.
[0221] As used herein, the term "prodrug" refers to a precursor or derivative form of a pharmaceutically active agent that has lower activity, reactivity, or side effect tendency than the parent drug and can be enzymatically activated in vivo or otherwise converted to a more active form. Prodrugs compatible with the present invention include, but are not limited to, phosphate-containing prodrugs, amino acid-containing prodrugs, thiophosphate-containing prodrugs, sulfate-containing prodrugs, peptide-containing prodrugs, β-lactam-containing prodrugs, optionally substituted phenoxyacetamide-containing prodrugs, or optionally substituted phenylacetamide-containing prodrugs, 5-fluorocytosine and other 5-fluorouridine prodrugs that can be converted to more active non-cytotoxic drugs. One skilled in the art can chemically modify the desired drug moiety or its prodrug to make the reaction of the compound more suitable for the purpose of preparing the modified binding protein of the present invention. Drug moieties also include derivatives, pharmaceutically acceptable salts, esters, amides, and ethers of the drug moieties described herein.
[0222] "Affinity resin" is a chemical surface that can bind affinity domains with high affinity to help separate proteins bound to affinity domains from other components of a reaction mixture. Affinity resins can be coated on the surface of a solid support or a portion thereof. Alternatively, affinity resins can comprise a solid support. The solid support can comprise a chromatographic column, microtiter plate, bead, or biochip (e.g., glass wafer) that is appropriately modified. Exemplary affinity resins are composed of nickel, chitin, amylase, etc. The terms "vector" or "expression vector" are used herein to refer to vectors used as a vehicle for introducing and expressing desired polynucleotides in a cell according to the present invention. As known to those skilled in the art, these vectors can be easily selected from the group consisting of plasmids, phages, viruses, and retroviruses. In general, vectors compatible with the present invention will comprise selection markers, appropriate restriction sites to help clone desired genes and the ability to enter eukaryotic or prokaryotic cells and / or replicate therein.
[0223] Those of ordinary skill in the art will understand that if the polynucleotide (e.g., DNA sequence) encoding the antibody described herein (or its fragment or chain) is contained in an expression vector that also includes regulatory elements (e.g., promoter, enhancer and / or poly A tail), the polynucleotide will be expressed as a protein in the host cell introduced into the vector. Thus, the polynucleotide inserted into the expression vector can be referred to as "positioned to be expressed" in the vector and thus expressed in the host cell introduced into the vector. However, the polynucleotide (e.g., DNA sequence) does not need to be inserted into the expression vector in order to be positioned to be expressed in the host cell. Well-known methods for positioning polynucleotides to be expressed in cells are known. For example, a DNA sequence can be inserted into the genome of the host cell using, for example, homologous recombination so that the expression of the inserted DNA sequence is regulated by the endogenous promoter and other regulatory elements of the host cell. These homologous recombination techniques are well-known.
[0224] For the purposes of the present invention, numerous expression vector systems can be used. For example, a class of vectors utilizes DNA elements derived from animal viruses, such as bovine papilloma virus, polyoma virus, adenovirus, vaccinia virus, baculovirus, retrovirus (RSV, MMTV or MOMLV) or SV40 virus. Other vectors relate to the use of polycistronic systems with internal ribosome binding sites. Exemplary vectors include those described in U.S. Patent Nos. 6,159,730 and 6,413,777 and U.S. Patent Application No. 2003 0157641A1. In addition, one or more markers can be introduced to allow selection of transfected host cells to select cells having DNA integrated into their chromosomes. Markers can provide prototrophy, biocide (e.g., antibiotic) resistance or resistance to heavy metals such as copper to auxotrophic hosts. Selectable marker genes can be directly connected to the DNA sequence to be expressed, or introduced into the same cell by co-transformation. In one embodiment, an inducible expression system can be adopted. Additional elements may also be needed to carry out the optimal synthesis of mRNA. These elements may include signal sequences, splicing signals, and transcriptional promoters, enhancers, and termination signals. In one embodiment, a secretion signal, such as any of several well-characterized bacterial leader peptides (e.g., pelB, phoA, or ompA), may be fused in-frame to the N-terminus of a polypeptide of the invention to achieve optimal secretion of the polypeptide. (Lei et al., (1988), Nature, 331:543; Better et al., (1988) Science, 240:1041; Mullinax et al., (1990). PNAS, 87:8095).
[0225] The term "host cell" refers to a cell transformed with a vector constructed using recombinant DNA technology and encoding at least one heterologous gene. In the description of a method for isolating a protein from a recombinant host, unless otherwise explicitly stated, the terms "cell" and "cell culture" are used interchangeably to represent the source of the protein. In other words, recovering a protein from a "cell" may mean recovering it from whole cells centrifuged at low speed or from a cell culture containing both culture medium and suspension cells. Host cell lines used for protein expression have, for example, mammalian origin. It is believed that those skilled in the art will be able to preferentially determine the specific host cell line that is most suitable for expressing the desired gene product therein. Exemplary host cell lines include, but are not limited to, DG44 and DUXBII (Chinese hamster ovary cell lines, DHFR-), HELA (human cervical carcinoma), CVI (monkey kidney cell line), COS (CVI derivative with SV40 T antigen), R1610 (Chinese hamster fibroblasts), BALBC / 3T3 (mouse fibroblasts), HAK (hamster kidney cell line), SP2 / O (mouse myeloma), P3x63-Ag3.653 (mouse myeloma), BFA-IcIBPT (bovine endothelial cell line), RAJI (human lymphocytes) and 293 (human kidney). CHO cells (and variants thereof, including CHO-K1 cells lacking DHFR activity) are suitable host cells. Host cell lines are generally available from commercial services, American Tissue Culture Collection, or published literature. The polypeptides of the present invention can also be expressed in non-mammalian cells, such as bacteria or yeast or plant cells. In this regard, it will be appreciated that various unicellular non-mammalian microorganisms, such as bacteria, can also be transformed; that is, those unicellular non-mammalian microorganisms that are capable of growth or fermentation in culture. Bacteria readily transformed include members of the Enterobacteriaceae family, such as Escherichia coli or Salmonella strains; Bacillaceae, such as Bacillus subtilis; Pneumococcus; Streptococcus; and Haemophilus influenzae. It will be further appreciated that, when expressed in bacteria, polypeptides typically become part of inclusion bodies. The polypeptides must be isolated, purified, and then assembled into functional molecules.
[0226] In addition to prokaryotes, eukaryotic microorganisms can also be used. Saccharomyces cerevisiae, or common baker's yeast, is the most commonly used eukaryotic microorganism, but many other strains are generally available, including Pichia pastoris. For expression in yeast, plasmid YRp7 is commonly used (Stinchcomb et al., (1979), Nature, 282:39; Kingsman et al., (1979), Gene, 7:141; Tschemper et al., (1980), Gene, 10:157). This plasmid already contains the TRP1 gene, which provides a selection marker for yeast mutants lacking the ability to grow in tryptophan, such as ATCC No. 44076 or PEP4-1 (Jones, (1977), Genetics, 85:12). The presence of a trp1 lesion, a characteristic of the yeast host cell genome, provides an effective environment for detecting transformation by growth in the absence of tryptophan.
[0227] In vitro production allows for scaling up to produce a large amount of desired altered binding polypeptides of the present invention. The technology of carrying out mammalian cell culture under tissue culture conditions is known in the art and includes homogeneous suspension cultivation, such as in an airlift reactor or in a continuous stirred reactor, or fixed or embedded cell culture, such as in a hollow fiber, in a microcapsule, on agarose microbeads or in a ceramic filter cartridge. If necessary and / or desired, the polypeptide solution can be purified by conventional chromatographic methods, such as gel filtration, ion exchange chromatography, hydrophobic interaction chromatography (HIC), chromatography on DEAE-cellulose or affinity chromatography.
[0228] As used herein, the phrase "a subject who will benefit from the administration of a binding polypeptide" includes subjects, such as mammalian subjects, who will benefit from the administration of the binding polypeptide used for, for example, detecting an antigen recognized and specifically bound by a binding polypeptide of the invention (e.g., for a diagnostic procedure) and / or benefit from treatment with a binding polypeptide to reduce or eliminate the target recognized and specifically bound by the binding polypeptide. For example, in one embodiment, a subject may benefit from the reduction or elimination of soluble or particulate molecules (e.g., toxins or pathogens) from the circulation or serum or from the reduction or elimination of a cell population (e.g., tumor cells) expressing the target. As discussed above, the binding polypeptide may be used in an unconjugated form or may be conjugated to, for example, a drug, prodrug, or isotope to form a modified binding polypeptide for administration to the subject.
[0229] The term "PEGylated," "polyethylene glycol," or "PEG" includes polyalkylene glycol compounds or derivatives thereof, with or without a coupling agent or derivatized with a coupling or activating moiety (e.g., with a thiol, triflate, tresylate, aziridine, ethylene oxide, or with a maleimide moiety, such as PEG-maleimide). Other suitable polyalkylene glycol compounds include, but are not limited to, maleimidomonomethoxy PEG, activated PEG polypropylene glycol, and charged or neutral polymers of the following types: polydextrose, polysialic acid, or other carbohydrate-based polymers, amino acid polymers, and biotin derivatives.
[0230] I. Variable Region
[0231] The present invention provides α4 binding antibodies and fragments thereof, wherein the variable light chain (VL) and variable heavy chain (VH) frameworks have receptor sequences constructed from germline or germline engineered antibody sequences, such as IGKV4-1 or geAAH70335.1 or IGHV1-f antibodies. The CDR sequences are derived from non-human anti-α4 binding antibodies, such as anti-VLA-4 antibodies HP1 / 2. See PCT Publication No. WO2011 / 130603, which is incorporated herein by reference in its entirety. The antibodies described herein may have an affinity increase of at least 1.5, 2.0, 2.5, or 3.0 times, for example, relative to their murine parent. In one embodiment, the affinity increase is at least 1.5, 2.0, 2.5, or 3.0 times, but less than 25, 20, or 15 times, respectively.
[0232] The murine monoclonal antibody (mAb) HP1 / 2 is a member of the B1 subclass of α4 mAbs and inhibits cell adhesion to VCAM1 and fibronectin in vitro with a potency of approximately 0.1 nM. The cryo-EM structure of the HP1 / 2 Fab was resolved as a complex with the extracellular domain of α4β1. HP1 / 2 binds to the α4β propeller domain outside the ligand-binding groove and non-competitively antagonizes ligand binding. The epitope and conformation of α4 integrin recognized and specifically bound by HP1 / 2 are similar to those observed in the natalizumab α4 integrin crystal structure.
[0233] mAbs directed against α4 integrin are potent blockers of lymphocyte, eosinophil, and monocyte infiltration into tissues and have shown disease-modifying effects in vivo. In particular, mAb HP1 / 2 has been shown to be effective in animal models of anaphylactic hyperreactivity in sheep (Lobb et al., Ann. NY Acad. Sci 796:113-123, 1996), bronchial airway hyperreactivity in guinea pigs (Pretolani et al., J. Ex. Med. 180(3):795-805, 1994; Kraneveld et al., J. Allergy Clin. Immunol. 100(2):242-50, 1997), ulcerative colitis in primates (Podolsky et al., J. Clin Invest. 92(1):372-380, 1993), and carotid intimal hyperplasia after intra-arterial resection of NHPs (Lumsden et al., J. Vasc. Surg. 26(1):87-93, 1997), reducing neoadventitia formation and subsequent luminal stenosis after balloon injury (Labinaz et al., Can J Med 2001). J. Cardiol. 16(2):187-96, 2000), inflammatory response to stent implantation in rabbits (Ma et al., 2004), and prevention of cardiac allograft rejection in rabbits (Sadahiro et al., Am. J. Pathol. 142(3):675-683, 1993). In addition, HP1 / 2 stimulates the peripheralization of hematopoietic progenitor cells from baboon bone marrow stroma (Papayannopoulou and Nakamoto, Proc. Natl. Acad. Sci 90(20):9374-9378, 1993).
[0234] HP1 / 2 antibodies were generated in Balb / c mice injected with the JM (immature T-cell leukemia) cell line (Sanchez-Madrid et al., Eur. J. Immunol. 16:1343-1349, 1986). Splenocytes from two mice were fused with SP2 or P3-X63Ag8.653 mouse myeloma cells. The antibody was humanized in 1993 but then rehumanized in 2010 to take advantage of advances in humanization design.
[0235] The α4-binding antibody or fragment thereof may comprise a variable light chain having the sequence of SEQ ID NO: 8, 9, 10, or 11. The α4-binding antibody or fragment thereof may comprise a variable heavy chain having the sequence of SEQ ID NO: 3, 4, or 5.
[0236] In certain embodiments, the α4-binding antibody comprises a variable light chain having the sequence of SEQ ID NO: 11 and a variable heavy chain having the sequence of SEQ ID NO:4.
[0237] The α4-binding antibodies may also comprise a variant Fc region as discussed in more detail herein.
[0238] II. Parent Fc Polypeptide
[0239] Variant Fc polypeptides can be derived from a parent or starting Fc polypeptide known in the art. In one embodiment, the parent Fc polypeptide is an antibody, such as an IgG immunoglobulin, which includes all subtypes of IgG and combinations thereof. In some embodiments, the parent Fc polypeptide of an IgG antibody belongs to an IgG subtype, or a combination of different parts of the Fc region of two or more IgG subtypes. In humans, IgG subtypes include IgG1, IgG2, IgG3, and IgG4. The parent Fc polypeptide comprises an Fc region derived from an immunoglobulin, but may optionally further comprise a binding site operably linked or fused to the Fc region. In some embodiments, the aforementioned polypeptide binds to an antigen such as a ligand, cytokine, receptor, cell surface antigen, or cancer cell antigen. Although the examples herein employ IgG antibodies, it should be understood that the method can be equally applied to the Fc region within any Fc polypeptide. When the Fc polypeptide is an antibody, the antibody may be synthetic, naturally derived (e.g., from serum), produced by a cell line (e.g., a hybridoma), or produced in a transgenic organism.
[0240] In certain embodiments, the Fc polypeptide of the present invention comprises a single Fc portion of an Fc region. In other embodiments, the Fc polypeptide is a dcFc polypeptide. A dcFc polypeptide refers to a polypeptide comprising a dimeric Fc (or dcFc) region. In other embodiments, the Fc polypeptide of the present invention is a scFc polypeptide. As used herein, the term scFc polypeptide refers to a polypeptide comprising a single-chain Fc (scFc) region, e.g., an scFc polypeptide comprising at least two Fc portions genetically fused, e.g., via a flexible polypeptide linker inserted between the at least two Fc portions. Exemplary scFc regions are disclosed in PCT Application No. PCT / US2008 / 006260, filed May 14, 2008, which is incorporated herein by reference.
[0241] In certain embodiments, the polypeptides of the invention may comprise an Fc region comprising an Fc portion having identical or substantially identical sequence composition (referred to herein as a "homomeric Fc region"). In other embodiments, the polypeptides of the invention may comprise an Fc region comprising at least two Fc portions having different sequence compositions (i.e., referred to herein as a "heteromeric Fc region"). In certain embodiments, the binding polypeptides of the invention comprise an Fc region comprising at least one insertion or amino acid substitution. In an exemplary embodiment, the heteromeric Fc region comprises an amino acid substitution in the first Fc portion but not in the second Fc portion.
[0242] In one embodiment, the binding polypeptide of the present invention may include two or more Fc regions that are independently selected from the Fc regions described herein. In one embodiment, the Fc regions are identical. In another embodiment, at least two Fc regions are different. For example, the Fc regions of the Fc polypeptides of the present invention comprise the same number of amino acid residues, or their lengths may differ by one or more amino acid residues (e.g., about 5 amino acid residues (e.g., 1, 2, 3, 4, or 5 amino acid residues), about 10 residues, about 15 residues, about 20 residues, about 30 residues, about 40 residues, or about 50 residues). In other embodiments, the Fc regions may differ in sequence at one or more amino acid positions. For example, at least two Fc regions may differ at about 5 amino acid positions (e.g., 1, 2, 3, 4, or 5 amino acid positions), about 10 positions, about 15 positions, about 20 positions, about 30 positions, about 40 positions, or about 50 positions).
[0243] Parent Fc polypeptides can be assembled together or together with other polypeptides to form multimeric Fc polypeptides or proteins (also referred to herein as "multimers"). The multimeric Fc polypeptides or proteins of the present invention comprise at least one parent Fc polypeptide of the present invention. Thus, parent polypeptides include, but are not limited to, monomers and multimeric (e.g., dimers, trimers, tetramers, and hexamer) Fc polypeptides or proteins, etc. In certain embodiments, the constituent Fc polypeptides of the multimer are identical (i.e., homomeric multimers, e.g., homodimers, homotrimers, homotetramers). In other embodiments, at least two constituent Fc polypeptides of the multimeric protein of the present invention are different (i.e., heteromeric multimers, e.g., heterodimers, heterotrimers, heterotetramers). In certain embodiments, at least two Fc polypeptides are capable of forming a dimer.
[0244] In another embodiment, the Fc polypeptide of the present invention comprises a dimeric Fc region (a single-chain polypeptide that forms a dimer or a two-chain polypeptide that forms a dimer) and is monomeric with respect to the biologically active portion present in the molecule. For example, such an Fc construct may comprise only one biologically active portion. One or two chain stabilized Fc monomer constructs are ideal, for example, when cross-linking of the target molecule is not required (for example, in the case of certain antibodies, such as anti-CD40 antibodies). In another embodiment, such an Fc construct may comprise two different biologically active portions. In another embodiment, such an Fc construct may comprise two identical biologically active portions. In another embodiment, such an Fc construct may comprise more than two identical biologically active portions.
[0245] A. Fc part
[0246] The Fc portion suitable for producing the parent Fc polypeptide of the present invention can be obtained from many different sources. In some embodiments, the Fc portion of the binding polypeptide is derived from human immunoglobulin. However, it should be understood that the Fc portion can be derived from another mammalian species, including, for example, immunoglobulins of rodents (e.g., mice, rats, rabbits, guinea pigs) or non-human primates (e.g., chimpanzees, macaques). In addition, Fc can be derived from any immunoglobulin class, including IgM, IgG, IgD, IgA, and IgE, and any immunoglobulin isotype, including IgG1, IgG2, IgG3, and IgG4. For example, Fc can be derived from IgG1, but with specific mutations in the sequence. In some embodiments, human isotypes IgG1 or IgG4 are used. In some embodiments, Fc can be a chimera containing a portion taken from one Ig immunoglobulin type (e.g., the CH3 domain from IgG1) and other portions from another Ig immunoglobulin type (e.g., the CH1 domain from IgG4).
[0247] A variety of Fc portion gene sequences (e.g., human constant region gene sequences) are available in the form of publicly accessible deposits. The constant region domains comprising the Fc portion sequence can be selected to have specific effector functions (or lack specific effector functions) or to have specific modifications to reduce immunogenicity. The sequences of many antibodies and antibody encoding genes have been published, and these sequences can be obtained from suitable Fc portion sequences (e.g., hinge, CH2 and / or CH3 sequences or portions thereof) using techniques recognized in the art. The genetic material obtained using any of the above methods can then be altered or synthesized to obtain the Fc polypeptides of the present invention. It should be further understood that the scope of the present invention encompasses alleles, variants, and mutations of the constant region DNA sequence.
[0248] The Fc portion sequence can be cloned, for example, using the polymerase chain reaction and primers selected for amplification of the relevant domains. To clone the Fc portion sequence from an antibody, mRNA can be isolated from a hybridoma, spleen, or lymphocytes, reverse transcribed into DNA, and the antibody gene amplified by PCR. The PCR amplification method is described in detail in: U.S. Patent Nos. 4,683,195; 4,683,202; 4,800,159; 4,965,188; and, for example, "PCR Protocols: A Guide to Methods and Applications" by Innis et al., eds., Academic Press, San Diego, CA (1990); Ho et al., 1989. Gene 77:51; Horton et al., 1993. Methods Enzymol. 217:270). PCR can be initiated by consensus constant region primers or by more specific primers based on published heavy and light chain DNA and amino acid sequences. As discussed above, PCR can also be used to separate DNA clones encoding antibody light and heavy chains. In this case, the library can be screened by a common primer or a larger homologous probe (such as a mouse constant region probe). Many primer sets suitable for amplifying antibody genes are known in the art (for example, 5' primers (Benhar and Pastan.1994.Protein Engineering 7:1509) based on the N-terminal sequence of purified antibodies; rapid amplification of cDNA ends (Ruberti, F. et al., 1994.J.Immunol.Methods 173:33); antibody leader sequences (Larrick et al., 1989Biochem.Biophys.Res.Commun.160:1250). The cloning of antibody sequences is further described in Newman et al., U.S. Patent No. 5,658,570, filed January 25, 1995, which is incorporated herein by reference.
[0249] The parent Fc polypeptide of the present invention may comprise a single Fc portion or multiple Fc portions. When two or more Fc portions are present (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more Fc portions), at least two Fc portions associate to form a properly folded Fc region (e.g., a dimeric Fc region or a single-chain Fc region (scFc)). In one embodiment, the Fc portions may be of different types. In one embodiment, at least one Fc portion present in the parent Fc polypeptide comprises a hinge domain or a portion thereof. In another embodiment, the parent Fc polypeptide comprises at least one Fc portion comprising at least one CH2 domain or a portion thereof. In another embodiment, the parent Fc polypeptide comprises at least one Fc portion comprising at least one CH3 domain or a portion thereof. In another embodiment, the parent Fc polypeptide comprises at least one Fc portion comprising at least one CH4 domain or a portion thereof. In another embodiment, the parent Fc polypeptide comprises at least one Fc portion comprising at least one hinge domain or portion thereof and at least one CH2 domain or portion thereof (e.g., in a hinge-CH2 orientation). In another embodiment, the parent Fc polypeptide comprises at least one Fc portion comprising at least one CH2 domain or portion thereof and at least one CH3 domain or portion thereof (e.g., in a CH2-CH3 orientation). In another embodiment, the parent Fc polypeptide comprises at least one Fc portion comprising at least one hinge domain or portion thereof, at least one CH2 domain or portion thereof, and at least one CH3 domain or portion thereof, e.g., in a hinge-CH2-CH3, hinge-CH3-CH2, or CH2-CH3-hinge orientation.
[0250] In certain embodiments, the parent Fc polypeptide comprises at least one complete Fc region derived from one or more immunoglobulin heavy chains (e.g., an Fc portion comprising hinge, CH2, and CH3 domains, but these domains need not be derived from the same antibody). In other embodiments, the parent Fc polypeptide comprises at least two complete Fc regions derived from one or more immunoglobulin heavy chains. In some embodiments, the complete Fc portion is derived from a human IgG immunoglobulin heavy chain (e.g., human IgG1 or human IgG4).
[0251] In another embodiment, the parent Fc polypeptide comprises at least one Fc portion comprising a complete CH3 domain (according to EU numbering, about amino acids 341-438 of the antibody Fc region). In another embodiment, the parent Fc polypeptide comprises at least one Fc portion comprising a complete CH2 domain (according to EU numbering, about amino acids 231-340 of the antibody Fc region). In another embodiment, the parent Fc polypeptide comprises at least one Fc portion comprising at least a CH3 domain, and at least one hinge region (according to EU numbering, about amino acids 216-230 of the antibody Fc region), and a CH2 domain. In one embodiment, the parent Fc polypeptide comprises at least one Fc portion comprising a hinge and a CH3 domain. In another embodiment, the parent Fc polypeptide comprises at least one Fc portion comprising a hinge, a CH2, and a CH3 domain. In some embodiments, the Fc portion is derived from a human IgG immunoglobulin heavy chain.
[0252] The constant region domains or portions thereof that make up the Fc portion can be derived from different immunoglobulin molecules. For example, a parent Fc polypeptide can comprise a hinge and / or CH2 domain or portions thereof derived from an IgG4 molecule and a CH3 region or portions thereof derived from an IgG1 molecule. In another embodiment, the parent Fc polypeptide can comprise a chimeric hinge domain. For example, a chimeric hinge can comprise a hinge domain that is partially derived from an IgG1 molecule and partially derived from an IgG3 molecule. In another embodiment, a chimeric hinge comprises a middle hinge domain from an IgG1 molecule and upper and lower hinge domains from an IgG4 molecule.
[0253] As described herein, it will be understood by those of ordinary skill in the art that the parent Fc portion may be identical to the corresponding Fc portion of a naturally occurring immunoglobulin, or may be altered to vary its amino acid sequence. In certain embodiments, the parent Fc polypeptide is altered, for example, by amino acid mutations (e.g., additions, deletions, or substitutions). For example, the parent Fc polypeptide may be an Fc portion having at least one amino acid substitution compared to the wild-type Fc from which the Fc portion is derived. For example, where the Fc portion is derived from a human IgG1 antibody, the variant comprises at least one amino acid mutation (e.g., substitution) compared to the wild-type amino acid at the corresponding position of the human IgG1 Fc region.
[0254] One or more amino acid substitutions may be made at positions within the Fc portion that are said to "correspond" to the position number that would be given to that residue in the Fc region of an antibody (as described using the EU numbering convention). One skilled in the art can readily generate an alignment to determine the EU numbering that would "correspond" to a position in the Fc portion.
[0255] In one embodiment, the substitution is at an amino acid position located in the hinge domain or a portion thereof. In another embodiment, the substitution is at an amino acid position located in the CH2 domain or a portion thereof. In another embodiment, the substitution is at an amino acid position located in the CH3 domain or a portion thereof. In another embodiment, the substitution is at an amino acid position located in the CH4 domain or a portion thereof.
[0256] In certain embodiments, the parent Fc polypeptide comprises more than one amino acid substitution. The parent Fc polypeptide may comprise, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acid substitutions relative to the wild-type Fc region. In some embodiments, the amino acid substitutions are spatially positioned at least 1 or more amino acid positions apart from each other, for example, at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more amino acid positions apart. In some embodiments, the engineered amino acids are spatially positioned at least 5, 10, 15, 20 or 25 or more amino acid positions apart from each other.
[0257] In certain embodiments, the substitutions alter at least one effector function conferred by an Fc region comprising a wild-type Fc portion (e.g., reduces the ability of the Fc region to bind to an Fc receptor (e.g., FcγRI, FcγRII, or FcγRIII) or a complement protein (e.g., C1q), or to trigger antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, or complement-dependent cytotoxicity (CDC)).
[0258] The parent Fc polypeptide may employ substitutions known in the art to alter effector function. Specifically, the parent Fc polypeptide of the present invention may include changes (e.g., substitutions) at one or more amino acid positions as disclosed in, for example, International PCT Publications WO88 / 07089A1, WO96 / 14339A1, WO98 / 05787A1, WO98 / 23289A1, WO99 / 51642A1, WO99 / 58572A1, WO00 / 09560A2, WO00 / 32767A1, WO00 / 42072A2, WO02 / 44215A2, WO02 / 44215A1, WO02 / 060919A2、WO03 / 074569A2、WO04 / 016750A2、WO04 / 029207A2、WO04 / 035752A2、WO04 / 063351A2、WO04 / 074455A2、WO 04 / 099249A2, WO05 / 040217A2, WO04 / 044859, WO05 / 070963A1, WO05 / 077981A2, WO05 / 092925A2, WO05 / 123780A2, WO 06 / 019447A1, WO06 / 047350A2, and WO06 / 085967A2; U.S. Patent Publication Nos. US2007 / 0231329, US2007 / 0231329, US2007 / 0237765, US2007 / 0237766, US2007 / 0237767, US2007 / 0243188, US20070248603, US20070286859, and US20080057 056;Or U.S. Patent No. 5,648,260、5,739,277、5,834,250、5,869,046、6,096,871、6,121,022、6,194,551、6,242,195、6,277,375、6,528,624、6,538,124、6,737,056、6,821,505、6,998,253、7,083,784 and 7,317,091, the parts about Fc mutation in each document are incorporated herein by reference. In one embodiment, specific changes (e.g., specific substitutions of one or more amino acids disclosed in the art) can be made at one or more disclosed amino acid positions. In another embodiment, different changes (e.g., different substitutions of one or more amino acid positions disclosed in the art) can be made at one or more disclosed amino acid positions.
[0259] In some embodiments, a parent Fc polypeptide may comprise an Fc portion comprising an amino acid substitution at an amino acid position corresponding to an EU amino acid position within the "15 Angstrom contact zone" of the Fc portion. The 15 Angstrom region includes residues located at EU positions 243 to 261, 275 to 280, 282 to 293, 302 to 319, 336 to 348, 367, 369, 372 to 389, 391, 393, 408, and 424 to 440 of a full-length wild-type Fc portion.
[0260] In another embodiment, the parent Fc polypeptide comprises an Fc region comprising one or more truncated Fc portions that are still sufficient to confer one or more functions upon the Fc region. For example, the portion of the Fc portion that binds to FcRn (i.e., the FcRn binding portion) comprises approximately amino acids 282-438 (EU numbering). Thus, the Fc portion of the parent Fc polypeptide may comprise or consist of an FcRn binding portion. The FcRn binding portion may be derived from any isotype, including the heavy chains of IgG1, IgG2, IgG3, and IgG4. In one embodiment, an FcRn binding portion from an antibody of the human isotype IgG1 is used. In another embodiment, an FcRn binding portion from an antibody of the human isotype IgG4 is used. In certain embodiments, the FcRn binding portion is aglycosylated. In other embodiments, the FcRn binding portion is glycosylated.
[0261] In certain embodiments, the parent Fc polypeptide comprises an amino acid substitution to the Fc portion that changes the antigen-independent effector function of the antibody, particularly the circulating half-life of the antibody. These polypeptides exhibit increased or decreased FcRn binding when compared to polypeptides lacking these substitutions, and therefore have a serum half-life that is increased or decreased, respectively. It is expected that parent Fc polypeptides with increased FcRn affinity have a longer serum half-life, and these molecules are suitable for use in methods for treating mammals where it is desired that the administered polypeptide have a long half-life, such as to treat chronic diseases or conditions. On the contrary, it is expected that parent Fc polypeptides with reduced FcRn binding affinity have a shorter half-life, and these molecules can also be used, for example, in cases where shortening the circulation time may be advantageous (e.g., for in vivo diagnostic imaging) or where the starting polypeptide is present in the circulation for a long time and has toxic side effects, to be administered to mammals. Parent Fc polypeptides with reduced FcRn binding affinity are also less likely to cross the placenta, and are therefore also suitable for treating diseases or conditions in pregnant women. In addition, other applications that may need to reduce FcRn binding affinity include those that need to locate the brain, kidney and / or liver. In an exemplary embodiment, the parent Fc polypeptide shows a reduction in transport across glomerular epithelial cells from blood vessels. In another embodiment, the binding polypeptide of the present invention shows a reduction in transport across the blood-brain barrier (BBB) from the brain into the vascular space. In one embodiment, the parent Fc polypeptide with altered FcRn binding comprises at least one Fc portion (e.g., one or two Fc portions), and the at least one Fc portion has one or more amino acid substitutions in the "FcRn binding loop" of the Fc portion. The FcRn binding loop comprises amino acid residues 280-299 (according to EU numbering) of the wild-type full-length Fc portion. In other embodiments, the parent Fc polypeptide with altered FcRn binding affinity comprises at least one Fc portion (e.g., one or two Fc portions), and the at least one Fc portion has one or more amino acid substitutions in the 15A FcRn "contact zone."
[0262] As used herein, the term 15A FcRn "contact region" includes residues at the following positions of the wild-type full-length Fc portion: 243-261, 275-280, 282-293, 302-319, 336-348, 367, 369, 372-389, 391, 393, 408, 424, 425-440 (EU numbering). In some embodiments, the parent Fc polypeptide with altered FcRn binding affinity comprises at least one Fc portion (e.g., one or two Fc portions) having one or more amino acid substitutions at amino acid positions corresponding to any of the following EU positions: 256, 277-281, 283-288, 303-309, 313, 338, 342, 376, 381, 384, 385, 387, 434 (e.g., N434A or N434K), and 438. Exemplary amino acid substitutions that alter FcRn binding activity are disclosed in International PCT Publication No. WO05 / 047327, which is incorporated herein by reference. In other embodiments, the parent Fc polypeptide comprises at least one Fc portion having an engineered cysteine residue or its analog located on a solvent-exposed surface. In some embodiments, the engineered cysteine residue or its analog does not interfere with the effector function conferred by the Fc region. In some embodiments, the Fc polypeptide comprises an Fc portion comprising at least one engineered free cysteine residue or its analog that is substantially free of a disulfide bond to a second cysteine residue. In some embodiments, the Fc polypeptide may comprise an Fc portion having an engineered cysteine residue or its analog at one or more of the following CH3 domain positions: 349-371, 390, 392, 394-423, 441-446, and 446b (EU numbering). In further embodiments, the Fc polypeptide comprises an Fc variant having an engineered cysteine residue or its analog at any of the following positions: 350, 355, 359, 360, 361, 389, 413, 415, 418, 422, 441, 443, and EU position 446b (EU numbering). Any of the above engineered cysteine residues or analogs thereof can then be conjugated to a functional moiety using art-recognized techniques (eg, conjugation with a thiol-reactive heterobifunctional linker).
[0263] B. No effector Fc peptide
[0264] In certain embodiments, the parent Fc polypeptide is an "effector-less" Fc polypeptide with altered or reduced effector function. In some embodiments, the reduced or altered effector function is an antigen-dependent effector function. For example, the parent Fc polypeptide may comprise sequence variations (e.g., amino acid substitutions) that, for example, reduce the antigen-dependent effector function, particularly ADCC or complement activation, of the polypeptide compared to a wild-type Fc polypeptide. Unfortunately, these parent Fc polypeptides often have reduced stability, making them ideal candidates for stabilization according to the methods of the present invention.
[0265] Fc polypeptides with reduced FcγR binding affinity are expected to reduce effector function, and these molecules are also useful, for example, in treating conditions where target cell destruction is undesirable, for example, where normal cells may express the target molecule, or where chronic administration of the polypeptide may cause unwanted immune system activation. In one embodiment, the Fc polypeptide exhibits reduced at least one antigen-dependent effector function selected from the group consisting of opsonization, phagocytosis, complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), or effector cell modulation compared to an Fc polypeptide comprising a wild-type Fc region. In one embodiment, the Fc polypeptide exhibits altered binding to an activating FcγR (e.g., FcγRI, FcγRIIa, or FcγRIIIa). In another embodiment, the Fc polypeptide exhibits altered binding affinity to an inhibitory FcγR (e.g., FcγRIIb). In other embodiments, the Fc polypeptide with decreased FcγR binding affinity (e.g., decreased FcγRI, FcγRII or FcγRIIIa binding affinity) comprises at least one Fc portion (e.g., one or two Fc portions) having an amino acid substitution at an amino acid position corresponding to one or more of the following positions: 234, 236, 239, 241, 251, 252, 261, 265, 268, 293, 294, 296, 298, 299, 301, 326, 328, 332, 334, 338, 376, 378, and 435 (EU numbering). In other embodiments, the Fc polypeptide with decreased complement binding affinity (e.g., decreased C1q binding affinity) comprises an Fc portion (e.g., one or two Fc portions) having an amino acid substitution at an amino acid position corresponding to one or more of the following positions: 239, 294, 296, 301, 328, 333, and 376 (EU numbering).
[0266] Exemplary amino acid substitutions that alter FcγR or complement binding activity are disclosed in International PCT Publication No. WO 05 / 063815, which is incorporated herein by reference. In certain embodiments, the binding polypeptides of the invention may comprise one or more of the following specific substitutions: S239D, S239E, M252T, H268D, H268E, I332D, I332E, N434A, and N434K (i.e., one or more of these substitutions at amino acid positions corresponding to one or more of these EU numbering positions in the Fc region of an antibody).
[0267] In certain exemplary embodiments, the effector function of the parent "effector-free" polypeptide may be altered or reduced due to the presence of an aglycosylated Fc region within the parent Fc polypeptide. In certain embodiments, the aglycosylated Fc region is generated by amino acid substitutions that alter the glycosylation of the Fc region. For example, the asparagine at EU position 297 within the Fc region can be altered (e.g., by substitution, insertion, deletion, or chemical modification) to inhibit its glycosylation. In another exemplary embodiment, the amino acid residue at EU position 299 (e.g., threonine (T)) is substituted (e.g., with alanine (A)) to reduce glycosylation at the adjacent residue 297. Exemplary amino acid substitutions that reduce or alter glycosylation are disclosed in International PCT Publication No. WO05 / 018572 and U.S. Patent Publication No. 2007 / 0111281, which are incorporated herein by reference. In other embodiments, an aglycosylated Fc region is produced by enzymatic or chemical removal of oligosaccharides or by expressing the Fc polypeptide in a host cell that is unable to glycosylate the Fc region (e.g., a bacterial host cell or a mammalian host cell with impaired glycosylation machinery).
[0268] In certain embodiments, the aglycosylated Fc region is partially aglycosylated or hemiglycosylated. For example, the Fc region may comprise a first glycosylated Fc portion (e.g., a glycosylated CH2 region) and a second aglycosylated Fc portion (e.g., an aglycosylated CH2 region). In other embodiments, the Fc region may be completely aglycosylated, i.e., none of its Fc portions are glycosylated.
[0269] The aglycosylated Fc region of the "effector-free" polypeptide may belong to any IgG isotype (e.g., IgG1, IgG2, IgG3, or IgG4). In an exemplary embodiment, the parent Fc polypeptide may comprise an aglycosylated Fc region of an IgG4 antibody, such as "agly IgG4.P". Agly IgG4.P is an engineered form of an IgG4 antibody comprising a proline substitution (Ser228Pro) in the hinge region and a Thr299Ala mutation in the CH2 domain to produce an aglycosylated Fc region (EU numbering). Agly IgG4.P has been shown to have no measurable immune effector function in vitro. In another exemplary embodiment, the parent Fc polypeptide comprises an aglycosylated Fc region of an IgG1 antibody, such as "agly IgG1". Agly IgG1 is an aglycosylated form of the IgG immunoglobulin IgG1 having a Thr299Ala mutation (EU numbering) that imparts a low effector function profile. Both agly IgG4.P and aglyIgG1 antibodies represent an important class of therapeutic agents where immune effector functions are not required.
[0270] In certain exemplary embodiments, the "effector-free" parent Fc polypeptide comprises an Fc region derived from an IgG4 antibody. The IgG4 Fc region may be identical to a wild-type Fc region, or it may have one or more modifications to the wild-type IgG4 sequence. These IgG4-like Fc polypeptides have reduced effector function due to the inherently reduced ability of IgG4 antibodies to bind to complement and / or Fc receptors. The parent Fc polypeptide of the IgG4 isotype may be glycosylated or aglycosylated. In addition, the Fc region of the IgG4-like Fc polypeptide may comprise the complete Fc portion of an IgG4 antibody, or it may comprise a chimeric Fc portion, wherein a portion of the Fc portion is derived from an IgG4 antibody and the remainder is derived from an antibody of another isotype. In an exemplary embodiment, the chimeric Fc portion comprises a CH3 domain from an IgG1 antibody and a CH2 domain from an IgG4 antibody. In another embodiment, the IgG4 antibody comprises a chimeric hinge, wherein the upper hinge domain and the lower hinge domain are derived from an IgG4 antibody, but due to a proline substitution (Ser228Pro) in the hinge region, the middle hinge domain is derived from an IgG1 antibody. In another embodiment, the parent chimeric IgG4 antibody comprises a chimeric hinge, wherein the upper hinge domain and the lower hinge domain are derived from an IgG4 antibody, but due to a proline substitution (Ser228Pro) in the hinge region, the middle hinge domain is derived from an IgG1 antibody, the CH1 domain is derived from an IgG1 or IgG4 antibody, the CH2 domain (or EU numbering positions 292-340) is derived from an IgG4 antibody, and the CH1 and / or CH3 domains are derived from an IgG1 antibody.
[0271] In certain embodiments, the reduction in effector function of an "effector-free" Fc polypeptide is a reduction in binding to an Fc receptor (FcR), such as FcγRI, FcγRII, FcγRIII and / or FcγRIIIb receptor, or a complement protein (e.g., complement protein C1q). This change in binding can be about 1-fold or more, such as about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 50, or 100-fold or more, or any interval or range thereof. These reductions in effector function (e.g., binding of Fc to an Fc receptor or complement protein) are readily calculated based on the percentage reduction in binding activity, for example, as determined using an assay described herein or an assay known in the art.
[0272] In one embodiment of the present invention, the stabilized Fc polypeptide comprises a single-chain Fc region. These single-chain Fc regions are known in the art (see, for example, WO200801243, WO2008131242, WO2008153954) and can be manufactured using known methods. Stabilizing amino acids as taught herein can be incorporated into one or more Fc portions of these constructs using methods known to those skilled in the art. These single-chain Fc regions or gene-fused Fc regions are synthetic Fc regions comprising an Fc domain (or Fc portion) genetically linked to a single polypeptide chain (i.e., encoded in a single continuous gene sequence). Therefore, a gene-fused Fc region (i.e., scFc region) is a monomer because it comprises one polypeptide chain, but the appropriate portion of the molecule dimerizes to form an n Fc region. It should be understood that the teachings herein about the Fc portion are applicable to double-chain Fc dimers and single-chain Fc dimers. For example, either type of Fc region construct can be derived from, for example, an IgG1 or IgG4 antibody, or can be chimeric (e.g., comprising a chimeric hinge and / or comprising a CH2 domain from an IgG4 antibody and a CH3 domain from an IgG1 antibody).
[0273] III. Variant Fc Polypeptides with Stabilized Fc Regions
[0274] In certain aspects, the present invention provides variant Fc polypeptides comprising an amino acid sequence that is a variant of any parent Fc polypeptide described above. In particular, the variant Fc polypeptides of the present invention comprise an Fc region (or Fc portion) having an amino acid sequence derived from the Fc region (or Fc portion) of a parent Fc polypeptide. In some embodiments, the variant Fc polypeptide differs from the parent Fc polypeptide in that there is at least one stabilizing Fc mutation described herein. In certain embodiments, the Fc variant may comprise other amino acid sequence changes. In some embodiments, the Fc variant will have enhanced stability compared to the parent Fc polypeptide and optionally have altered effector functions compared to the parent Fc polypeptide. For example, the variant Fc polypeptide may have an antigen-dependent effector function (e.g., ADCC and / or CDC) equivalent to or lower than the antigen-dependent effector function of the parent Fc polypeptide. Additionally or alternatively, the variant Fc polypeptide may have an antigen-independent effector function (e.g., an extended half-life) relative to the parent Fc polypeptide.
[0275] In certain embodiments, the variant Fc polypeptide comprises an Fc region (or Fc portion) that is substantially identical to the Fc region (or Fc portion) of the parent Fc polypeptide but has about one or more mutations (e.g., about 1 to about 20, about 1 to about 15, about 1 to about 10, about 1 to about 5, about 1 to about 4, about 1 to about 3, about 2 to about 20, about 2 to about 15, about 2 to about 10, about 5 to about 20, or about 5 to about 10) relative to the starting or parent polypeptide, such as an Fc region (or Fc portion) in which one or more amino acid residues have been substituted with another amino acid residue or have one or more amino acid residue insertions or deletions. In certain embodiments, the variant Fc polypeptide has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mutations relative to the starting polypeptide. In some embodiments, the variant polypeptide comprises a non-naturally occurring amino acid sequence.
[0276] In some embodiments, the variants will have an amino acid sequence that is less than 100% identical or similar to the starting polypeptide. In some embodiments, the variant will have an amino acid sequence that is, for example, about 75% to less than 100% identical or similar to the amino acid sequence of the starting polypeptide over the entire length of the variant molecule or portion thereof (e.g., Fc region or Fc portion), such as about 80% to less than 100%, or about 85% to less than 100%, or about 90% to less than 100% (e.g., 91-99%, 92-99%, 93-99%, 94-99%, 95-99%, 96-99%, 97-99%, 98-99% or 99%) or about 95% to less than 100%. In one embodiment, there is one amino acid difference between the starting polypeptide sequence (e.g., the Fc region of a parent Fc polypeptide) and the sequence derived therefrom (e.g., the Fc region of a variant Fc polypeptide).
[0277] In certain embodiments, the variant Fc polypeptide of the present invention is a stabilized Fc polypeptide. That is, the stabilized polypeptide comprises at least one sequence variation or mutation that is a stabilized Fc mutation. As used herein, the term "stabilized Fc mutation" includes mutations in the Fc region of the variant Fc polypeptide that confer enhanced protein stability (e.g., thermal stability) to the variant Fc polypeptide compared to the parent Fc polypeptide from which it is derived. In some embodiments, the stabilizing mutation comprises replacing the destabilizing amino acid in the Fc region with a replacement amino acid (herein, "stabilizing amino acid") that confer enhanced protein stability to the Fc region. In one embodiment, the stabilized Fc polypeptide of the present invention comprises one or more amino acid stabilized Fc mutations (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 stabilizing mutations). Stabilized Fc mutations can be introduced into, for example, the CH2 domain, CH3 domain, or both the CH2 domain and the CH3 domain of the Fc region.
[0278] In certain exemplary embodiments, the variant Fc polypeptides of the present invention are stabilized variants of the "effector-free" parent Fc polypeptides described above. That is, the stabilized variants have enhanced stability relative to the "effector-free parent Fc polypeptide." In one exemplary embodiment, the variant Fc polypeptide is a stabilized variant of a parent Fc polypeptide comprising an aglycosylated Fc region of an IgG1 antibody, such as an aglycosylated IgG1 Fc region comprising a T299A mutation (EU numbering). In another exemplary embodiment, the variant Fc polypeptide is a stabilized variant of a parent Fc polypeptide comprising an Fc region of a glycosylated or aglycosylated IgG4 antibody. For example, the variant Fc polypeptide may comprise a stabilizing mutation in an Fc region derived from an "agly IgG4.P" antibody.
[0279] In some embodiments, the stabilized Fc polypeptides of the present invention exhibit enhanced stability under the same measurement conditions compared to variant Fc polypeptides. However, it should be recognized that the degree of enhancement of the stability of Fc variant polypeptides relative to their parent Fc polypeptides may vary under the selected measurement conditions. For example, the enhancement of stability can be observed at a specific pH, such as an acidic, neutral or alkaline pH. In one embodiment, enhanced stability is observed at an acidic pH lower than about 6.0 (e.g., about 6.0, about 5.5, about 5.0, about 4.5 or about 4.0). In another embodiment, enhanced stability is observed at a neutral pH of about 6.0 to about 8.0 (e.g., about 6.0, about 6.5, about 7.0, about 7.5, about 8.0). In another embodiment, enhanced stability is observed at an alkaline pH of about 8.0 to about 10.0 (e.g., about 8.0, about 8.5, about 9.0, about 9.5, about 10.0).
[0280] Enhanced thermal stability of variant Fc polypeptides can be assessed, for example, using any of the methods described below. In certain embodiments, a stabilized Fc polypeptide comprises an Fc region (or Fc portion) that has a thermal stability (e.g., melting temperature or Tm) that is about 0.1, about 0.25, about 0.5, about 0.75, about 1, about 1.25, about 1.5, about 1.75, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 25, about 30, about 40, or about 50 degrees Celsius higher than the parent polypeptide from which it is derived. In certain embodiments, the stabilized Fc polypeptide variants of the invention are expressed as monomeric soluble proteins, with no more than 25% (e.g., less than about 25%, about 20%, about 15%, about 10%, or about 5%) dimeric, tetrameric, or other aggregated forms.
[0281] In another embodiment, the stabilized Fc polypeptide has a T50 in a thermal challenge assay of greater than 40°C (e.g., 40, 41, 42, 43, 44, 45, 46, 47, 48, 49°C or higher) (see U.S. Patent Application No. 11 / 725,970, incorporated herein by reference, and Example 4 below). In some embodiments, the stabilized Fc molecules of the invention have a T50 of greater than 50°C (e.g., 50, 51, 52, 53, 54, 55, 56, 57, 58°C or higher). In some embodiments, the stabilized Fc molecules of the invention have a T50 of greater than 60°C (e.g., 60, 61, 62, 63, 64, 65°C or higher). In other embodiments, the stabilized Fc molecules of the invention have a T50 of greater than 65°C (e.g., 65, 66, 67, 68, 69, 70°C or higher). In other embodiments, the stabilized Fc molecules of the invention have a T50 greater than 70°C (e.g., 70, 71, 73, 74, 75°C or greater).
[0282] In certain embodiments, the stabilized Fc molecules of the invention have a CH2 domain with a Tm value of greater than about 60°C (e.g., about 61, 62, 63, 64, 65°C or higher), greater than 65°C (e.g., 65, 66, 67, 68, 69°C or higher), or greater than about 70°C (e.g., 71, 72, 73, 74, 75°C or higher). In other embodiments, the stabilized Fc molecules of the invention have a CH3 domain with a Tm value of greater than about 70°C (e.g., about 71, 72, 73, 74, 75°C or higher), greater than about 75°C (e.g., 76, 77, 78, 79, 80°C or higher), or greater than 80°C (e.g., 81, 82, 83, 84, 85°C or higher). In specific embodiments, the stabilized Fc polypeptide is a variant of a parent Fc polypeptide comprising an aglycosylated or glycosylated Fc region of an IgG4 antibody (e.g., aglyIgG4.P). In other embodiments, the stabilized Fc polypeptide is a variant of a parent Fc polypeptide comprising an aglycosylated Fc region of an IgG1 antibody (e.g., agly IgG1). In other embodiments, the stabilized Fc molecules of the invention have an Fc region or Fc portion (e.g., CH2 and / or CH3 domains) having a thermal stability substantially equal to or greater than that of a glycosylated IgG1 antibody.
[0283] In certain embodiments, the variant Fc polypeptides of the present invention cause reduced aggregation compared to the parent Fc polypeptide from which they are derived. In one embodiment, the stabilized Fc molecules produced by the methods of the present invention have at least 1% reduced aggregation relative to the parent Fc molecule. In other embodiments, the stabilized Fc polypeptides have at least 2%, at least 5%, at least 10%, at least 20%, at least 30%, at least 50%, at least 75%, or at least 100% reduced aggregation relative to the parent molecule.
[0284] In other embodiments, the stabilized Fc polypeptides of the present invention result in an increase in long-term stability or shelf life compared to the parent Fc polypeptide from which they are derived. In one embodiment, the stabilized Fc molecules produced by the methods of the present invention have an increase in shelf life of at least 1 day relative to the unstabilized binding molecule. This means that the stabilized Fc polypeptide preparation has substantially the same amount of biologically active variant Fc polypeptide as was present the day before, and the preparation does not have any significant aggregation or decomposition of the variant polypeptide. In other embodiments, the shelf life of the stabilized Fc molecule is increased by at least 2 days, at least 5 days, at least 1 week, at least 2 weeks, at least 1 month, at least 2 months, at least 6 months, or at least 1 year relative to the unstabilized Fc molecule.
[0285] In certain embodiments, the stabilized Fc polypeptides of the present invention are expressed with increased yield compared to their parent Fc polypeptides. In one embodiment, the yield of the stabilized Fc polypeptides of the present invention is increased by at least 1% relative to the parent Fc molecule. In other embodiments, the yield of the stabilized Fc polypeptides is increased by at least 2%, at least 5%, at least 10%, at least 20%, at least 30%, at least 50%, at least 75%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 100% relative to the parent Fc molecule.
[0286] In an exemplary embodiment, the stabilized Fc polypeptides of the present invention are expressed in host cells, such as bacteria or eukaryotic (e.g., yeast or mammalian) host cells, with increased yield (compared to their parent Fc polypeptides). Exemplary mammalian host cells that can be used to express nucleic acid molecules encoding stabilized Fc polypeptides of the present invention include Chinese hamster ovary (CHO) cells, HELA (human cervical carcinoma) cells, CVI (monkey kidney cell line) cells, COS (CVI derivative with SV40 T antigen) cells, R1610 (Chinese hamster fibroblast) cells, BALBC / 3T3 (mouse fibroblast) cells, HAK (hamster kidney cell line) cells, SP2 / O (mouse myeloma) cells, BFA-1c1BPT cells (bovine endothelial cells), RAJI (human lymphocyte) cells, (human retinal derived cell line, Crucell, The Netherlands) and 293 cells (human kidney).
[0287] In other embodiments, the stabilized Fc polypeptides of the present invention are expressed in host cells at an increased yield (relative to their parent Fc polypeptide) under large-scale (e.g., industrial-scale) conditions. In an exemplary embodiment, the stabilized Fc molecules have an increased yield when expressed in at least 10 liters of culture medium. In other embodiments, the stabilized Fc binding molecules have an increased yield when expressed by host cells in at least 20 liters, at least 50 liters, at least 75 liters, at least 100 liters, at least 200 liters, at least 500 liters, at least 1000 liters, at least 2000 liters, at least 5,000 liters or at least 10,000 liters of culture medium. In an exemplary embodiment, at least 10 mg (e.g., 10 mg, 20 mg, 50 mg or 100 mg) of stabilized Fc molecules are produced per liter of culture medium.
[0288] (i) Stabilizing Fc Amino Acids
[0289] In certain embodiments, the stabilized Fc polypeptide of the invention comprises the CH2 domain (or amino acids 292-340 thereof) of an IgG4 molecule and the CH3 domain from an IgG1 molecule, with a Gln (Q) residue at position 297. In another embodiment, the stabilized Fc polypeptide of the invention comprises the CH2 and CH3 domains of an IgG1 molecule and a Lys (K) residue at position 299, either alone or in combination with an Asp (D) residue at position 297.
[0290] (ii) Exemplary stabilized Fc moieties
[0291] Exemplary stabilized Fc portions of the invention can be found throughout the application, in the Examples and in the Sequence Listing.
[0292] In certain exemplary embodiments, the stabilized Fc polypeptide of the invention comprises a stabilized IgG4 Fc region comprising one, two, or more Fc amino acid sequences shown in Table 1.1 below. Stabilizing Fc mutations are shown in bold and underlined.
[0293] Table 1.1: Stabilized IgG4 Fc fraction
[0294]
[0295]
[0296]
[0297]
[0298]
[0299] In certain exemplary embodiments, the stabilized Fc polypeptides of the invention comprise a stabilized chimeric Fc region having one, two, or more chimeric Fc portion amino acid sequences shown in Table 1.2 below.
[0300] Table 1.2: Stabilized chimeric Fc moieties
[0301]
[0302]
[0303] In other exemplary embodiments, the stabilized Fc polypeptide of the invention comprises a stabilized aglycosylated IgG1 Fc region having one, two, or more IgG1 Fc portion amino acid sequences shown in Table 1.3 below.
[0304] Table 1.3: Stabilized aglycosylated IgG1 Fc fraction
[0305]
[0306]
[0307] IV. Methods for Stabilizing Variant Fc Polypeptides
[0308] In certain aspects, the invention relates to a method of stabilizing a polypeptide comprising an Fc region (e.g., an aglycosylated Fc region), the method comprising: (a) selecting one or more amino acid positions within at least one Fc portion of a starting Fc region for mutation; and (b) mutating the one or more amino acid positions selected for mutation, thereby stabilizing the polypeptide.
[0309] In one embodiment, the starting Fc region is an IgG1 Fc region. In another embodiment, the starting Fc region is an IgG4 Fc region. In another embodiment, the starting Fc region is a chimeric Fc region. In one embodiment, the starting Fc region is an aglycosylated IgG1 Fc region. In another embodiment, the starting Fc region is an aglycosylated IgG4 Fc region.
[0310] In some embodiments, the Fc region of an antibody (or fragment thereof) as described herein has the sequence shown in SEQ ID NO:85.
[0311] In one embodiment, the amino acid position selected for mutation is in the extended loop in the Fc district of the starting IgG molecule (such as IgG4 molecule). In another embodiment, the amino acid position selected for mutation is present in the interface between the CH3 domains. In another embodiment, the amino acid position selected for mutation is near the contact site (such as, V264, R292 or V303) with the carbohydrate in the 1hzh crystal structure. In other embodiments, the amino acid position can be near the CH3 / CH2 interface, or near the CH3 / CH2 interface (such as H310). In another embodiment, one or more mutations that change the overall surface charge of the Fc district can be carried out, for example, in one or more of a group of surface-exposed glutamine residues (Q268, Q274 or Q355). In another embodiment, the amino acid position is the valine residue found in the " valine core " of CH2 and CH3. The "valine core" in CH2 is five valine residues (V240, V255, V263, V302, and V323) all oriented to the same proximal inner core of the CH2 domain. For CH3, a similar "valine core" (V348, V369, V379, V397, V412, and V427) was observed. In another embodiment, the amino acid position selected for mutation is a position expected to interact or contact with the N-linked carbohydrate at amino acid 297. The amino acid position can be identified by examining the crystal structure of the Fc region bound to a cognate Fc receptor (e.g., FcγRIIIa). Exemplary amino acids that interact with N297 include a loop formed by residues 262-270.
[0312] Exemplary amino acid positions include amino acid positions 240, 255, 262-266, 267-271, 292-299, 302-309, 379, 397-399, 409, 412, and 427 according to the EU numbering convention. In certain embodiments, the one or more amino acid positions selected for mutation are one or more amino acid positions selected from the group consisting of: 240, 255, 262, 263, 264, 266, 268, 274, 292, 299, 302, 303, 307, 309, 323, 348, 355, 369, 379, 397, 399, 409, 412, and 427. In certain embodiments, the one or more amino acid positions selected for mutation are one or more amino acid positions selected from the group consisting of: 240, 262, 264, 266, 297, 299, 307, 309, 399, 409, and 427. In another embodiment, the one or more amino acid positions are one or more amino acid positions selected from the group consisting of: 297, 299, 307, 309, 409, and 427. In another embodiment, the one or more amino acid positions are selected from amino acid residues 240, 262, 264, and 266. In another embodiment, at least one amino acid position is EU position 297. In another embodiment, at least one amino acid position is EU position 299. In another embodiment, at least one amino acid position is EU position 307. In another embodiment, at least one amino acid position is EU position 309. In another embodiment, at least one amino acid position is EU position 399. In another embodiment, at least one amino acid position is EU position 409. In another embodiment, at least one amino acid position is EU position 427.
[0313] In certain embodiments, the Fc region is an IgG1 Fc region. In certain embodiments, wherein the Fc region is an IgG1 Fc region, one or more amino acid positions are selected from amino acid residues 240, 262, 264, 299, 297, and 266 according to EU numbering. In other embodiments, wherein the Fc region is an IgG4 Fc region, one or more amino acid positions are selected from amino acid residues 297, 299, 307, 309, 399, 409, and 427 according to EU numbering.
[0314] In one embodiment, the mutation reduces the size of the amino acid side chain at the amino acid position (e.g., substitution with alanine (A), serine (S), or threonine (T)). In another embodiment, the mutation is substitution with an amino acid having a non-polar side chain (e.g., substitution with glycine (G), alanine (A), valine (V), leucine (L), isoleucine (I), methionine (M), proline (P), phenylalanine (F), and tryptophan (W)). In another embodiment, the mutation increases the hydrophobicity of the CH3 interface, for example, increasing the association between the two interaction domains (e.g., Y349F, T350V, and T394V) or increasing the volume of the interface side chain (e.g., F405Y). In another embodiment, one or more amino acids of the "valine core" are substituted with isoleucine or phenylalanine to increase its stability. In another embodiment, the amino acids (e.g., L351 and / or L368) are mutated to more highly branched hydrophobic side chains.
[0315] In one embodiment, the mutation is a substitution with alanine (A). In one embodiment, the mutation is a substitution with phenylalanine (F). In another embodiment, the mutation is a substitution with leucine (L). In one embodiment, the mutation is a substitution with threonine (T). In another embodiment, the mutation is a substitution with lysine (K). In one embodiment, the mutation is a substitution with proline (P). In one embodiment, the mutation is a substitution with phenylalanine (F).
[0316] In one embodiment, the mutation comprises one or more mutations or substitutions shown in Table 5.1, Table 5.2, Table 5.3, and / or Table 5.4 below.
[0317] In certain embodiments, the mutation comprises one or more substitutions selected from the group consisting of: 240F, 262L, 264T, 266F, 297Q, 297S, 297D, 299A, 299K, 307P, 309K, 309M, 309P, 323F, 399S, 409M, and 427F (EU numbering convention). In another embodiment, the mutation comprises one or more substitutions selected from the group consisting of: 299A, 299K, 307P, 309K, 309M, 309P, 323F, 399E, 399S, 409K, 409M, and 427F. In another embodiment, the one or more amino acid positions are selected from amino acid residues 240F, 262L, 264T, and 266F. In another embodiment, at least one substitution is 299A. In another embodiment, at least one substitution is 299K. In another embodiment, at least one substitution is 307P. In another embodiment, at least one substitution is 309K. In another embodiment, at least one substitution is 309M. In another embodiment, at least one substitution is 309P. In another embodiment, at least one substitution is 323F. In another embodiment, at least one substitution is 399S. In another embodiment, at least one substitution is 399E. In another embodiment, at least one substitution is 409K. In another embodiment, at least one substitution is 409M. In another embodiment, at least one substitution is 427F.
[0318] In another embodiment, the mutation comprises two or more substitutions (e.g., 2, 3, 4, or 5). In another embodiment, the mutation comprises three or more substitutions (e.g., 3, 4, 5, or 6). In another embodiment, the stabilized Fc region comprises four or more substitutions (e.g., 4, 5, 6, or 7).
[0319] In another aspect, the present invention relates to a method for producing a stabilized binding molecule comprising a stabilized Fc region, the method comprising genetically fusing a polypeptide comprising a stabilized Fc region of the invention to the amino terminus or carboxyl terminus of a binding moiety. In certain embodiments, the stabilized Fc region is stabilized according to the methods of the invention.
[0320] In another embodiment, therapeutic antibodies can eliminate disturbances or reduce the susceptibility of antibodies to disturbances. Certain antibodies, such as antibodies with wild-type IgG4 constant regions (e.g., including hinge regions), may be prone to disturbing endogenous IgG4 antibodies to produce two copies of functional monovalent products (see, e.g., Aalberse and Schuurman, Immunology 105:9-19, 2002). The rate of disturbance may depend on endogenous IgG4 levels and this is variable. Therefore, therapeutic antibodies with wild-type human IgG4 constant regions have variable pharmacokinetic / pharmacodynamic (PK / PD) profiles. Antibody disturbances with wild-type IgG4 constant regions can produce bispecific antibodies that are monovalent with respect to VLA4 and monovalent with respect to another antigen. Thus, in some embodiments, the therapeutic antibodies described herein have a more consistent PK profile compared to antibodies with the same specificity (e.g., specifically binding to α4) but with wild-type IgG4 constant regions. In some embodiments, the more consistent PK profiles of the therapeutic antibodies described herein may increase the safety, increase the purity, and / or increase the potency of the antibodies described herein compared to an antibody with the same specificity (e.g., specifically binds to α4) but with a wild-type IgG4 constant region.
[0321] In some embodiments, therapeutic antibodies comprising a heavy chain hinge and Fc region that are chimeras or hybrids between human IgG1 and human IgG4 antibodies can reduce or eliminate perturbations of antibodies comprising hinges and Fc regions from human IgG4 molecules. In one embodiment, the antibodies described herein with chimeric or hybrid heavy chain constant regions can eliminate perturbations or reduce the susceptibility of antibodies to perturbations, thereby reducing PK / PD variability. In some embodiments, the therapeutic antibodies described herein have lower PK / PD variability compared to antibodies with the same specificity (e.g., specific binding to α4) but with a wild-type IgG4 constant region. In certain embodiments, the antibodies described herein can increase the potency of bivalent monoclonal antibodies and / or eliminate bispecificity due to perturbations. In certain embodiments, the antibodies described herein can exhibit higher binding affinity compared to their unmutated counterparts or compared to antibodies with the same specificity (e.g., specific binding to α4) but with a wild-type IgG4 constant region and / or showing higher sustained receptor occupancy. In some embodiments, the therapeutic antibodies described herein with lower PK / PK variability and / or higher binding affinity and / or reduced or eliminated scrambling can increase the safety, purity, and / or potency of the antibodies described herein compared to antibodies with the same specificity (e.g., specifically binding to α4) but with a wild-type IgG4 constant region. In a preferred embodiment, the antibody that eliminates scrambling or reduces the susceptibility of the antibody to scrambling is a recombinant anti-α4 antibody comprising: (a) a heavy chain comprising, consisting essentially of, or consisting of the sequence of SEQ ID NO: 80; and (b) a light chain comprising, consisting essentially of, or consisting of the sequence of SEQ ID NO: 81.
[0322] V. Methods for Assessing Protein Stability
[0323] The stability of the present composition can be analyzed using methods known in the art. Stability parameters acceptable to those skilled in the art can be used. Exemplary parameters are described in more detail below. In exemplary embodiments, thermal stability is assessed. In some embodiments, the expression level of the present composition is assessed (e.g., as measured by % yield). In some embodiments, the aggregation level of the present composition is assessed.
[0324] In certain embodiments, the stability of the Fc polypeptide is compared to the stability of a suitable control. Exemplary controls include a parent Fc polypeptide, such as a wild-type Fc polypeptide, a wild-type (glycosylated) IgG1 or IgG4 antibody. Another exemplary control is an aglycosylated Fc polypeptide, an aglycosylated IgG1 or IgG4 antibody. In one embodiment, one or more parameters described below are measured.
[0325] In one embodiment, one or more of these parameters are measured following expression in mammalian cells. In one embodiment, one or more of the parameters described below are measured under large-scale manufacturing conditions (e.g., expression of an Fc polypeptide or a molecule comprising an Fc polypeptide in a bioreactor).
[0326] A. Thermal stability
[0327] The thermal stability of the compositions of the present invention can be analyzed using a number of non-limiting biophysical or biochemical techniques known in the art. In certain embodiments, thermal stability is assessed by analytical spectroscopy. An exemplary analytical spectroscopy method is differential scanning calorimetry (DSC). DSC uses a calorimeter that is sensitive to the unfolding of most proteins or protein domains accompanied by heat absorption (see, for example, Sanchez-Ruiz et al., Biochemistry, 27:1648-52, 1988). In order to determine the thermal stability of a protein, a protein sample is inserted into a calorimeter and the temperature is raised until the Fc polypeptide (or its CH2 or CH3 domain) unfolds. The temperature during protein unfolding indicates overall protein stability.
[0328] Another exemplary analytical spectroscopy method is circular dichroism (CD) spectroscopy. CD spectroscopy measures the change in the optical activity of a composition as temperature increases. Circular dichroism (CD) spectroscopy measures the difference in absorption of left-polarized light relative to right-polarized light due to structural asymmetry. Disordered or unfolded structures give rise to CD spectra that are very different from those of ordered or folded structures. CD spectra reflect the sensitivity of a protein to denaturation by increasing temperature and are therefore indicative of its thermal stability (see van Mierlo and Steemsma, J. Biotechnol, 79(3):281-98, 2000).
[0329] Another exemplary analytical spectroscopy method for measuring thermal stability is fluorescence emission spectroscopy (see van Mierlo and Steemsma, supra). Another exemplary analytical spectroscopy method for measuring thermal stability is nuclear magnetic resonance (NMR) spectroscopy (see, e.g., van Mierlo and Steemsma, supra).
[0330] In other embodiments, the thermal stability of the compositions of the present invention is measured by biochemical means. An exemplary biochemical method for assessing thermal stability is a thermal attack assay. In a "thermal attack assay," the compositions of the present invention are subjected to a range of elevated temperatures for a set period of time. For example, in one embodiment, a test Fc polypeptide comprising an Fc region is subjected to a range of elevated temperatures, for example, for 1-1.5 hours. The ability of the Fc region to bind to an Fc receptor (e.g., FcγR, protein A, or protein G) is then determined by a relevant biochemical assay (e.g., ELISA or DELFIA). An exemplary thermal attack assay is described in Example 4 below.
[0331] In one embodiment, this assay can be performed in a high-throughput format. In another embodiment, a library of Fc variants can be created using methods known in the art. Fc expression can be induced and the Fc can be thermally challenged. Binding of the challenged test samples can be determined and those stabilizing Fc polypeptides can be scaled up and further characterized.
[0332] In certain embodiments, thermal stability is assessed by measuring the melting temperature (Tm) of the compositions of the invention using any of the above techniques (e.g., analytical spectroscopy techniques). The melting temperature is the temperature at the midpoint of the thermal transition curve where 50% of the molecules of the composition are in a folded state.
[0333] In other embodiments, thermal stability is assessed by measuring the specific heat or heat capacity (Cp) of the composition of the present invention using analytical calorimetry techniques (e.g., DSC). The specific heat of a composition is the energy (e.g., in kcal / mol) required to raise the temperature of 1 mol of water by 1°C. Because a large Cp is a hallmark of a denatured or inactive protein composition, in certain embodiments, the change in heat capacity (ΔCp) of the composition is measured by measuring its specific heat before and after thermal transfer of the composition. In other embodiments, thermal stability can be assessed by measuring or determining other thermodynamic stability parameters, including Gibbs free energy of unfolding (ΔG), enthalpy of unfolding (ΔH), or entropy of unfolding (ΔS).
[0334] In other embodiments, one or more of the above biochemical assays (eg, thermal challenge assays) is used to determine the temperature at which 50% of a composition retains its activity (eg, binding activity) (ie, Tc value).
[0335] B. Aggregation %
[0336] In certain embodiments, the stability of the present composition is determined by measuring its aggregation tendency. Aggregation can be measured by many non-restrictive biochemical or biophysical techniques. For example, chromatography, such as size exclusion chromatography (SEC), can be used to assess the aggregation of the present composition. SEC separates molecules based on size. The column is filled with semi-solid beads of a polymer gel, thereby allowing ions and small molecules but not allowing macromolecules to enter its interior. When the protein composition is applied to the top of the column, tightly folded proteins (i.e., non-aggregated proteins) are distributed to a larger volume of solvent than the available volume of large protein aggregates. Therefore, large aggregates move through the column more quickly, and the mixture can be separated or graded into its components in this way. Each fraction can be quantified (e.g., by light scattering) when it is eluted from the gel. Therefore, the aggregation % of the present composition can be determined by comparing the concentration of the fraction with the total concentration of the protein applied to the gel. The stable composition is eluted as a basic single fraction from the column and is presented as a basic single peak in the elution curve or chromatogram.
[0337] In some embodiments, SEC is combined with tandem light scattering (e.g., classical or dynamic light scattering) to determine the aggregation % of the composition. In certain embodiments, static light scattering is used to measure the mass of each fraction or peak, regardless of the molecular shape or elution position. In some embodiments, dynamic light scattering is used to measure the hydrodynamic size of the composition. Other exemplary methods for evaluating protein stability include high-speed SEC (see, e.g., Corbett et al., Biochemistry. 23 (8): 1888-94, 1984).
[0338] In one non-limiting embodiment, the % aggregation is determined by measuring the fraction of protein aggregates within the protein sample. In some embodiments, the % aggregation of a composition is measured by determining the fraction of folded protein within the protein sample.
[0339] C. Yield %
[0340] In other embodiments, the stability of the compositions of the invention is assessed by measuring the amount of protein recovered (herein "% yield") after protein expression (e.g., recombinant expression). For example, % yield can be measured by determining milligrams of protein recovered per ml of host culture medium (i.e., mg / ml protein). In some embodiments, % yield is assessed after expression in mammalian host cells (e.g., CHO cells).
[0341] D. Loss %
[0342] In other embodiments, the stability of the present composition is assessed by monitoring the protein loss after storing a limited time period under a certain range of temperature (e.g., -80°C to 25°C). Any protein quantification method known in the art can be used to measure the amount or concentration of the recovered protein and compared with the initial concentration of the protein. Exemplary protein quantification methods include SDS-PAGE analysis or Bradford assay (Bradford et al., Anal.Biochem.72,248, (1976)). Any analytical SEC method described above is used to assess the non-limiting method of loss %. It should be understood that the loss % measurement can be measured under any desired storage conditions or storage formulations, including, for example, freeze-dried protein formulations.
[0343] E. Protein hydrolysis%
[0344] In other embodiments, the stability of the compositions of the invention is assessed by measuring the amount of protein that undergoes proteolysis after storage under standard conditions. In one exemplary embodiment, proteolysis of a protein sample is measured by SDS-PAGE, where the amount of intact protein is compared to the amount of low molecular weight fragments that appear on the SDS-PAGE gel. In another exemplary embodiment, proteolysis is measured by mass spectrometry (MS), where the amount of protein with an expected molecular weight is compared to the amount of low molecular weight protein fragments within the sample.
[0345] F. Binding affinity
[0346] In other embodiments, the stability of the compositions of the present invention can be assessed by measuring their target binding affinity. Various methods for determining binding affinity are known in the art. An exemplary method for determining binding affinity employs surface plasmon resonance. Surface plasmon resonance is an optical phenomenon that allows for analysis of real-time biospecific interactions by detecting changes in protein concentration within a biosensor matrix, for example using a BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ). For further description, see Jonsson, U. et al., (1993) Ann. Biol. Clin. 51: 19-26; Jonsson, U. et al., (1991) Biotechniques 11: 620-627; Johnsson, B. et al., (1995) / . MoI. Recognit. 8: 125-131; and Johnnson, B. et al., (1991) Anal. Biochem. 198: 268-277.
[0347] G. Other Combination Studies
[0348] In other embodiments, the stability of the compositions of the invention can be assessed by quantifying the binding of labeled compounds to the denatured or unfolded portion of the binding molecule. These molecules can be hydrophobic, as they may bind to or interact with large hydrophobic amino acid patches that are normally buried within native proteins but are exposed in denatured or unfolded binding molecules. An exemplary labeled compound is the hydrophobic fluorescent dye 1-anilino-8-naphthalenesulfonate (ANS).
[0349] VI. Stabilized Binding Polypeptides Comprising Stabilized Fc Regions
[0350] In one embodiment, the polypeptide of the present invention comprises a CH1 domain from an IgG4 antibody, a CH2 domain from an IgG4 antibody, and a CH3 domain from an IgG1 antibody. In one embodiment, the polypeptide further comprises a Ser228Pro substitution. The polypeptide may further comprise a mutation at amino acid 297 and / or 299, such as 297Q and / or 299K or 297S and / or 299K. The polypeptide may further comprise a CH1 domain from an IgG1 or IgG4 antibody, a CH2 domain from an IgG4 antibody, and a CH3 domain from an IgG1 antibody; the polypeptide may comprise one or more of Ser228Pro, 297Q, or 299K substitutions. The amino acid sequence of an Fc region consisting of a CH1 domain from an IgG4 molecule (with a Ser228Pro substitution), a CH2 domain from an IgG4 antibody, and a CH3 domain from an IgG1 antibody is provided as SEQ ID NO: 43. In one embodiment, the stabilized Fc polypeptide of the present invention comprises the amino acid sequence set forth in SEQ ID NO: 40. In one embodiment, the stabilized Fc polypeptide of the present invention comprises the amino acid sequence set forth in SEQ ID NO: 74. In one embodiment, the stabilized Fc polypeptide of the present invention comprises the amino acid sequence set forth in SEQ ID NO: 75. In one embodiment, the stabilized Fc polypeptide of the present invention comprises the amino acid sequence set forth in SEQ ID NO: 76. In one embodiment, the stabilized Fc polypeptide of the present invention comprises the amino acid sequence set forth in SEQ ID NO: 77.
[0351] In one embodiment, the Fc region of the polypeptide of the present invention is a single chain (scFc). In one embodiment, the molecule comprising the Fc region described in this paragraph is monovalent. In one embodiment, the molecule comprising the Fc region described in this paragraph is monovalent and the Fc region is a scFc. The molecule comprising the Fc region described herein may also comprise an scFv.
[0352] VII. Stabilized Fc-containing polypeptides comprising functional moieties
[0353] The variant Fc-containing polypeptides of the present invention can be further modified to provide desired effects. For example, the Fc region of the variant Fc polypeptide can be linked, for example covalently linked, to additional moieties, i.e., functional moieties, such as blocking moieties, detectable moieties, diagnostic moieties, and / or therapeutic moieties. Exemplary functional moieties are described below, followed by suitable chemical reactions for chemically linking these functional moieties to various amino acid side chains.
[0354] Examples of applicable functional moieties include, but are not limited to, blocking moieties, detectable moieties, diagnostic moieties, and therapeutic moieties. Exemplary blocking moieties include moieties with a spatial volume and / or charge sufficient to reduce effector function (e.g., by inhibiting the ability of Fc region binding receptors or complement proteins). Non-restrictive blocking moieties include polyalkylene glycol moieties, such as PEG moieties or PEG-maleimide moieties. Non-restrictive PEGylation moieties (or related polymers) can be, for example, polyethylene glycol ("PEG"), polypropylene glycol ("PPG"), polyoxyethylated glycerol ("POG"), and other polyoxyethylated polyols, polyvinyl alcohol ("PVA"), and other polyalkylene oxides, polyoxyethylated sorbitol, or polyoxyethylated glucose. Polymers can be homopolymers, random or block copolymers, terpolymers based on the monomers listed above, straight or branched, substituted or unsubstituted, as long as they have at least one active sulfone moiety. Polymer moieties can have any length or molecular weight, but these features may affect biological properties. The average molecular weight of polymers particularly suitable for reducing clearance in pharmaceutical applications is in the range of 2,000 to 35,000 daltons. In addition, if two groups are attached to the polymer, one at each end, the length of the polymer can affect the effective distance and other spatial relationships between the two groups. Thus, those skilled in the art can vary the length of the polymer to optimize or impart the desired biological activity. PEG is suitable for biological applications for several reasons. PEG is generally transparent, colorless, odorless, soluble in water, heat-stable, inert to many chemical reagents, non-hydrolyzed, and non-toxic. PEGylation can improve the pharmacokinetic properties of a molecule by increasing its apparent molecular weight. Increased apparent molecular weight reduces the rate of clearance from the body after subcutaneous or systemic administration. In many cases, PEGylation can reduce antigenicity and immunogenicity. In addition, PEGylation can increase the solubility of bioactive molecules.
[0355] Pegylated antibodies and antibody fragments are generally useful for treating diseases that can be alleviated or regulated by administering the antibodies and antibody fragments described herein. In general, pegylated aglycosylated antibodies and antibody fragments have an increased half-life compared to non-pegylated aglycosylated antibodies and antibody fragments. Pegylated aglycosylated antibodies and antibody fragments can be used alone, together, or in combination with other pharmaceutical compositions. Examples of detectable moieties suitable for use in the methods and polypeptides of the present invention include fluorescent moieties, radioisotope moieties, radiopaque moieties, etc., such as detectable markers, such as biotin, fluorophores, chromophores, spin resonance probes, or radiolabeled markers. Exemplary fluorophores include fluorescent dyes (e.g., fluorescein, rhodamine, etc.) and other luminescent molecules (e.g., luminal). Fluorophores can be environmentally sensitive so that if they are located near one or more residues in the modified protein that undergo structural changes after binding to a substrate (e.g., dansyl probe), their fluorescence changes. Exemplary radiolabels include small molecules containing atoms with one or more low-sensitivity nuclei (13C, 15N, 2H, 125I, 123I, 99Tc, 43K, 52Fe, 67Ga, 68Ga, 111In, etc. Other suitable moieties are known in the art.
[0356] Examples of diagnostic moieties suitable for use in the methods and polypeptides of the present invention include detectable moieties suitable for revealing the presence of a disease or illness. Typically, diagnostic moieties allow determination of the presence, absence, or level of a molecule (e.g., a target peptide, one or more proteins) associated with a disease or illness. These diagnostic agents are also suitable for prognosis and / or diagnosis of a disease or illness and its progression.
[0357] Examples of therapeutic moieties suitable for use in the methods and polypeptides of the invention include, for example, anti-inflammatory agents, anti-cancer agents, anti-neurodegenerative agents, and anti-infective agents.A functional moiety may also have one or more of the functions described above.
[0358] Exemplary therapeutic agents include radionuclides with high-energy ionizing radiation that can cause multiple strand breaks in nuclear DNA and are therefore suitable for inducing cell death (e.g., cancer). Exemplary high-energy radionuclides include: Y, I, I, I, In, Rh, Sm, Cu, Ga, Ho, Lu, Re, and Re. These isotopes typically produce high-energy OC particles or beta particles with short path lengths. These radionuclides kill cells in their immediate vicinity, such as neoplastic cells to which the conjugate has attached or entered. They have little or no effect on non-localized cells and are substantially non-immunogenic.
[0359] Exemplary therapeutic agents also include cytotoxic agents, such as cytostatic agents (e.g., alkylating agents, DNA synthesis inhibitors, DNA intercalating or cross-linking agents, or DNA-RNA transcription regulators), enzyme inhibitors, gene regulatory agents, cytotoxic nucleosides, tubulin binding agents, hormones and hormone antagonists, anti-angiogenic agents, and the like.
[0360] Exemplary therapeutic agents also include alkylating agents, such as anthracycline drugs (e.g., adrinomycin, carminomycin, cyclosporin A, chloroquine, methotrexate, mithramycin, porfiromycin, streptomycin, porfiromycin, anthracenedione, and aziridine). In another embodiment, the chemotherapeutic moiety is a cytostatic agent, such as a DNA synthesis inhibitor. Examples of DNA synthesis inhibitors include, but are not limited to, methotrexate and dichloromethotrexate, 3-amino-1,2,4-benzotriazine 1,4-dioxide, aminopterin, cytosine β-D-arabinofuranoside, 5-fluoro-5'-deoxyuridine, 5-fluorouracil, ganciclovir, hydroxyurea, actinomycin D, and mitomycin C. Exemplary DNA intercalating agents or cross-linking agents include, but are not limited to, bleomycin, carboplatin, carmustine, chlorambucil, cyclophosphamide, cisplatin (II) (cisplatin), melphalan, mitoxantrone, and oxaliplatin. Exemplary therapeutic agents also include transcriptional regulators, such as actinomycin D, daunorubicin, doxorubicin, homoharringtonine, and idarubicin. Other exemplary cytostatics compatible with the present invention include ansamycin benzoquinone, quinone-like derivatives (e.g., quinolones, genistein, bactacyclin), busulfan, ifosfamide, mechlorethamine, triaziquone, diaziquone, carbazilquinone, indoloquinone EO9, diaziridinyl-benzoquinonemethide DZQ, triethylenephosphoramide, and nitrosourea compounds (e.g., carmustine, lomustine, semustine).
[0361] Exemplary therapeutic agents also include cytotoxic nucleosides, such as adenosine, cytarabine, cytosine arabinoside, 5-fluorouracil, fludarabine, floxuridine, ftorafur, and 6-mercaptopurine; tubulin-binding agents, such as taxoids (e.g., paclitaxel, docetaxel, taxanes), nocodazole, rhizoctonia solani, dolastatin (e.g., dolastatin-10, dolastatin-11, or dolastatin-15), colchicine, and colchicine (e.g., ZD6126). , Combretastatins (e.g., Combretastatin A-4, AVE-6032) and Vinca alkaloids (e.g., vinblastine, vincristine, vindesine and vinorelbine (navelbine)); anti-angiogenic compounds, such as angiostatin K1-3, DL-α-difluoromethyl-ornithine, endostatin, fumagillin, genistein, minocycline, staurosporine and (±)-thalidomide. Exemplary therapeutic agents also include hormones and hormone antagonists, such as corticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone or medroprogesterone), estrogens (e.g., diethylstilbestrol), antiestrogens (e.g., tamoxifen), androgens (e.g., testosterone), aromatase inhibitors (e.g., aminogluthetimide), 17-(allyl)-1,1-diol, 1,1-dapoxetine ... 4-Amino-1,8-naphthalimide, apigenin, brefeldin A, cimetidine, dichloromethylene diphosphonic acid, leuprolide (leuprorelin), luteinizing hormone-releasing hormone, pifithrin-alpha, rapamycin, sex hormone-binding globulin, and thapsigargin.
[0362] Exemplary therapeutic agents also include enzyme inhibitors such as S(+)-camptothecin, curcumin, (-)-deguelin, 5,6-dichlorobenzimidazole 1-β-D-ribofuranoside, ethopreside, formestane, forstrexin, sclerostin, 2-imino-1-imidazolidineacetic acid (cyclocreatine), mevinolin, trichostatin A, tyrosine phosphotin AG 34, and tyrosine phosphotin AG 879. Exemplary therapeutic agents also include gene modulators such as 5-aza-2'-deoxycytidine, 5-azacytidine, cholecalciferol (vitamin D3), 4-hydroxytamoxifen, melatonin, mifepristone, raloxifene, trans-retinal (vitamin A aldehyde), retinoic acid, tretinoic acid, 9-cis-retinoic acid, 13-cis-retinoic acid, retinol (vitamin A), tamoxifen, and troglitazone.
[0363] Exemplary therapeutic agents also include cytotoxic agents such as the pteridine family of drugs, diacetylenes, and podophyllotoxins. Particularly suitable members of those classes include, for example, methylpterin, podophyllotoxin, or podophyllotoxin derivatives such as ethopreside or ethopreside phosphate, isovinblastine, vindesine, vinblastine epoxide, and the like.
[0364] Other cytotoxins compatible with the teachings herein include auristatins (e.g., auristatin E and monomethyl auristatin E), calicheamicin, gramicidin D, maytansines (e.g., maytansine), neocarzinostatin, topotecan, taxanes, cytokinin B, ethidium bromide, emetine, tenoposide, colchicine, dihydroxyanthracenediones, mitoxantrone, procaine, tetracaine, lidocaine, propranolol, puromycin, and analogs or homologs thereof. Other types of functional moieties are known in the art and can be readily used in the methods and compositions of the present invention based on the teachings contained herein.
[0365] Chemical reactions for attaching the above-mentioned functional moieties, small molecules, nucleic acids, polymers, peptides, proteins, chemotherapeutic agents or other types of molecules to specific amino acid side chains are known in the art (for a detailed review of specific linkers, see, e.g., Hermanson, GT, Bioconjugate Techniques, Academic Press (1996)).
[0366] VIII. Pharmaceutical Compositions
[0367] α4 binding agents (e.g., VLA-4 binding antibodies with stabilized Fc regions) can be formulated as pharmaceutical compositions. Typically, pharmaceutical compositions include a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
[0368] "Pharmaceutically acceptable salts" refers to salts that retain the desired biological activity of the parent compound and do not impart any undesirable toxicological effects (see, for example, Berge, SM et al., (1977) J. Pharm. Sci. 66: 1-19). Examples of such salts include acid addition salts and base addition salts. Acid addition salts include those derived from non-toxic inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, and the like; and non-toxic organic acids such as aliphatic monocarboxylic acids and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, aromatic acids, aliphatic and aromatic sulfonic acids, and the like. Base addition salts include those derived from alkaline earth metals such as sodium, potassium, magnesium, calcium, and the like; and non-toxic organic amines such as N,N'-diphenylmethylethylenediamine, N-methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine, and the like.
[0369] Antibody compositions described herein can be prepared according to methods known in the art. Pharmaceutical formulations are established technologies and are further described in: Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20th edition, Lippincott, Williams & Wilkins (2000) (ISBN: 0683306472); Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th edition, Lippincott Williams & Wilkins Publishers (1999) (ISBN: 0683305727); and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3rd edition (2000) (ISBN: 091733096X).
[0370] In one embodiment, the α4 antibody can be formulated with excipient materials such as sodium chloride, disodium hydrogen phosphate heptahydrate, sodium dihydrogen phosphate, and polysorbate 80. In another embodiment, the α4 antibody can be formulated in a citrate buffer, for example, at a pH of 5, 5.5, 6, 6.5, 7, or 7.5. In another embodiment, the α4 antibody can be formulated in a solution comprising 2%, 4%, 5%, 6%, 8%, 10%, 12%, 14%, or 15% sucrose. It can be provided, for example, at a concentration of about 20 mg / ml in a buffered solution and can be stored at 2-8°C.
[0371] Pharmaceutical compositions can also be in a variety of other forms. These include, for example, liquid, semisolid and solid dosage forms, such as liquid solutions (e.g., injectable solutions and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The form can depend on the intended mode of administration and therapeutic application. Typically, the compositions of the agents described herein are in the form of injectable or infusible solutions.
[0372] These compositions can be administered by parenteral modes (e.g., intravenous, subcutaneous, intraperitoneal or intramuscular injection). As used herein, the phrases "parenteral administration" and "parenteral administration" mean modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion.
[0373] Pharmaceutical compositions generally must be sterile and stable under the conditions of manufacture and storage.Pharmaceutical compositions can also be tested to ensure that they meet regulatory and industry standards for administration.
[0374] The composition can be formulated as a solution, microemulsion, dispersion, liposome or other ordered structures suitable for high drug concentration. Sterile injectable solutions can be prepared by optionally incorporating the agent described herein into a suitable solvent with one or combination of the ingredients listed above in the required amount, followed by filtration sterilization. In general, dispersions are prepared by incorporating the agent described herein into a sterile vehicle containing a basic dispersion medium and other required components from those ingredients listed above. In the case of sterile powders for the preparation of sterile injectable solutions, typical preparation methods are vacuum drying and freeze drying, thereby producing the agent described herein plus the powder of any other required components by its previously aseptically filtered solution. For example, the coating agent can be by using lecithin, by maintaining the required particle size and by using a surfactant to maintain the appropriate fluidity of the solution in the case of a dispersion. The absorption of the injectable composition can be extended by including an absorption delay agent (such as monostearate and gelatin) in the composition.
[0375] IX. Administration
[0376] The α4 binding antibody with a stabilized Fc region can be administered to a subject, such as a human subject, by a variety of methods. For many applications, the route of administration is one of: intravenous injection or infusion, subcutaneous injection, or intramuscular injection. The α4 binding antibody can be administered as a fixed dose or in a mg / kg dosage form. The antibody can be administered intravenously (IV) or subcutaneously (SC). For example, the antibody can be administered in a fixed unit dose of about 50-600 mg IV (e.g., every 4 weeks) or about 50-100 mg SC (e.g., 75 mg), for example, at least once a week (e.g., twice a week). In one embodiment, the antibody is administered intravenously in a fixed unit dose of 50 mg, 60 mg, 80 mg, 100 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 180 mg, 200 mg, 300 mg, 400 mg, 500 mg, or 600 mg or more. Intravenous doses may be administered once, twice, three times or more weekly, or once every two, three, four or five weeks, or less frequently.
[0377] In one embodiment, the antibody is administered subcutaneously in a fixed unit dose of 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 100 mg or 120 mg or more. The subcutaneous dose may be administered once, twice, three times or more per week, or once every two weeks, three weeks, four weeks or five weeks, or less frequently.
[0378] Anti-α4 antibodies with stabilized Fc regions can also be administered in bolus form at a dose of between about 1 and 10 mg / kg, for example, about 6.0 mg / kg, 4.0 mg / kg, 3.0 mg / kg, 2.0 mg / kg, 1.0 mg / kg. Improved dose ranges include doses of less than about 600 mg / subject, about 400 mg / subject, about 300 mg / subject, about 250 mg / subject, about 200 mg / subject, or about 150 mg / subject, typically for administration every four weeks or monthly. α4-binding antibodies can be administered, for example, every three to five weeks, for example, every four weeks or monthly.
[0379] The dosage may be adjusted based on the clearance rate of the patient's previously administered anti-α4 antibody. For example, a second or subsequent dose may not be administered to the patient until the level of anti-α4 antibody in the patient's system has fallen below a predetermined level. In one embodiment, a sample from the patient (e.g., plasma, serum, blood, urine, or cerebrospinal fluid (CSF)) is assayed for the presence of anti-α4 antibody, and if the level of anti-α4 antibody is above a predetermined level, the patient will not be administered a second or subsequent dose. If the level of anti-α4 antibody in the patient's system is below a predetermined level, the patient will be administered a second or subsequent dose. A patient whose anti-α4 level is determined to be too high (above a predetermined level) may be tested again one day, two days, three days, or one week later, and if the level of anti-α4 antibody in the patient's sample has fallen below a predetermined level, the patient may be administered a second or subsequent dose of the antibody.
[0380] The dose can also be selected to reduce or avoid the production of antibodies against the α4 binding antibody, to achieve an α4 subunit saturation of more than 40%, 50%, 70%, 75% or 80%, to achieve an α4 subunit saturation of less than 80%, 70%, 60%, 50% or 40%, or to prevent increases in circulating leukocyte levels.
[0381] In certain embodiments, the active agent can be prepared with a carrier that will prevent the rapid release of the compound, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Many methods for preparing these formulations are patented or generally known. See, for example, Controlled Drug Delivery (Drugs and the Pharmaceutical Sciences), Second Edition, J. Robinson and VHL Lee, eds., Marcel Dekker, Inc., New York, 1987.
[0382] The pharmaceutical composition can be administered using a medical device. For example, the pharmaceutical composition can be administered using a needle-free subcutaneous injection device, such as those disclosed in U.S. Pat. Nos. 5,399,163, 5,383,851, 5,312,335, 5,064,413, 4,941,880, 4,790,824, or 4,596,556. Examples of well-known implants and modules are discussed in, for example, U.S. Patent No. 4,487,603, which discloses an implantable microinfusion pump for dispensing drugs at a controlled rate; U.S. Patent No. 4,486,194, which discloses a therapeutic device for administering drugs through the skin; U.S. Patent No. 4,447,233, which discloses a drug infusion pump for delivering drugs at a precise infusion rate; U.S. Patent No. 4,447,224, which discloses a variable flow implantable infusion device for continuous drug delivery; U.S. Patent No. 4,439,196, which discloses an osmotic drug delivery system with multiple chamber compartments; and U.S. Patent No. 4,475,196, which discloses an osmotic drug delivery system. Of course, many other such implants, delivery systems, and modules are also known.
[0383] The present invention also provides a device for administering a first dose and a second dose. The device may include, for example, one or more housings for storing pharmaceutical formulations and may be configured to deliver unit doses of the first and second doses. The first and second doses may be stored in the same or separate compartments. For example, the device may combine the doses prior to administration. It is also possible to administer the first and second doses using different devices.
[0384] Dosage regimens are adjusted to provide a desired response, eg, a therapeutic response or a combined therapeutic effect. Generally, any dosage combination of the VLA-4 binding agent and the second agent (separate or co-formulated) can be used to provide both agents to the subject in bioavailable amounts.
[0385] Dosage unit form or "fixed dose" as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier and, optionally, other agents.
[0386] Pharmaceutical compositions can include a "therapeutically effective amount" of an agent described herein. These effective amounts can be determined based on the combined effects of the first and second agents administered. The therapeutically effective amount of an agent can also vary based on factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual (e.g., to improve at least one parameter of the condition, such as a parameter of multiple sclerosis, or to improve at least one symptom of the condition, such as a symptom of multiple sclerosis, such as muscle atrophy, ataxia, and tremor). A therapeutically effective amount is also an amount in which the therapeutically beneficial effects of the composition outweigh any toxic or adverse effects.
[0387] X. Devices and Kits
[0388] The formulations containing the antibodies described herein can be administered using medical devices. The devices can be designed to be portable, room temperature storable, and easy to use, so they can be used in emergency situations, such as by untrained subjects or by emergency personnel moving to medical facilities and other medical equipment. The devices can include, for example, one or more housings for storing a pharmaceutical formulation comprising an α4-binding antibody and can be configured to deliver one or more unit doses of the formulation.
[0389] For example, the pharmaceutical composition can be administered using a transdermal delivery device, such as a syringe, including a subcutaneous syringe or a multi-chamber syringe. Other suitable delivery devices include stents, catheters, microneedles, and implantable controlled-release devices. The composition can be administered intravenously using standard intravenous equipment, including, for example, intravenous tubing, with or without an inline filter. In certain embodiments, the device will be a syringe for subcutaneous or intramuscular administration.
[0390] The pharmaceutical composition can be administered using a medical device. For example, the pharmaceutical composition can be administered using a needle-free subcutaneous injection device, such as those disclosed in U.S. Pat. Nos. 5,399,163, 5,383,851, 5,312,335, 5,064,413, 4,941,880, 4,790,824, or 4,596,556. Examples of well-known implants and modules are described, for example, in the following documents: U.S. Patent No. 4,487,603, which discloses an implantable microinfusion pump for dispensing drugs at a controlled rate; U.S. Patent No. 4,486,194, which discloses a therapeutic device for administering drugs through the skin; U.S. Patent No. 4,447,233, which discloses a drug infusion pump for delivering drugs at a precise infusion rate; U.S. Patent No. 4,447,224, which discloses a variable flow implantable infusion device for continuous drug delivery; U.S. Patent No. 4,439,196, which discloses an osmotic drug delivery system with a multi-chamber compartment; and U.S. Patent No. 4,475,196, which discloses an osmotic drug delivery system. The therapeutic composition can also be in the form of a biodegradable or non-biodegradable sustained-release formulation for subcutaneous or intramuscular administration. Methods for these compositions are known in the art. Continuous administration can also be achieved using an implantable pump or an external pump. Administration can also be performed intermittently, such as by injection once daily, or continuously at low doses, such as in a sustained release formulation. The delivery device can be modified to be optimally suited for administering the α4-binding antibody. For example, the syringe can be siliconized to an optimal degree for antibody storage and delivery. Of course, many other such implants, delivery systems, and modules are also known.
[0391] The present invention also provides a device for administering a first and a second dose (e.g., an antibody and a second dose). The device may include, for example, one or more shells for storing a pharmaceutical preparation, and may be configured to deliver the first and second doses of the unit dose. The first and second doses may be stored in the same or separate compartments. In one embodiment, the device may combine the doses before administration. In some embodiments, the first and second doses are administered by different devices.
[0392] The α4-binding antibody can be provided in a kit. In one embodiment, the kit includes (a) a container containing a composition comprising a high concentration of the VLA-4-binding antibody, optionally (b) a container containing a composition comprising a second dose, and optionally (c) informational material. The informational material can be descriptive material, instructional material, marketing material, or other material related to the methods described herein and / or the use of the agent for therapeutic benefit. In one embodiment, the kit also includes a second dose. For example, the kit includes a first container containing a composition comprising the α4-binding antibody and a second container comprising the second dose.
[0393] The informational material of the kit is not limited in its form. In one embodiment, the informational material may include information about antibody production, concentration, expiration date, batch or production site information, etc. In one embodiment, the informational material relates to methods of administering the α4-binding antibody, for example, at a suitable dose, dosage form, or mode of administration (e.g., a dose, dosage form, or mode of administration described herein), to treat a subject having an acute condition (e.g., spinal cord injury or traumatic brain injury) or an inflammatory disease (e.g., MS) or at risk of experiencing an acute attack associated with an inflammatory disease. The information can be provided in various forms, including printed text, computer-readable material, video recording, or audio recording, or information providing a link or address to the actual material.
[0394] In addition to the agent, the composition in the test kit may include other ingredients, such as solvents or buffers, stabilizers or preservatives. The agent can be provided in any form, such as liquid, dry or lyophilized form, and is substantially pure and / or sterile. When the agent is provided in a liquid solution form, the liquid solution is typically an aqueous solution. When the agent is provided in a dry form, it is generally reconstructed by adding a suitable solvent. Solvents, such as sterile water or buffer, can optionally be provided in the test kit.
[0395] The kit may include one or more containers for one or more compositions containing the agent. In some embodiments, the kit contains separate containers, dispensers, or compartments for the composition and informational material. For example, the composition may be contained in a bottle, vial, or syringe, and the informational material may be contained in a plastic sleeve or packaging. In other embodiments, the individual elements of the kit are contained in a single, undivided container. For example, the composition is contained in a bottle, vial, or syringe affixed with informational material in the form of a label. In some embodiments, the kit includes multiple (e.g., a pack) of separate containers, each container containing one or more unit dosage forms of the agent (e.g., the dosage forms described herein). The container may include a combined unit dose, such as a unit comprising an α4 binding antibody and a second agent, such as in a desired ratio. For example, the kit may include multiple syringes, ampoules, foil packets, blister packs, or medical devices, each containing, for example, a single combined unit dose. The container of the kit may be airtight, waterproof (e.g., impermeable to moisture changes or evaporation), and / or lightproof.
[0396] The kit optionally includes a device suitable for administering the composition, such as a syringe or other suitable delivery device. The device may be pre-filled with one or both of the agents, or may be empty but suitable for loading.
[0397] XI. Oncology
[0398] The α4-binding antibodies and methods described herein can be used to treat cancer, including solid cancers and hematological malignancies. Exemplary solid cancers include sarcomas and carcinomas, such as lung cancer, breast cancer, pancreatic cancer, colon cancer, prostate cancer, bladder cancer, and brain cancer. Hematological malignancies include cancers such as multiple myeloma, leukemia, and lymphoma.
[0399] Methods of treating patients with hematological malignancies using compositions containing α4-binding antibodies, such as the anti-VLA-4 antibodies described herein, are provided. Hematological malignancies are cancers of the blood-forming and immune systems in the body. These types of cancers affect the blood, bone marrow, and / or lymph nodes. Hematologic malignancies include leukemias such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), acute promyelocytic leukemia, acute erythroleukemia, and hairy cell leukemia (HCL); lymphomas such as Hodgkin's disease and non-Hodgkin's lymphoma; and multiple myeloma; Waldenstrom's macroglobulinemia; myelodysplastic syndromes (MDS) (which ultimately lead to AML); myeloproliferative disorders such as polycythemia vera (also known as PV, PCV, or polycythemia vera (PRV)), primary thrombocythemia (ET), myelofibrosis, heavy chain disease; and amyloidosis caused by light chain disease.
[0400] Patients with hematological malignancies can be identified by analyzing blood counts and blood films, for example, with light microscopy, which can be used to identify malignant cells. Malignant cells can also be identified using, for example, biopsies from the bone marrow, and biopsies from lymph nodes can be used to identify lymphadenopathy.
[0401] α4 binding antibodies (e.g., humanized anti-VLA-4 antibodies, such as HuHP1 / 2, H1L0, H1L1, H1L2 or H1L3) can be used to treat leukemias, such as AML. Leukemia is a cancer that originates in the bone marrow, in which the malignant cells are white blood cells (leukocytes). AML (also known as acute myeloid leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia) is a malignancy that occurs in granulocytes or monocytes. AML is characterized by an inability to function as normal blood cells and blocking the production of normal bone marrow cells, resulting in an uncontrolled overgrowth and accumulation of cells (called leukemic blasts) that lack red blood cells (anemia) and platelets (thrombocytopenia) and normal white blood cells (especially neutrophils, i.e., neutropenia) in the blood.
[0402] All AML subtypes are suitable for treatment with VLA-4 binding antibodies. AML subtypes are classified based on the developmental stage that the bone marrow blasts have reached at the time of diagnosis. The categories and subsets allow the physician to determine which treatment is best for the cell type and how rapidly the disease is progressing. The subsets are: M0, myeloblasts, undergoing special analysis; M1, myeloblasts, immature; M2, myeloblasts, mature; M3, promyeloblasts; M4, myelomonocytic; M5, monocytes; M6, erythroleukemia; and M7, megakaryocytes. VLA-4 antibodies can be administered with a second agent specifically suited for the AML subtype. For example, acute promyelocytic leukemia (APL) and acute monocytic leukemia are AML subtypes that require different treatment than other AML subtypes. A second agent for treating APL may include all-trans retinoic acid (ATRA) or an antimetabolite, such as cytarabine. A second agent used to treat acute monocytic leukemia may include a deoxyadenosine analog, such as 2-chloro-2'-deoxyadenosine (2-CDA).
[0403] Risk factors for AML include the presence of certain genetic disorders, such as Down syndrome, Fanconi anemia, Shwachman-Diamond syndrome, and other disorders. Patients with AML and a genetic disorder can be administered a VLA-4 binding antibody and a second agent to treat the symptoms of the genetic disorder. For example, a patient with AML and Fanconi anemia can be administered a VLA-4 binding antibody and an antibiotic.
[0404] Other risk factors for AML include chemotherapy or radiation therapy used to treat different cancers, smoking, and exposure to high amounts of benzene.
[0405] Other cancers suitable for treatment with α4-binding antibodies include solid tumors, such as sarcomas and carcinomas (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma), Ewing's tumors, (including ovarian cancer, uterine cancer, uterine cancer, testicular cancer, small cell lung cancer, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, meningioma, melanoma, and retinoblastoma).
[0406] XII. Other diseases
[0407] The formulations and methods described herein can also be used to treat other inflammatory, immune, or autoimmune disorders, such as central nervous system inflammation (e.g., in addition to multiple sclerosis, meningitis, neuromyelitis optica, neurosarcoidosis, CNS vasculitis, encephalitis, and transverse myelitis); tissue or organ transplant rejection or graft-versus-host disease; acute CNS injury, such as stroke or spinal cord injury (SCI); chronic kidney disease; allergies, such as allergic asthma, moderate to severe allergic rhinitis, ocular allergies; type 1 diabetes; inflammatory bowel disease, such as Crohn's disease, ulcerative colitis (e.g., for the treatment or maintenance of remission) epilepsy; eosinophilic gastroenteritis; myasthenia gravis; fibromyalgia; rheumatology / immunology-related conditions, such as arthritic conditions, e.g., rheumatoid arthritis, psoriatic arthritis; dermatology conditions, such as inflammatory / immune skin conditions, e.g., psoriasis, vitiligo, dermatitis (e.g., atopic dermatitis), lichen planus, moderate to severe chronic urticaria; systemic lupus erythematosus (SLE; e.g., lupus nephritis); scleroderma (e.g., progressive systemic sclerosis (PSS), e.g., pulmonary PSS); acute or chronic primary eosinophilic pneumonia; Sjogren's syndrome Syndrome); acute coronary syndrome (ACS); acute myocardial infarction; atherosclerosis; and fibrotic disorders, such as pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis), pulmonary fibrosis (e.g., XRT-induced), myelofibrosis, cirrhosis, mesangial proliferative glomerulonephritis, crescentic glomerulonephritis, diabetic nephropathy, and renal interstitial fibrosis. In a preferred embodiment, the formulation can be used to treat epilepsy.
[0408] The formulations and methods described herein can also be used to treat neurological disorders, such as cerebral ischemia, including preventing transient ischemic attacks and / or arterial stenosis in patients. Other exemplary neurological disorders include chronic inflammatory demyelinating polyneuropathy (CIDP); Guillain-Barre syndrome (GBS); ocular diseases, such as macular degeneration (e.g., wet macular degeneration) and anterior ischemic optic neuropathy; neuropathic pain (e.g., symptomatic neuropathic pain); Alzheimer's disease; amyotrophic lateral sclerosis (ALS) (e.g., disease-modified ALS) and Parkinson's disease.
[0409] The formulations and methods described herein can also be used to treat patients who have undergone a transplant, such as a kidney, heart, or bone marrow transplant.
[0410] XIII. Multiple sclerosis
[0411] Formulations containing the α4-binding antibodies described herein can be used to treat inflammatory diseases, such as multiple sclerosis (MS).MS is a disease of the central nervous system characterized by inflammation and loss of myelin.
[0412] Patients with MS can be identified by the criteria for determining the diagnosis of clinically definitive MS as defined by the MS Diagnosis Workshop (Poser et al., Ann. Neurol. 13: 227, 1983). For example, an individual with clinically definitive MS must have clinical evidence of two attacks and two lesions or clinical evidence of one lesion and approximate clinical evidence of another independent lesion. Deterministic MS can also be diagnosed by evidence of two attacks and IgG oligomeric clonal bands in the cerebrospinal fluid or by a combination of attacks, clinical evidence of two lesions and IgG oligomeric clonal bands in the cerebrospinal fluid. MS can also be diagnosed using the McDonald criteria. (McDonald et al., 2001, "Recommended diagnostic criteria for multiplesclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis," Ann. Neurol. 50: 121-127). The McDonald criteria include using MRI evidence of CNS damage within a certain time period to be used for diagnosing MS in the absence of multiple clinical attacks to diagnose MS. Effective treatments for multiple sclerosis can be evaluated in several different ways. The following parameters can be used to measure the effectiveness of treatment. Two exemplary criteria include: EDSS (Expanded Disability Status Scale) and worsening on MRI (Magnetic Resonance Imaging). EDSS is a method for grading clinical damage caused by MS (Kurtzke, Neurology 33:1444, 1983). It assesses the type and severity of neurological damage in eight functional systems. In brief, before treatment, the patient is assessed for damage in the following systems: pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral and other. Follow-up is performed at defined intervals. The scale ranges from 0 (normal) to 10 (death due to MS). A reduction of one complete step indicates effective treatment (Kurtzke, Ann. Neurol. 36:573-79, 1994). Other criteria used by those skilled in the art can also be used to diagnose patients.
[0413] Exacerbation is defined as the occurrence of new symptoms attributable to MS and with appropriate new neurological abnormalities (IFNB MS Research Group, ibid.). In addition, exacerbation must continue for at least 24 hours and continue for at least 30 days before stabilization or improvement. In brief, a standard neurological examination is performed on the patient by a clinician. According to the changes in the neurological grading scale, exacerbation is mild, moderate or severe (Sipe et al., Neurology 34:1368,1984). Determine the annual exacerbation rate and the ratio of patients without exacerbation.
[0414] For any one of these measurements, if there is a statistically significant difference in the ratio or proportion of no worsening or no relapse patients between the treatment group and the placebo group, then the treatment can be considered to be effective. In addition, the time of first worsening and the duration and severity of worsening can also be measured. In this regard, the measure of therapeutic effectiveness is that the treatment group has a statistically significant difference in the time of first worsening or duration and severity compared to the control group. No worsening or no relapse period for more than one year, 18 months or 20 months is particularly noteworthy. Any method used in the art can also be used to assess efficacy, for example, to assess the symptoms of MS, including using the timed walk test used alone or in combination with other criteria to assess activity improvement.
[0415] The efficacy of administering the first and optionally the second dose can also be assessed based on one or more of the following criteria: the frequency of MBP-reactive T cells as determined by limiting dilution, the proliferative response of MBP-reactive T cell lines and clones, the cytokine profile of T cell lines and clones established from the patient to MBP. Efficacy is indicated by a decrease in the frequency of reactive cells, the presence of decreased thymidine incorporation and peptide alterations compared to native cells, and a decrease in TNF and IFN-α.
[0416] Clinical outcome measures included relapse rates at one and two years, and changes in the EDSS, including time to a 1.0-unit improvement from baseline in the EDSS at six months. Delay in sustained disability progression on a Kaplan-Meier curve indicated efficacy. Other criteria included changes in area and volume on T2-weighted MRI scans and the number and volume of lesions determined by gadolinium-enhanced imaging.
[0417] MRI can be used to measure active lesions using gadolinium-DTPA enhanced imaging (McDonald et al., Ann. Neurol. 36:14, 1994) or use T2 weighted techniques to measure lesion location and extent. In short, a baseline MRI is obtained. Each subsequent study uses the same imaging plane and patient position. Positioning and imaging sequences can be selected to optimize lesion detection and facilitate lesion tracking. The same positioning and imaging sequences can be used for subsequent studies. Radiologists can determine the presence, location, and extent of MS lesions. The lesion area can be summarized and summed slice by slice for the total lesion area. Three analyses can be performed: new lesion evidence, active lesion incidence, and lesion area change percentage (Paty et al., Neurology 43:665, 1993). The improvement achieved due to treatment can be determined by statistically significant improvements in individual patients compared to baseline or in the treatment group relative to the placebo group.
[0418] Exemplary symptoms associated with multiple sclerosis that can be treated using the methods described herein include: optic neuritis, diplopia, nystagmus, dysmetria, internuclear ophthalmoplegia, motion and sound phosphenes, pupillary afferent defect, paresis, monoparesis, paraparesis, hemiparesis, quadriplegia, paralysis, paraplegia, hemiplegia, quadriplegia, quadriplegia, spasticity, dysarthria, muscle atrophy, muscle spasm, cramps, hypotonia, clonus, myoclonus, myokymia, restless legs syndrome, foot drop, reflex dysfunction, paresthesia, numbness, neuralgia, neuropathic and neurogenic pain, rahmitia Hermitte's syndrome, proprioceptive dysfunction, trigeminal neuralgia, ataxia, intention tremor, dysmetria, vestibular ataxia, vertigo, speech ataxia, dystonia, diatrogenic dyskinesis, frequent urination, bladder spasm, flaccid bladder, detrusor-sphincter dyssynergia, erectile dysfunction, anorgasmia, low libido, constipation, fecal urgency, fecal incontinence, depression, cognitive dysfunction, dementia, mood swings, emotional lability, euphoria, bipolar syndrome, anxiety, aphasia, language disorders, fatigue, Uthoff's syndrome, gastroesophageal reflux, and sleep disorders.
[0419] Each MS case shows one of several presentation patterns and subsequent processes. Most commonly, MS first manifests itself as a series of attacks, followed by complete or partial remission, as symptoms mysteriously alleviate and only recover after a period of stability. This is called relapsing-remitting (RR)MS. Clinically isolated syndrome (CIS) is another relapsing form of MS. CIS refers to the neurological symptoms of the first acute attack that lasts for at least 24 hours and is caused by inflammation or demyelination (the myelin sheath covering nerve cells) in the central nervous system (CNS). Primary progressive (PP)MS is characterized by a gentle clinical remission without significant relief, but there may be a temporary plateau or mild symptom relief. Active primary progressive MS occurs when the patient experiences occasional relapses or evidence of new lesions on MRI. "Inactive" or "progressive" means that there is evidence that symptoms worsen over time, with or without relapses or MRI showing with or without new lesions. Secondary progressive (SP)MS begins with a relapsing-remitting process, followed by a later primary progressive process. Active secondary progressive MS is considered one of the relapsing forms of MS. Rarely, patients may have a progressive relapsing (PR) course, in which the disease takes a progressive path interspersed with acute attacks. PP, SP, and PR are sometimes lumped together and referred to as chronic progressive MS.
[0420] Thus, relapsing forms of multiple sclerosis (or simply relapsing multiple sclerosis) include, but are not limited to, clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (active SPMS).
[0421] A small number of patients experience aggressive MS, defined as a rapid, unrelenting decline that causes severe disability or even death soon after disease onset. This decline can be halted or slowed by administering the therapies described herein.
[0422] Administration of the anti-α4 antibodies provided herein can be effective in alleviating one or more symptoms of MS, such as one or more of the symptoms described above. For example, administration of the anti-α4 antibodies described herein can be used to treat primary or secondary progressive multiple sclerosis (PPMS or SPMS, respectively), and treatment with the anti-α4 antibodies can be effective in preventing relapses.
[0423] In addition to human studies or before conducting human studies, animal models can be used to assess the efficacy of using two agents. An exemplary animal model for multiple sclerosis is an experimental autoimmune encephalitis (EAE) mouse model, for example, as described in (Tuohy et al., (J. Immunol. (1988) 141: 1126-1130), Sobel et al., (J. Immunol. (1984) 132: 2393-2401) and Traugott (Cell Immunol. (1989) 119: 114-129). Before EAE induction, the first and second agents described herein can be administered to mice. Subsequently, mice are assessed for characteristic criteria to determine the efficacy of using two agents in the model.
[0424] XIV. Epilepsy
[0425] Formulations containing the α4 binding antibodies described herein are useful for treating epilepsy.
[0426] Epileptic seizures are paroxysmal attacks caused by abnormal discharge neurons that can be detected by electroencephalograms or clinical means, in which the specific affected parts of the brain affect clinical expression. Epileptic seizures are fundamentally caused by an imbalance in the basic excitability of neurons, which may be related to neuronal membranes or excitatory and inhibitory processes. See also Holmes et al., Epilepsy 45 (12): 1568-1579, 2004). Epilepsy is conceptually defined as a brain disorder characterized by a persistent predisposition to epileptic seizures and the neurobiological, cognitive, psychological and social consequences of this disorder (Fisher RS, Curr Opin Neurol. 28 (2): 130-5, 2015). A recent review of the prevalence and incidence of epilepsy reported a lifetime prevalence of 7.6 per 1000 people and an annual cumulative incidence of 67.77 per 100,000 people (Fiest et al., Neurology 88 (3): 296-303, 2017).
[0427] Prior to the present invention, the common therapy for patients with epilepsy was antiepileptic drugs (AEDs), and it was estimated that approximately 70% of patients achieved good seizure control with AED therapy. Patients who failed to tolerate two (or more) adequate trials and appropriately selected and used AEDs were defined as having drug-resistant epilepsy (see Kwan et al., Epilepsia .51(6):1069-77,2010; and erratumin Epilepsia. 51(9):1922, 2010). For these patients, other therapies are considered, including epilepsy surgery, neurostimulation devices, specialized diets, behavioral therapies, and other experimental treatments. AEDs generally work by modulating voltage-dependent or ligand-gated ion channels or by acting on inhibitory or excitatory neurotransmitter systems. Currently, there are more than 20 commercially available AEDs. Although many newer AEDs have been introduced in recent years, newer and older drugs are generally equally effective in controlling epilepsy, and few patients with previously drug-resistant epilepsy have become seizure-free with the newer therapies.
[0428] There remains an unmet need for the development of therapies that can improve seizure control or eliminate seizures in drug-resistant epilepsy. The potential role of targeting the immune system and inflammation in the pathogenesis of epilepsy represents an understudied area in AED development and clinical research. Evidence from experimental models of epilepsy and human patients with epilepsy suggests a role for inflammation.
[0429] The formulations disclosed herein can be used to treat epilepsy. For example, a formulation comprising a recombinant anti-α4 antibody or α4-binding fragment thereof comprising: (a) a heavy chain comprising the sequence of SEQ ID NO: 80; and (b) a light chain comprising the sequence of SEQ ID NO: 81 can be administered to a patient suffering from epilepsy. It is hypothesized that blocking α4 integrin will reduce leukocyte-vascular interactions and stabilize BBB integrity. Additionally, it is hypothesized that reducing leukocyte-vascular interactions in epilepsy-induced seizures will reduce seizure frequency and severity.
[0430] XV. Antibody Production
[0431] Recombinant antibodies that bind to α4 can be generated by in vivo or in vitro methods, such as phage display. Such methods can be used to provide anti-α4 CDRs for use in the CDR-grafted antibodies described herein. In addition, in the case of germline frameworks disclosed herein, methods such as phage display can be used to select these CDRs, for example, by using a library whose framework is a germline framework.
[0432] EP 239 400 (Winter et al.) describes the method of changing antibodies by replacing the complementary determining region (CDR) of one species with the complementary determining region of another species (within a given variable region). CDR replacement antibodies are less likely to elicit an immune response in humans than true chimeric antibodies because CDR replacement antibodies contain significantly fewer non-human components. (Riechmann et al., 1988, Nature 332, 323-327; Verhoeyen et al., 1988, Science 239, 1534-1536). Typically, the CDR of a murine antibody is replaced into the corresponding region in a human antibody using recombinant nucleic acid technology to generate a sequence encoding the desired substituted antibody. The human constant region gene segment of the desired isotype (typically, γI for CH and κ for CL) can be added, and heavy and light chain genes can be co-expressed in mammalian cells to produce soluble antibodies. Large non-immune phage display libraries can also be used to isolate high affinity antibodies, which can be developed as human therapeutics using standard phage technology (see, e.g., Hoogenboom et al., (1998) Immunotechnology 4: 1-20; and Hoogenboom et al., (2000) Immunol Today 2: 371-8; US 2003-0232333).
[0433] The anti-α4 antibodies or antibody fragments described herein can recognize and specifically bind to antigens within the α4 subunit that are involved in binding to cognate ligands, such as VCAM-1 or fibronectin. In some embodiments, the anti-α4 antibodies or antibody fragments thereof recognize and specifically bind to the B epitope of the α4 integrin. Binding of the antibodies described herein can inhibit the binding of the α4 integrin to one or more cognate ligands (e.g., VCAM-1 and fibronectin).
[0434] In some embodiments, the antibodies provided herein can interact with VLA-4 on cells (eg, lymphocytes) but do not cause cell aggregation.
[0435] Exemplary α4-binding antibodies have one or more CDRs, e.g., all three heavy chain (HC) CDRs and / or all three light chain (LC) CDRs of a particular antibody disclosed herein, or CDRs that are at least 80%, 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99% identical to such an antibody overall. In one embodiment, the H1 and H2 hypervariable loops have the same canonical structures as the antibodies described herein. In one embodiment, the L1 and L2 hypervariable loops have the same canonical structures as the antibodies described herein.
[0436] In one embodiment, the amino acid sequence of the HC and / or LC variable domain sequence is at least 70%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or 100% identical to the amino acid sequence of the HC and / or LC variable domain of an antibody described herein. The amino acid sequence of the HC and / or LC variable domain sequence may differ from the corresponding sequence of an antibody described herein by at least one amino acid, but not more than ten, eight, six, five, four, three or two amino acids. For example, the differences may be primarily or entirely in the framework regions.
[0437] The amino acid sequences of the HC and LC variable domain sequences can be encoded by nucleic acid sequences that hybridize under high stringency conditions to the nucleic acid sequences described herein, or nucleic acid sequences encoding the variable domains or amino acid sequences described herein. In one embodiment, the amino acid sequences of one or more framework regions (e.g., FR1, FR2, FR3, and / or FR4) of the HC and / or LC variable domains are at least 70%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99%, or 100% identical to the corresponding framework regions of the HC and LC variable domains of the antibodies described herein. In one embodiment, one or more heavy or light chain framework regions (e.g., HC FR1, FR2, and FR3) are at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 100% identical to the sequences of the corresponding framework regions of human germline antibodies.
[0438] "Homology" or "sequence identity" (the terms are used interchangeably herein) between two sequences is calculated as follows. The sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of the first and second amino acid or nucleic acid sequences to achieve optimal alignment, and non-homologous sequences can be ignored for comparison purposes). Optimal alignment is determined as the best score using the GAP program in the GCG software package with a Blossum 62 scoring matrix, a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein, amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences.
[0439] As used herein, the term "hybridization under high stringency conditions" describes conditions for hybridization and washing. Guidance on performing hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6, which is incorporated by reference. Aqueous and non-aqueous methods are described in the reference, and either can be used. High stringency hybridization conditions include hybridization in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C, or under substantially similar conditions.
[0440] XVI. Antibody Production
[0441] Antibodies can be produced in prokaryotic and eukaryotic cells. In one embodiment, antibodies (e.g., scFv) are expressed in yeast cells such as Pichia (see, e.g., Powers et al., (2001) J. Immunol. Methods 251: 123-35), Hanseula or Saccharomyces.
[0442] In one embodiment, antibodies, particularly full-length antibodies, such as IgG, are produced in mammalian cells. Exemplary mammalian host cells for recombinant expression include Chinese hamster ovary (CHO cells) (including dhfr-CHO cells, described in Urlaub and Chasin (1980) Proc. Natl. Acad. Sci. USA 77: 4216-4220, used with a DHFR selectable marker, e.g., as described in Kaufman and Sharp (1982) Mol. Biol. 159: 601-621), lymphocyte lines, e.g., NSO myeloma cells and SP2 cells, COS cells, K562, and cells from transgenic animals, e.g., transgenic mammals. For example, the cells are mammary epithelial cells.
[0443] In addition to the nucleic acid sequence encoding the immunoglobulin domain, the recombinant expression vector can also carry additional nucleic acid sequences, such as sequences (e.g., origins of replication) and selectable marker genes that regulate the replication of the vector in the host cell. Selectable marker genes help select host cells into which the vector has been introduced (see, e.g., U.S. Patents 4,399,216, 4,634,665, and 5,179,017). Exemplary selectable marker genes include dihydrofolate reductase (DHFR) genes (for methotrexate selection / amplification in dhfr- host cells) and neo genes (for G418 selection).
[0444] In an exemplary system for recombinantly expressing an antibody (e.g., a full-length antibody or its antigen-binding portion thereof), a recombinant expression vector encoding both the heavy and light chains of the antibody is introduced into dhfr-CHO cells by calcium phosphate-mediated transfection. Within the recombinant expression vector, each of the heavy and light chain antibody genes is operably linked to an enhancer / promoter regulatory element (e.g., derived from SV40, CMV, adenovirus, etc., such as a CMV enhancer / AdMLP promoter regulatory element or an SV40 enhancer / AdMLP promoter regulatory element) to drive high-level transcription of the gene. The recombinant expression vector also carries the DHFR gene, which allows the use of methotrexate selection / amplification to select CHO cells transfected with the vector. The selected transformed host cells are cultured to allow expression of the heavy and light chains of the antibody, and the complete antibody is recovered from the culture medium. Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select the transformant, culture the host cells, and recover the antibody from the culture medium. For example, some antibodies can be separated by affinity chromatography using protein A or protein G. For example, purified α4-binding antibody can be concentrated to about 100 mg / mL to about 200 mg / mL using protein concentration techniques known in the art.
[0445] Antibodies may also include modifications, such as modifications that alter Fc function, such as to reduce or eliminate interaction with Fc receptors or with C1q, or both. For example, a human IgG4 constant region may have a Ser to Pro mutation at residue 228 to stabilize the hinge region. The amino acid sequence of IgG4 Fc (hinge + CH2 + CH3 domains) is provided in Figure 5 middle.
[0446] In another example, the human IgG1 constant region can be mutated at one or more residues, such as one or more of residues 234 and 237, e.g., according to the numbering of U.S. Patent No. 5,648,260. Other exemplary modifications include those described in U.S. Patent No. 5,648,260.
[0447] For some antibodies that include an Fc domain, an antibody production system can be designed to synthesize antibodies in which the Fc region is glycosylated. In another example, the Fc domain of an IgG molecule is glycosylated at asparagine 297 in the CH2 domain (see Figure 5This asparagine is modified with biantennary oligosaccharides. This glycosylation is involved in effector functions mediated by Fcγ receptors and complement C1q (Burton and Woof, (1992) Adv. Immunol. 51:1-84; Jefferis et al., (1998) Immunol. Rev. 163:59-76). Fc domains can be produced in mammalian expression systems that appropriately glycosylate the residue corresponding to asparagine 297. Fc domains may also include other eukaryotic post-translational modifications.
[0448] Other suitable Fc domain modifications include those described in WO2004 / 029207. For example, the Fc domain may be Fc (Xencor, Monrovia, CA). The Fc domain or fragment thereof may have substitutions in the Fcγ receptor (FcγR) binding region, such as the domains and fragments described in WO05 / 063815. In some embodiments, the Fc domain or fragment thereof has substitutions in the neonatal Fc receptor (FcRn) binding region, such as the domains and fragments described in WO05047327. In other embodiments, the Fc domain is a single chain or fragment thereof, or a modified form thereof, such as those described in WO2008143954. Other suitable Fc modifications are known and described in the art.
[0449] Antibodies can also be produced by transgenic animals. For example, U.S. Patent No. 5,849,992 describes a method for expressing antibodies in the mammary glands of transgenic mammals. A transgene is constructed comprising a milk-specific promoter and a nucleic acid sequence encoding an antibody of interest (e.g., an antibody described herein) and a secretion signal sequence. The milk produced by females of these transgenic mammals includes the secreted antibody of interest, e.g., an antibody described herein. The antibodies can be purified from the milk or, for some applications, used directly.
[0450] Antibodies can be modified, for example, with moieties that stabilize them and / or increase their retention in the circulation, for example in blood, serum, lymph, bronchoalveolar lavage, or other tissues, for example by at least 1.5, 2, 5, 10, or 50 fold.
[0451] For example, a VLA-4 binding antibody can be associated with a polymer, such as a substantially non-antigenic polymer, such as polyalkylene oxide or polyethylene oxide. Suitable polymers will vary substantially by weight. Polymers having a number average molecular weight in the range of about 200 to about 35,000 Daltons (or about 1,000 to about 15,000 and 2,000 to about 12,500) can be used.
[0452] For example, a VLA-4 binding antibody can be conjugated to a water-soluble polymer, such as a hydrophilic polyvinyl polymer, such as polyvinyl alcohol or polyvinyl pyrrolidone. A non-limiting list of these polymers includes polyalkylene oxide homopolymers, such as polyethylene glycol (PEG) or polypropylene glycol, polyoxyethylated polyols, copolymers thereof, and block copolymers thereof, provided that the water solubility of the block copolymer is maintained. Other suitable polymers include polyoxyalkylenes such as polyoxyethylene, polyoxypropylene and block copolymers of polyoxyethylene and polyoxypropylene (Pluronics); polymethacrylates; carbomers; branched or unbranched polysaccharides comprising the sugar monomers D-mannose, D-galactose and L-galactose, fucose, fructose, D-xylose, L-arabinose, D-glucuronic acid, sialic acid, D-galacturonic acid, D-mannuronic acid (e.g., polymannonic acid or alginic acid), D-glucosamine, D-galactosamine, D-glucose and neuraminic acid, including homo- and heteropolysaccharides such as lactose, amylopectin, starch, hydroxyethyl starch, amylose, dextran sulfate, polydextrose, dextrin, glycogen or polysaccharide subunits of acid mucopolysaccharides such as hyaluronic acid; sugar alcohol polymers such as polysorbate and polymannitol; heparin or heparinoids.
[0453] XVII. Exemplary Second Doses
[0454] In some cases, a formulation described herein, eg, a formulation containing an α4-binding antibody, includes a second agent, or is administered in combination with a formulation containing a second agent.
[0455] In one embodiment, the α4-binding antibody and the second agent are provided as a co-formulation, and the co-formulation is administered to the subject. It is also possible to administer a dose of the α4-binding antibody formulation, followed by a dose of the formulation containing the second agent, for example, at least 24 hours before or after administration of the co-formulation. In another embodiment, the antibody and the second agent are provided as separate formulations, and the administering step comprises administering the antibody and the second agent sequentially. Sequential administration can be provided on the same day (e.g., within one hour of each other or at least 3, 6, or 12 hours apart) or on different days.
[0456] In general, the antibody and the second agent are each administered in multiple doses separated in time. The antibody and the second agent are generally each administered according to a protocol. The protocol for one or both may have a regular periodicity. The protocol for the antibody may have a periodicity different from that for the second agent, for example, one may be administered more frequently than the other. In one implementation, one of the antibody and the second agent is administered once a week and the other is administered once a month. In another embodiment, one of the antibody and the second agent is administered continuously, for example, over 30 minutes but less than 1, 2, 4 or 12 hours, and the other is administered in a bolus form. The antibody and the second agent can be administered by any appropriate method, for example, subcutaneously, intramuscularly or intravenously.
[0457] In some embodiments, the antibody and the second agent are each administered at the same dose as the prescribed dose of each for monotherapy. In other embodiments, the antibody is administered at a dose equal to or less than the amount required to achieve efficacy when administered alone. Similarly, the second agent can be administered at a dose equal to or less than the amount required to achieve efficacy when administered alone.
[0458] Non-limiting examples of second agents for use in combination with α4-binding antibodies to treat multiple sclerosis include:
[0459] ■ Interferons, such as human interferon beta-1a (e.g. or )) and interferon beta-1b (BETASERON TM ; human interferon beta substituted at position 17; Berlex / Chiron);
[0460] ■ Glatiramer acetate (also known as copolymer 1, Cop-1; COPAXONE TM ;Teva Pharmaceutical Industries, Inc.);
[0461] ■ (rituximab) or another anti-CD20 antibody, including antibodies that compete with or bind to an overlapping epitope with rituximab;
[0462] ■Mitoxantrone (mixtoxantrone) Lederle);
[0463] Remyelinating agents, such as opicinumab;
[0464] ■ Chemotherapeutic agents, such as clabribine ( ), azathioprine ( ), cyclophosphamide ( ), cyclosporine-A, methotrexate, 4-aminopyridine, and tizanidine;
[0465] ■Corticosteroids, such as methylprednisolone ( Pfizer), prednisone;
[0466] ■Immunoglobulins, e.g. (rituximab); CTLA4Ig; alemtuzumab ( ) or daclizumab (an antibody that binds to CD25);
[0467] Statins; and
[0468] ■TNF antagonists.
[0469] Glatiramer acetate is a protein formed by a random chain of the amino acids glutamic acid, lysine, alanine, and tyrosine (hence GLATiramer). Glatiramer acetate can be synthesized in solution from these amino acids using N-carboxyamino acid anhydrides in a ratio of approximately 5 parts alanine to 3 parts lysine, 1.5 parts glutamic acid, and 1 part tyrosine.
[0470] Additional second agents include antibodies or antagonists to other human cytokines or growth factors, such as TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-12, IL-15, IL-16, IL-18, EMAP-11, GM-CSF, FGF, and PDGF. Other exemplary second agents include antibodies to cell surface molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD80, CD86, CD90, or their ligands. For example, daclizumab is an anti-CD25 antibody that can improve multiple sclerosis.
[0471] Other exemplary antibodies include antibodies that provide the activity of the agents described herein, such as antibodies that bind to an interferon receptor, such as an interferon beta receptor. Typically, in implementations where the second agent comprises an antibody, it specifically binds to a target protein other than VLA-4 or other than α4 integrin, or at least specifically binds to an epitope on VLA-4 that is not recognized and specifically bound by the first agent.
[0472] Other additional exemplary second agents include: FK506, rapamycin, mycophenolic acid, leflunomide; nonsteroidal anti-inflammatory drugs (NSAIDs), such as phosphodiesterase inhibitors; adenosine agonists, antithrombotic agents, complement inhibitors, adrenergic agonists, agents that interfere with signaling of proinflammatory cytokines as described herein, IL-1β converting enzyme inhibitors (e.g., Vx740), anti-P7, PSGL, TACE inhibitors; T cell signaling inhibitors, such as kinase inhibitors described herein, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptopurine, angiotensin converting enzyme inhibitors, soluble cytokine receptors and derivatives thereof; anti-inflammatory cytokines (e.g., IL-4, IL-10, IL-13 and TGF).
[0473] In some embodiments, the second dose can be used to treat one or more symptoms or side effects of MS. Such agents include, for example, amantadine, baclofen, papaverine, meclizine, hydroxyzine, sulfamethoxazole, ciprofloxacin, docusate, pemoline, dantrolene, desmopressin, dexamethasone, tolterodine, phenyloin, oxybutynin, bisacodyl, venlafaxine, amitriptyline, methenamine, clonazepam, isoniazid, vardenafil, nitrofurantoin, psyllium hydrophilic mucilage, and dapoxetine.
[0014] The second agent includes but is not limited to: mucilloid, alprostadil, gabapentin, nortriptyline, paroxetine, propantheline bromide, modafinil, fluoxetine, phenazopyridine, methylprednisolone, carbamazepine, imipramine, diazepam, sildenafil, bupropion, and sertraline. Many second agents that are small molecules have a molecular weight between 150 and 5000 daltons.
[0474] Examples of TNF antagonists include chimeric, humanized, human or in vitro generated antibodies (or antigen-binding fragments thereof) directed against TNF (e.g., human TNFα), such as D2E7 (human TNFα antibody, U.S. Patent No. 6,258,562; BASF), CDP-571 / CDP-870 / BAY-10-3356 (humanized anti-TNFα antibody; Celltech / Pharmacia), cA2 (chimeric anti-TNFα antibody; REMICADE), and TNFα. TM, Centocor); anti-TNF antibody fragments (e.g., CPD870); soluble fragments of TNF receptors, such as p55 or p75 human TNF receptors or derivatives thereof, such as 75kdTNFR-IgG (75kD TNF receptor-IgG fusion protein, ENBREL TM ; Immunex; see, for example, Arthritis & Rheumatism (1994) Vol. 37, S295; J. Invest. Med. (1996) Vol. 44, 235A), p55 kdTNFR-IgG (55kD TNF receptor-IgG fusion protein (LENERCEPT TM )); enzyme antagonists, such as TNFα converting enzyme (TACE) inhibitors (e.g., α-sulfonyl hydroxamic acid derivatives, WO 01 / 55112 and N-hydroxycarboxamide TACE inhibitors GW 3333, GW-005 or GW-022); and TNF-bp / s-TNFR (soluble TNF binding protein; see, e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (Suppl.), S284; Amer. J. Physiol.-Heart and Circulatory Physiology (1995) Vol. 268, pp. 37-42).
[0475] In addition to the second dose, it is also possible to deliver other agents to the subject. However, in some embodiments, no protein or biologic agent in the form of a pharmaceutical composition is administered to the subject in addition to the α4-binding antibody and the second dose. The α4-binding antibody and the second dose may be the only agents delivered by injection. In embodiments where the second dose is a recombinant protein, the α4-binding antibody and the second dose may be the only recombinant agents administered to the subject, or at least the only recombinant agents that modulate an immune or inflammatory response. In other embodiments, the α4-binding antibody alone is the only recombinant agent or the only biologic agent administered to the subject.
[0476] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present invention belongs. Although methods and materials similar to or equivalent to the methods and materials described herein can be used for implementing or testing the present invention, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. In the event of conflict, this specification (including definitions) will be taken as the criterion. In addition, materials, methods and embodiments are only illustrative and are not intended to be restrictive.
[0477] Example
[0478] Unless otherwise indicated, all amino acid numbering in these examples uses the EU numbering.
[0479] Example 1. Variant anti-VLA-4 antibodies are more potent than humanized HP1 / 2.
[0480] Anti-VLA-4 antibodies were constructed using the germline framework IGKV4-1 (for designing L1 and L2) or germline engineered AAH7033.1 (for designing L3) for the VL chain and the germline framework IGHV1-f for the VH. These antibodies have fewer back mutations than the humanized HP1 / 2 antibodies described in U.S. Patent No. 6,602,503.
[0481] Heavy chain variants
[0482] The sequences of the three variants of the heavy chain are shown as design H0, design H1 and design H2. Figure 1 Each design grafted the CDRs of murine HP1 / 2 onto the IGHV1-f framework. Design H0 did not include back mutations in the framework regions, while designs H1 and H2 included varying degrees of back mutations in the framework regions to optimize the affinity of the humanized antibodies.
[0483] Light chain variants
[0484] The sequences of the four variations of the light chain are shown as Design L0, Design L1, Design L2, and Design L3. Figure 2 The humanized antibodies were constructed using the IGKV4-1 germline framework (also referred to as L0, L1, L2, and L3). Each design transplanted the CDRs of murine HP1 / 2 into the germline framework. The IGKV4-1 germline framework was used to design L0, L1, and L2, while the AAH70335 germline engineered framework was used to design L3. The L0 design did not include back mutations in the framework regions, while the L1, L2, and L3 designs had varying degrees of back mutations in the framework region sequences to optimize the affinity of the humanized antibodies.
[0485] The results of the competitive ELISA assay are shown in Tables 2 and Figure 3 In this experiment, α4β1 was pre-incubated with the test mAb and then murine HP1 / 2 was used as a competing agent. The results of this experiment indicate that antibodies with light chains L2 or L3 were more effective than the antibodies described in U.S. Patent No. 6,602,503. The results are shown in Table 2 and Figure 3 The heavy chain (H1) of the antibody used in this assay has Figure 1 The "design H1" sequence shown in , while L1 refers to Figure 2 Design L1 in.
[0486] Table 2. Competition assay by ELISA
[0487] mAbs IC50 nM Chimeric HP1 / 2 1.06 H1L0 1.87 H1L1 1.67 H1L2 0.9 H1L3 0.49 HuHP1 / 2 1.05
[0488] In Table 2, the chimeric mAb is a chimeric HP1 / 2 antibody in which the murine variable heavy and light chain genes are fused to the human IgG1 constant region. This antibody has essentially the same binding affinity as the original murine HP1 / 2 antibody (Sanchez-Madrid et al., Eur. J. Immunol. 16:1343-1349, 1996). The experimental results indicate that it is possible to improve the affinity of monoclonal antibodies relative to their murine parental sequences by humanizing the germline engineered receptor framework.
[0489] Another competition assay compared the new antibodies with the humanized 21.6 anti-α4 antibody described in US 5,840,299 ( In this experiment, the binding affinity of a mixture of mouse HP1 / 2 and the test mAb to α4β1 was determined. The results of this experiment are shown in Figure 4 The neutralization is shown in Table 3 below and indicates that the newly designed antibody is approximately 10-fold more potent than natalizumab.
[0490] Table 3. Competition assay by ELISA
[0491]
[0492] Example 2. Humanized HP1 / 2 (HuHP1 / 2) binds to VLA-4 on tumor cell lines.
[0493] The anti-VLA-4 antibody HuHP1 / 2 was tested for binding to various cell lines by flow cytometry. Binding was tested for CLL (chronic lymphocytic leukemia) cell lines Mec1 and JM1; MM (multiple myeloma) cell lines U266 and H929; and AML (acute myeloid leukemia) cell lines HL60 and KG1. HuHP1 / 2 bound to all tested tumor cell lines ( Figure 6 Flow cytometry data was used to calculate the EC50 values for antibody binding to each of the different cell lines. This information is shown in Table 4 below.
[0494] HuHP1 / 2 was also found to block adhesion of AML cell lines to fibronectin (FN) and VCAM1-Ig fusion protein. To test whether the antibody could block adhesion, the AML cell lines HL60 or KG1 were allowed to adhere to FN-coated wells ( Figure 7A ) or VCAM1-Ig-coated wells ( Figure 7B HuHP1 / 2 blocked adhesion of both cell types to wells coated with FN and wells coated with VCAM1-Ig. Maximum inhibition of binding of HL60 cells to both ligands was achieved with 20 μg / ml HuHP1 / 2 ( Figure 7C ).
[0495] HuHP1 / 2 was also found to block adhesion of MM cell lines to FN and VCAM1-Ig fusion protein. MM cell lines U266 and H929 were allowed to adhere to FN-coated wells ( Figure 8A ) or VCAM1-Ig-coated wells ( Figure 8B HuHP1 / 2 b...
Claims
1. A recombinant anti-α4 antibody or an α4-binding fragment thereof, comprising: (a) a variable light chain comprising the sequence of SEQ ID NO: 11; (b) a variable heavy chain comprising the sequence of SEQ ID NO: 4; (c) the constant light chain of human kappa light chain (SEQ ID NO: 82); and (d) a constant heavy chain of human IgG1, the constant region comprising at least one mutation selected from the group consisting of S127C, K129R, G135E, G136S, Q203K, I207T, N211D, K222R, P227S, S232Y, C233G, D234 deletion, K235 deletion, T236 deletion, H237P, T238P, L247F, H281Q, K287Q, Y313F, N314Q, A346G, A349S, P350S and K478 deletion according to the Kabat numbering scheme.
2. The recombinant anti-α4 antibody or α4 binding fragment of claim 1, wherein the constant heavy chain of the human IgG1 comprises at least two mutations selected from the group consisting of S127C, K129R, G135E, G136S, Q203K, I207T, N211D, K222R, P227S, S232Y, C233G, D234 deletion, K235 deletion, T236 deletion, H237P, T238P, L247F, H281Q, K287Q, Y313F, N314Q, A346G, A349S, P350S and K478 deletion according to the Kabat numbering scheme.
3. The recombinant anti-α4 antibody or α4 binding fragment of claim 1, wherein the constant heavy chain of human IgG1 comprises at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight, or at least nine, or at least ten, or at least eleven, or at least twelve, or at least thirteen, or at least fourteen, or at least fifteen, or at least sixteen, or at least seventeen, or at least eighteen, or at least nineteen, or at least twenty, or at least twenty-one, or at least twenty-two, or at least twenty-three, or at least twenty Four, or at least twenty-five mutations selected from the group consisting of S127C, K129R, G135E, G136S, Q203K, I207T, N211D, K222R, P227S, S232Y, C233G, D234 deletion, K235 deletion, T236 deletion, H237P, T238P, L247F, H281Q, K287Q, Y313F, N314Q, A346G, A349S, P350S, and K478 deletion according to the Kabat numbering scheme.
4. The recombinant anti-α4 antibody or α4 binding fragment of claim 1, wherein the constant heavy chain of the human IgG1 comprises a mutation selected from the group consisting of S127C, K129R, G135E, G136S, Q203K, I207T, N211D, K222R, P227S, S232Y, C233G, D234 deletion, K235 deletion, T236 deletion, H237P, T238P, L247F, H281Q, K287Q, Y313F, N314Q, A346G, A349S, P350S and K478 deletion according to the Kabat numbering scheme.
5. A recombinant anti-α4 antibody or an α4-binding fragment thereof, comprising: (a) a variable light chain comprising the sequence of SEQ ID NO: 11; (b) a variable heavy chain comprising the sequence of SEQ ID NO: 4; (c) the constant light chain of human kappa light chain (SEQ ID NO: 82); and (d) a chimeric Fc region, comprising a hinge, a CH1 domain and a CH2 domain from an IgG antibody of the IgG4 isotype and a CH3 domain from an IgG antibody of the IgG1 isotype, the chimeric Fc region comprising at least one mutation selected from the group consisting of: substitution of glutamine (Q) at position 297 by EU numbering (position 314 by Kabat numbering) in the CH2 region; substitution of proline (P) at amino acid position 228 by EU numbering (position 241 by Kabat numbering) in the hinge region; and deletion of lysine (K) at position 447 by EU numbering (position 478 by Kabat numbering) in the CH3 region.
6. A recombinant anti-α4 antibody or α4 binding fragment as described in claim 5, wherein the antibody or fragment has increased thermal stability compared to an antibody comprising: (a) a variable light chain comprising the sequence of SEQ ID NO: 11; (b) a variable heavy chain comprising the sequence of SEQ ID NO: 4; (c) a constant light chain of a human κ light chain (SEQ ID NO: 82); and (d) an Fc region comprising the hinge, CH1 domain, CH2 domain and CH3 domain of an IgG antibody of the IgG4 isotype, wherein the Fc region comprises or consists of a substitution of a non-asparagine residue at position 297 in EU numbering (position 314 in Kabat numbering).
7. A recombinant anti-α4 antibody or an α4-binding fragment thereof, comprising: (a) a variable light chain comprising the sequence of SEQ ID NO: 11; (b) a variable heavy chain comprising the sequence of SEQ ID NO: 4; (c) a constant light chain of a human κ light chain (SEQ ID NO: 82); and (d) a constant heavy chain of human IgG4, wherein the constant region comprises at least one mutation selected from the group consisting of: S241P, N314Q, Q376R, E377D, M381L, R440K, E450Q, L476P and K478 deletion according to the Kabat numbering scheme.
8. The recombinant anti-α4 antibody or α4 binding fragment of claim 7, wherein the constant heavy chain of the human IgG4 comprises at least two mutations selected from the group consisting of S241P, N314Q, Q376R, E377D, M381L, R440K, E450Q, L476P and K478 deletion according to the Kabat numbering scheme.
9. The recombinant anti-α4 antibody or α4 binding fragment of claim 7, wherein the constant heavy chain of the human IgG4 comprises at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight, or at least nine mutations selected from the group consisting of: S241P, N314Q, Q376R, E377D, M381L, R440K, E450Q, L476P, and K478 deletion according to the Kabat numbering scheme.
10. The recombinant anti-α4 antibody or α4 binding fragment of claim 7, wherein the constant heavy chain of human IgG4 comprises the following mutations: S241P, N314Q, Q376R, E377D, M381L, R440K, E450Q, L476P and K478 deletion according to the Kabat numbering scheme.
Citation Information
Patent Citations
Recombinant antibodies and methods for their production
EP0239400A2
Novel methods of constructing librabries comprising displayed and / or expressed members of a diverse family of peptides, polypeptides or proteins and the novel librabries
US20030232333A1
Purification and preferential synthesis of binding molecules
US20050163783A1
Antigen binding molecules having modified Fc regions and altered binding to Fc receptors
US20070111281A1
Fc Variants Having Increased Affinity for FcyRIIb
US20070231329A1
